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XSUMMARY
The present study investigated heterogeneity 
between the hepatic artery and the portal vein in the 
isolated perfused rat liver in situ. The extraction 
ratio of lignocaine was found to increase as portal 
vein flow contribution was raised under conditions 
of constant total liver blood flow. This change in 
the extraction ratio of the drug was also found to 
be related to the perfusion pressure in the hepatic 
artery. During increases in hepatic artery perfusion 
pressure the extraction ratio of lignocaine was red­
uced under conditions of constant HA:PV flow ratio.
The reduction in extraction ratio of lignocaine during 
changes in the HA:PV flow ratio are possibly due to 
mechanical changes induced by increases in hepatic 
artery perfusion pressure rather than a reflection of 
heterogeneous metabolic channels.
The metabolic profile of lignocaine was 
also found to alter during changes in HA:PV flow ratio. 
As the portal vein flow contribution increases so the 
recovery of 3-hydroxylignocaine is reduced and the 
recovery of deethylated metabolites increased. This 
effect was not caused by changes in perfusion pressure 
and reflects a degree of metabolic environment hetero­
geneity between the two blood supplies.
Both the hepatic artery and the portal 
vein were found to possess a and ft -adrenoreceptors.
A degree of heterogeneity exists between the /3 -adren­
oreceptor population of the hepatic artery and the 
portal vein. The hepatic artery has a predominance of 
jg^-adrenoreceptors and the portal vein a predom­
inance of /^-adrenoreceptors •
Studies using hydralazine in the rat 
showed that the drug has an effect on the rate of 
elimination of lignocaine and that this is probably 






The liver has two main blood supplies, 
the hepatic artery and the portal vein. The hepatic 
artery forms from the coeliac axis of the aorta. In 
the rat this gives rise to the common hepatic artery 
which divides into the left and right hepatic arteries, 
the right gastric artery and the gastroduodenal 
arteries. The portal vein stems from the confluence 
of the splenic, inferior mesenteric and superior 
mesenteric veins. Blood drains from the liver via 
three hepatic veins which are short and connect to the 
inferior vena cava. In the livers' of cats, dogs and 
man the hepatic artery supplies 25% to 30% of total 
liver blood flow, (Greenway, 1971). In rats this 
ratio may be lower, 19%, in normal tissue (Conway et 
al.,1984). However, it would seem that the artery may 
supply 65% of the total liver oxygen requirement 
(Greenway, 1971). The liver mass may be divided 
into the left and right major lobes; each may be 
further divided into a main and accessory lobe.
3(b) Fine Structure.
The hepatic artery and the portal vein 
enter the liver mass surrounded by a sheath of conn­
ective tissue known as Glissons capsule. Bile and lymph 
ducts also run within this capsule. These sheathed 
bundles, or portal triads, divide frequently, even­
tually giving rise to terminal branches which pass 
through the connective tissue sheath. Terminal 
branches of both the hepatic artery and the portal 
vein drain into the sinusoids. These sinusoids are the 
connecting channels between the two input vessels and 
the hepatic veins.
The sinusoids are numerous within the 
liver and run between folds of parenchymal cells only 
one or two cells thick. Measurements of sinusoid 
dimensions have yielded a wide variation in values 
depending on the preparation used. Rappaport (1973), 
reported the diameter of the sinusoids as 7-15um, 
Grisham et al. (1975), 20-40um and Koo et al. (1979c, 
1979d, 1979e), 6.2-6.4um. The results of studies to 
show the length of sinusoids also varies. Rappaport 
(1973), measured their length at 250um, Koo et al. 
(1979c, 1979d), found sinusoids to be 18-27um long. 
Rappaport (1981), studied human sinusoids and repor­
ted their length to be 225-477um. As well as showing
4a degree of variation in size sinusoids also cannot 
be considered to be a simple series of parallel 
channels between inflow and outflow. Brauer (1963), 
reported the presence of direct portal-venous sin- 
soids and also that smaller sinusoids exist which run 
at right angles to the general direction of flow. 
McCuskey (1966), reported these sinusoids to be inter- 
sinusoidal connections.
The walls of the sinusoids are composed 
of two types of cells, the epithelial cells and the 
Kupffer cells. The vast majority of cells present in 
the sinusoid walls are epithelial cells. These are 
flat and thin with an irregular circumference, (Jones 
et al., 1977). The Kupffer cells are thought to be 
reticuloendothelial in nature because of their ability 
to ingest dyes, (Ham, 1974). Kupffer cells are stell­
ate in appearance with ruffles on their surface 
(Jones et al., 1977).
The epithelial cells of the liver show 
two characteristics which allow intimate contact 
between fluid flowing in the sinusoids and the surr­
ounding parenchymal cells. Firstly they possess fenes­
trations, (Novikoff, 1959; Burkel, 1966; Jones et al., 
1977). These are holes in the epithelial cells which 
allow the passage of plasma out of the sinusoid lumen
5but not large protein molecules and blood cells. They 
may be classified into two types, large fenestrations 
between 1.0-3.0um in diameter and smaller fenest­
rations of O.lum diameter (Grisham et al., 1975; Wisse 
et al., 1983). Fenestrations are not found in the Kup­
ffer cells (Jones et al., 1977). Secondly, for much of 
its length the sinusoid lacks a basement membrane. 
Burkel (1966), showed that there are three distinct 
regions along the length of a sinusoid. Where the 
portal vein and the hepatic artery join the sinusoid, 
epithelial cells possess a basement membrane and lack 
fenestrations. In the middle portion of the sinusoid, 
which forms about 90% of the total sinusoid length, 
the epithelial cells have no basement membrane and 
have numerous fenestrations. Where the sinusoid 
connects to the venous outflow, the epithelial cells 
loose their fenestrations and gain a basement mem­
brane. For the majority of the sinusoids length, the 
lack of a basement membrane and the appearance of 
fenestrations permit intimate contact between plasma 
and the liver parenchymal cells.
Surrounding the epithelial cells are the 
parenchymal cells of the liver. These usually form 
cords which are two cells thick. Between these cords 
run bile canaliculi. Thus, parenchymal cells have one
6side exposed to the sinusoidal environment whilst the 
opposite side faces the bile canaliculus. The sinus­
oidal surface of the parenchymal cells is most 
important in the uptake of molecules into the cell 
and the surface of this side of the cell is rich in
microvilli. In the rat these microvilli are 0.5um long
2
and O.lum in diameter, with 25-50 microvilli per urn 
cell surface area, (Grisham et al., 1975). The micro­
villi protrude into the gap between the parenchymal 
cells and the epithelial cells. This area is known as 
the space of Disse. It is filled with plasma but de­
void of blood cells. The parenchymal microvilli incr­
ease the surface area of the cell in contact with the 
fluid in the space of Disse. This increases the uptake 
area of the cell and improves the efficiency of the 
removal process from the blood. Parenchymal cells are 
also rich in mitochondria (Loud, 1968) and endoplasmic 
reticulum, (Jones et al., 1977); two essential cell 
components required for metabolism.
The passage of blood through the sinus­
oidal system of the liver affords an excellent envir­
onment for metabolism. There is intimate contact 
between the blood and the metabolising parenchymal 
cells. These are well equipped to carry out both 
active transport and endoplasmic chemical reactions.
7Figure 1.2.1
A Low Power Photomicrograph of an H and E Section from 


















Taken from Ham (1974).
8Figure 1.2.2
A Diagram to Illustrate the Acinus Relation to the 
Classic Hexagonal lobule
\S*:




"1" = Acinus Zone 1 or the Periportal region.
"2" = Acinus Zone 2 or the Midzonal region.
"3" = Acinus Zone 3 or the Centrilobular region.
Taken from Ham (1974).
92) LIVER VASCULATURE,
(a) The Acinus,
The terminal branches of the hepatic 
artery and the portal vein are arranged in an approx- 
imately hexagonal form around a central vein. This is 
most clearly seen in the liver of pigs, (fig 1 .2 .1 ). 
However, these hepatic hexagonal lobules are not the 
functional units of the liver. Rappaport (1958), 
identified the functional unit of the liver as the 
acinus which he defined as the parenchymal mass that 
surrounds the axis of a terminal hepatic arteriole 
and the portal venule growing out of similar pre­
terminal branches. Since the terminal vascular 
branches follow an hexagonal pattern and since blood 
from these will drain into central veins on either 
side of the terminal axis the acinus has a roughly
diamond shape, (fig. 1 .2 .2 ).
Actual anatomical evidence for these
units has been shown by Jones et al. (1977). Rappaport
(1981), measured the maximum dimensions of human
liver acini and found them to be 1113-1908 urn in
length, 398-1113 urn in thickness and 636-1590 urn
2in width, with an average volume of 1.26 mm . It 
was also postulated by Rappaport (1958), that the
10
sinusoids closest to the terminal axes should contain 
blood of higher oxygen content than those nearer to 
the central vein. Miller J.A. et al. (1977), showed an 
oxygen gradient did indeed exist between blood in the 
sinusoids close to terminal branches and those sinu­
soids nearest to the central vein. This has led to 
the division of the acinus into three zones,
(Rappaport, 1980). Zone 1 or the periportal zone, 
consists of those sinusoids immediately surrounding 
the terminal branches of the portal vein and hepatic 
artery. This zone possesses blood which is rich in 
oxygen. Zone 3 or the centrilobular zone, consists of 
those sinusoids surrounding the central vein which 
contain blood of a lower oxygen concentration. Zone 2 
or the midlobular zone, consists of those sinusoids 
between zones 1 and 3 possessing an intermediate 
oxygen concentration, (fig. 1.2 .2 ).
(b) Intrahepatic connections.
The concept of the liver acinus being 
the functional unit of the liver has now been widely 
accepted. However, there still remains controversy 
over the arrangement of the terminal portal venule and 
hepatic arteriole connections with the sinusoids.
Elias et al. (1953), showed the presence of arterial
11
connections to thoroughfare artery channels which 
transverse the three acinar zones without mixing with 
portal blood. Observations by McCuskey (1966) in rats 
showed that portal venules commonly gave rise to sinu­
soids directly. However, connections between the 
hepatic artery and these sinusoids suggested that 
some sinusoids were perfused intermittently by 
arterial blood alone. He also observed direct 
arterio-portal anastomoses prior to the blood enter­
ing the sinusoids. He noted that the Kupffer cells 
often acted as sphincters and formed inlet and outlet 
controls for the sinusoids. Bloch (1955), had prev­
iously observed these sphincters and later confirmed 
that they were Kupffer cells, (Bloch, 1970).
Burkel (1970), reported the presence of 
direct arteriole connections between the intralobular 
and terminal distributing veins, however, these 
connections are rare and the majority of arterioles 
join to sinusoids directly or in conjunction with 
portal venule connections. Experiments by Grisham et 
al. (1981), using hepatic casts of microvessels showed 
that the majority of hepatic arteriole connections 
were supplied by the hepatic biliary plexus. This is 
a complex of capillaries which surrounds the portal 
tracts. Nopanitaya et al. (1978); Ohtani et al. (1978)
12
and Grisham et al. (1981), observed direct connections 
from arterioles to portal venules and direct arteriole 
connections to both zone 1 and zone 3 of the acinus? 
the latter being extremely rare. These findings are 
in contrast to those of Hase et al. (1966), who 
reported no such arteriole connections with zone 3.
The peribiliary plexus mainly supplies the sinusoids 
in zone 1 but it also has connections with the portal 
venules. These connections between both the hepatic 
artery and the peribiliary plexus with the portal 
vein confirm observations made by Geumei (1969), 
who showed unidirectional arterio-portal shunts. 
Grisham et al. (1981), provided evidence that the 
portal vein supplies direct connections only to zone 
1 of the acinus.
Efferent branches of the peribiliary 
plexus form an important source of blood for many 
sinusoids in those parts of the liver where the dist­
ributing portal venules are poorly developed, (Ohtani, 
1978 et al. and Nopanitaya et al., 1978). The peri­
biliary plexus sinusoid connections are especially 
important in the perihillar regions of the liver, 
(Grisham et al., 1981).
It would seem from these observations 
that the majority of the sinusoids are perfused by
13
both hepatic artery and portal venous blood but that 
some sinusoids may be perfused by portal or arterial 
blood alone. Also, although sinusoids may be perfused 
by a mixture of both hepatic artery and portal vein 
blood, the proportions of each supply may not be the 
same for each sinusoid. A problem that arises with 
the theory that sinusoids are perfused by a mixture 
of arterial and portal blood is how the portal vein 
blood under pressures of 3-4 mmHg flows against an 
hepatic artery pressure of 30-35 mmHg, (Rappaport, 
1981). The most likely answer involves a reduction in 
arteriole pressure through the peribiliary plexus 
and the control of arteriole blood by sphincters which 
intermittently allow jets of arteriole blood to pass 
into sinusoids. Seneviratne (1949), Elias et al.(1953) 
and Rappaport (1981), have observed pulsating blood 
flow in the sinusoids which may be a result of inter­
mittent flow.
Experimental observations have shown the 
existence of direct hepatic artery connections to 
sinusoids and also indirect connections via the peri­
biliary plexus. The complexity of the connections 
provides the scope for sinusoids to be perfused to 
varying degrees by the hepatic artery or portal vein.
14
3) ACINAR HETEROGENEITY.
As well as showing a degree of hetero­
geneity in the way in which blood supplies connect to 
the sinusoids in the various acinar zones, the 
three acinar zones also exhibit zone dependent charac­
teristics. These have been grouped under two sub­
headings: structural heterogeneity, (describing the 
structural differences) and biochemical heterogeneity, 
(describing the distribution of the enzymes and co­
factors between the zones).
(a) Structural Heterogeneity.
Hase et al. (1966), found in rats, that 
the sinusoids of acinar zone 1 are more anastomatic 
whereas the sinusoids of zone 3 tend to be straighter 
with fewer interconnections. Koo et al. (1975), showed 
that the blood flow within sinusoids differs. Some 
sinusoids connect the portal vein directly to the hep­
atic central vein; these have a fast flow. Branching 
sinusoids have a medium flow and interconnecting sin­
usoids a slow flow rate. Because there are more inter­
connecting sinusoids in zone 1, (Hase et al., 1966) 
these flow velocities may be zone dependent. Wisse et 
al. (1983), showed that the sinusoids of zone 1 were 
more tortuous.
15
Miller D.L. et al. (1979, 1981), showed 
that the internal surface area to volume ratio of 
sinusoids is larger in zone 1. These observations 
were confirmed by Wisse et al. (1983). The signif­
icance of the surface area to volume ratio is that 
the higher the ratio the more likely a given molecule 
will pass through the epithelial cell fenestrations 
and collide with the surface membrane of a paren­
chymal cell. This process is essential for metabolism 
and the rate at which solute makes contact with the 
cell wall affects the rate of metabolism.
Loud (1968), showed that the parenchy­
mal cells of zones 1 and 3 were similar in size. How­
ever, he did show that the mitochondria in cells of 
zone 3 occupied less of the total cell volume and 
although smaller they were more numerous in this zone. 
He showed that rough endoplasmic reticulum volume was 
similar in all zones but that the volume of smooth 
endoplasmic reticulum was higher in the cells of zone 
3. The significance of these findings may be too small 
to produce any zonal differences in metabolism as 80% 
of the liver parenchymal cells did not display these 
differences. It was only those cells at the extremes 
of the acinus which exhibited such heterogeneity.
16
Wisse et al. (1983), showed that the 
fenestrations observed in zone 1 were on average 
larger than those of zone 3. Grisham et al. (1975), 
found that the epithelial cells of zone 1 possessed 
more of the larger type of fenestrations. The epith­
elial cells of zone 1 therefore have a greater porosity. 
The overall result is that solute molecules have 
a greater chance of colliding with liver parenchymal 
cells in zone 1. In theory the rate of removal of 
solute would be higher in zone 1 than zone 3. The 
structural heterogeneity within the acinus tends to 
favour a higher uptake and metabolism in zone 1 but 
the acinus also shows a degree of biochemical hetero­
geneity with respect to enzyme distribution.
(b) Biochemical Heterogeneity.
Shank et al. (1959), showed that in rats 
glucose-6-phosphate dehydrogenase, phosphoglucoisomerase 
isomerase, lactate dehydrogenase and alkaline phosphatase 
activities were all higher in zone 1 than zone 3. Iso­
citrate dehydrogenase and glutamate dehydrogenase levels 
were lower in zone 1 than zone 3. Katz et al. (1976), 
demonstrated that glycolosis and gluconeogenesis may 
display some zonal heterogeneity. Later Katz et al. 
(1977), also fructose 1,6, biphosphatase levels to be
17
higher in zone 1 but that glucokinase activity was 
lower in zone 1. Guder et al. (1976), found more pyru­
vate kinase but less phosphenol pyruvate carboxykinase 
activity in zone 3. Wimmer et al. (1979), found higher 
levels of succinate dehydrogenase, malate dehydro­
genase and lactate dehydrogenase in zone 1 but greater 
isocitrate dehydrogenase and glutamate dehydrogenase 
activity in zone 3. These observed zonal differences 
have been taken to indicate that zone 1 is predomin­
antly involved in gluconeogenesis while cells of zone 
3 participate in glycolosis. Gumucio et al. (1981), 
pointed out that the heterogeneity shown by the cells 
of the acinus in respect to glycolosis or gluconeo­
genesis may reflect their position or the availability 
of co-factors in these zones rather than actual enzyme 
levels.
Recently attention has focused on the 
enzymes responsible for drug metabolism and their 
heterogeneity within the acinus. Gooding et al. (1978), 
showed that cytochrome P45q was generally concent­
rated in the centrilobular zone. Baron et al. (1978), 
looked at the different induceable forms of cytochrome 
P450* He s^owec  ^ that the phenobarbital induced form 
of cytochrome P45Q was concentrated in zone 3. How­
ever, the methylcholanthrene induced cytochrome P44g
18
was more evenly spread within the acinus. Baron et al. 
(1981), showed that the cytochrome P45Q forms are 
also more active in the centrilobular region. He 
believes that this may be in part due to co-factor 
differences.
An important enzyme involved in drug 
oxidation is NADPH-cytochrome P45Q reductase. Redick 
et al. (1980) and Ji et al. (1980), showed the levels 
of this enzyme were much lower in zone 1 than in zones 
2 and 3. To measure actual enzyme activities within 
the three zones Ji et al. (1981) and Thurman et al. 
(1983) looked at the conversion of the non-fluorescent 
7-ethoxycoumarin to the fluorescent 7-hyroxycoumarin 
by the mixed function oxidase systems. They found the 
enzyme activities to be higher in zone 3. James et al. 
(1981), using selective zone 1 and zone 3 damage 
showed that the mixed function oxidase systems were 
concentrated in zone 3.
Phase I I  metabolism has also been 
studied. Pang et al. (1981a), using normal and retro­
grade perfusion in the rat, showed that sulphate con­
jugation was concentrated in zone 1. Pang et al. 
(1981b), using harmol as an indicator again showed 
that sulphate conjugation was concentrated in zone 1. 
and that the enzyme sulphotransferase has a high
19
affinity but low capacity. Pang et al. (1981), using 
harmol and Conway et al. (1982), using 7-ethoxy- 
coumarin showed that glucuronide conjugation was 
evenly distributed within the acinus. James et al. 
(1981), using the less sensitive method of selective 
zonal damage, showed a zone 2 and 3 localisation of 
glucuronyl transferase, a zone 2 localisation of 
glutathione transferase and a zone 1 and 2 localis­
ation of N-acetyl transferase.
The process of uptake is also important 
for drug metabolism. This is an active process and 
Novikoff (1959), showed ATPase activity is higher in 
zone 1. Conway et al. (1982), found that all parench­
ymal cells can take up hydroxycoumarin at the same 
rate. Groothius et al. (1982), showed that bile salt 
uptake of individual cells is uniform throughout the 
acinus. However, what is more important is the relat­
ionship of these cells to the input of blood. As cells 
of zone 1 are normally exposed to the highest solute 
concentration, they may remove most of the drug before 
it reaches zone 2 and 3 and so it appears that uptake 
is highest in zone 1. If retrograde perfusion is perf­
ormed (Conway et al., 1982; Groothius et al., 1982), 
then the concentration gradient is reversed and the 
cells of zone 3 can take up more drug from the blood
20
stream. It appears with these drug metabolism markers 
that each parenchymal cell is capable of removing the 
drug from the circulation. However, because of their 
position within the acinus, cells of zone 3 do not 
appear to be as active in uptake as zone 3 solute 
levels are normally lower.
Care must be taken when interpreting the 
results of data on acinar heterogeneity. It is often 
not possible to distinguish whether zonal differences 
reflect actual biochemical alterations between the 
cells or are a result of the cells position with 
respect to blood input.
21
4) HETEROGENEITY BETWEEN THE HEPATIC ARTERY AND 
PORTAL VEIN.
The previous sections have outlined evi­
dence for acinus zonal heterogeneity of vascular conn­
ections and metabolism. The possibility also exists 
that drugs passing into the liver via the hepatic 
artery may be treated differently than if they entered 
by the portal vein. If this phenomenon is to occur two 
conditions must be met by the liver physiology. First, 
there must either be some separate channels for the 
passage of hepatic artery and portal vein blood or 
that some sinusoids are perfused by differing propor­
tions of the two blood supplies. Secondly, those sin­
usoids taking a preponderance of hepatic arterial or 
portal venous blood must have different enzyme 
environments to those carrying fully mixed blood.
(a) Evidence for separate hepatic artery 
and portal vein channels through the 
liver.
Most investigations in this field have 
been confined to cats and dogs and involve the use of 
radioactive tracers. Rees et al. (1964), using Xenon 
133 showed that the washout curves were different 
depending on whether the tracer was perfused into the
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hepatic artery or the portal vein. Hollenberg et al. 
(1966), using radiolabelled Krypton in dogs showed 
that injections into the hepatic artery gave a lower 
calculated total liver blood flow than injections into 
the portal vein. He concluded that separate channels 
must exist. Birtch et al. (1967), also using Krypton 
in dogs, divided the washout curves into three differ­
ent decay rates. He found marked differences in the 
parameters obtained for the hepatic artery than for the 
portal vein. He also measured the parameters from a 
combined hepatic artery and portal vein injection.
Thus, if the hepatic channels for each supply were 
totally separated then the sum of the hepatic artery 
and portal vein parameters should equal those found 
for the combined injection. This was not the case.
Also, if the blood was totally mixed prior to passage 
through the liver there would be no difference between 
the hepatic artery and portal vein parameters. This 
also was not true. The conclusion must be that both 
separate and mixed routes exist.
Blumgart et al. (1977), carried out 
experiments in dogs in which he found that extrahepatic 
shunts exist between the gastroduodenal artery and the 
portal vein. When these are ligated, the portal vein 
and hepatic artery washout times for radioactive trac­
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ers are identical. In the experiments of Rees et al. 
(1964), a gastroduodenal cannula was used to perfuse 
the hepatic artery and these extrahepatic shunts could 
account for the differences in transit times reported. 
However, in the experiments of Birtch et al. (1967), 
Krypton was injected into a cannula placed directly 
in the hepatic artery with the gastroduodenal artery 
ligated. In the experiments carried out by Hollenberg 
et al. (1966), a cannula was placed in the coeliac 
artery between the branching of the gastroduodenal 
artery and the liver. Therefore in the experiments 
by Birtch et al. (1967) and Hollenberg et al. (1966), 
shunts are unlikely to explain any differences in 
transit time.
Another possible explanation for the 
results obtained by Blumgart et al. (1977), is that 
ligation of the shunts prevented arterial blood from 
passing to the portal vein. This would result in an 
increase in hepatic artery flow and a decrease in 
portal vein flow. Thus, under ligated conditions the 
change in blood flow through each route may alter 
tracer transit times so that they become route indep­
endent. In the experiments of Blumgart et al. (1977), 
no measurements of flow are presented and so this 
remains purely conjecture.
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Work by Lifson et al. (1970) and 
Griffen et al. (1970), showed that some areas of the 
liver were more highly perfused than others. However, 
these areas were more highly perfused by both the 
hepatic artery and portal vein.
(b) Evidence for separate metabolising 
environments.
Experiments have been carried out to 
examine variations in the space of Disse between the 
two blood supplies. This normally involves using 
radiolabelled red blood cells and radiolabelled albu­
min. The transit time of the albumin is slower through 
the liver as it is able to pass into the space of 
Disse, whereas red blood cells cannot. The difference 
in transit time reflects the size or accessibility of 
the space of Disse. Experiments in dogs by Cohn et al. 
(1969), showed that these transit times were not route 
dependent. Work carried out by Ahmad (1982), in the 
perfused rat, showed that the apparent space of Disse 
was larger when livers were perfused by the hepatic 
artery than the portal vein. This seems to indicate a 
difference in the space of Disse between the two 
routes.
Lautt et al. (1984), used the dye indo-
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cyanine green as an indicator of liver uptake and 
and showed the process was not route dependent. 
However this work was carried out in cats where the 
extraction ratio of indocyanine green is only 25% and 
so may not represent the best marker of metabolism.
Experiments by Ahmad et al. (1981), 
have shown that the extraction ratio of lignocaine is 
dependent on the hepatic artery to portal vein flow 
ratio under conditions of constant total blood flow. 
This provides evidence for possible differences in 
enzyme environments between the two routes.
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5) VASCULATURE RESPONSES WITHIN THE LIVER.
There is thus speculative evidence 
pointing to the existence of separate channels for 
the passage of arterial and portal blood through the 
liver and that these channels may metabolise drugs 
differently. If the route by which a drug takes into 
the liver is to have any physiological significance, 
there must exist the possibility that the blood flow 
through each route may be altered to vary the hepatic 
artery portal vein flow ratio.
(a) Methods of study.
The study of changes in vascular resis­
tance in the beds of the hepatic artery and portal 
vein has been in the main confined to large animals 
such as cats and dogs where surgery is easier. Four 
preparations are commonly used to study the vascular 
beds of the liver.
i) The isolated perfused system.
In this preparation the liver is isolated from the 
general circulation and perfusion takes place using 
media with carefully controlled constituents. The 
preparations are also denervated as the rest of the 
animal is deprived of blood and therefore of oxygen.
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ii) Long circuited preparations.
These preparations require careful surgery. They 
involve the cannulation of the hepatic artery and the 
transfer of femoral artery output via a second cannula 
to the hepatic artery. External flow meters and press­
ure gauges may be attached to this external connection 
The portal vein is also cannulated and perfused with 
the blood obtained from the mesenteric veins. An 
alternative method developed by Lautt (1977a), allows 
direct sampling of hepatic venous blood. In this prep­
aration the inferior vena cava is cannulated and blood 
returned to the heart from the lower part of the body 
by connections from the femoral veins to the external 
jugular veins. The flows and pressures are measured 
using external probes in the hepatic artery and the 
portal vein. In both of these types of preparations the 
liver is not isolated from the general circulation and is 
innervated. Physiological changes induced elsewhere in 
the body, for example, increases in heart rate or 
release of hormones, may affect the liver vasculature.
The advantage of these preparations is that they offer 
a much more physiological environment for experiment­
ation and allow assessment of nerve function.
28
iii) Transillumination techniques.
These involve direct microscopic observation of the 
liver vasculature in situ or after excision. Changes 
in vessel diameter can be directly observed using this 
technique and it has been successfully employed to 
observe the effects of nerve stimulation on sinusoid 
diameter (Koo et al., 1979b, 1979c).
iv) Intravenous injections.
These techniques are the least disruptive when applied 
to liver circulation. They involves simple intraven­
ous injections of vasoactive substances (for example, 
cimetidine, Jackson 1981), and measurement of liver 
blood flow using electromagnetic flow meters. They 
may therefore be used for studies in humans.
(b) Arterial buffer response.
The hepatic artery and the portal vein 
do not behave independently of each other. Studies 
carried out by Burton-Opitz in dogs (1911a), showed 
that a decrease in portal vein flow may cause an sign­
ificant increase in hepatic artery flow. This increase 
in artery flow compensates, in part, for the decrease 
in portal vein flow, keeping total blood flow const­
ant. Initially this effect was thought to be related 
to oxygen concentrations within the liver. Experiments
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by Lautt et al. (1977b, 1977c, 1980a, 1981), have also 
demonstrated this effect, known as the "arterial 
buffer response". Lautt et al. (1977b, 1977c, 1980a, 
1981), have shown that the response is independent of 
the oxygen consumption of the liver. It is believed 
that the role of this response is to keep total liver 
blood flow constant so that substances may be removed 
at a constant rate. The portal vein vasculature has 
little control over the flow of blood into the portal 
vein. This is mainly controlled by blood flow to the
gut. It is the artery which takes on the role of a
buffer to changes in portal venous blood flow. Lautt 
believes that the mechanism responsible for these 
changes involves the rate of washout of adenosine. He 
has shown this to be a potent hepatic artery dilator 
(Lautt 1984, 1985b). The metabolite washout theory 
works on the principle that adenosine is being contin­
ually produced within the vasculature. The slower the 
total blood flow the longer the adenosine has to act
leading to greater dilation and increasing blood flow.
An increased liver blood flow will cause a decrease in 
the dilator effect of adenosine and so provide a feed­
back control mechanism for arterial blood flow.
This arterial buffer response may 
produce physiological changes in the hepatic artery:
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portal vein flow ratio. It must also be borne in mind 
when considering the effects of vasoactive substances 
in the vascular beds of the hepatic artery and the 
portal vein.
(c) Vasoactive effects on the vascular 
bed of the hepatic artery and portal 
vein.
i )Adrenoreceptors.
Chakravarti et al. (1940), in isolated 
dog livers, showed that adrenaline causes an increase 
in hepatic artery and portal vein perfusion pressure. 
Mesenteric vein injections of adrenaline in rats may 
also cause an increase in portal vein pressure,
Daniel et al. (1951). Using transillumination tech­
niques Seneviratne (1949), and Ho (1972), have demon­
strated adrenaline and noradrenaline induced sinus- 
soid constriction. Andrews et al. (1955), noted that 
in perfused dog livers, injections of both adrenaline 
and noradrenaline into the hepatic artery or the 
portal vein increased resistance in either vessel. 
Using long circuited dog preparations, Green et al. 
(1959), was able to increase hepatic arterial resis­
tance but could only produce slight changes in portal 
vein resistance using adrenaline and noradrenaline
injections into the hepatic artery. Introduction of 
the same substances into the portal vein resulted in 
an increase in both input vessel resistances. These 
constrictor responses would seem to be a-adreno- 
receptor mediated as they were antagonised by diben- 
zyline. However, noradrenaline mediated portal vein 
constriction, during hepatic artery infusion, has 
been demonstrated by Noguchi et al. (1970), in the 
isolated perfused rat liver.
Hagino et al. (1974), reported the
presence of only a-adrenoreceptors in the rat liver.
Hirsch et al. (1976), using dogs, found propranolol t
be ineffective at antagonising noradrenaline or adren
aline vasoconstriction in either the portal vein or
hepatic artery. Richardson et al. (1977a, 1978),
using dogs showed that noradrenaline or adrenaline
induced vasoconstriction, in both vessels, was dose
related and could be antagonised by the a-adrenorec-
eptor blocker phentolamine but not by the j3-adreno-
receptor blocker propranolol. Studies by Koo et al.
(1977), using transillumination techniques in the rat
-9 -7indicate low doses (10 to 10 mol/litre) of 
adrenaline and noradrenaline may induce sinusoid 
dilation. At higher concentrations a dose related vas 
oconstriction was obtained which could be antagonised
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by the a-adrenoreceptor blocker phenoxybenzamine. 
Hepatic nerve stimulation may also cause constriction 
of the vascular bed which may be antagonised by the 
a-adrenoreceptor blocker phentolamine (Greenway 1979).
jg-adrenoreceptor activity has been more 
difficult to elicit in the liver vasculature. Green et 
al. (1959), using dogs, could not find any jg-receptor 
activity in either the hepatic artery or portal vein 
vascular beds. Nylidrin, a jg-adrenoreceptor agonist, 
was shown to produce a jg-mediated hepatic artery vaso­
dilation but a vasoconstriction of the portal vein 
which was 'potentiated by propranolol, in isolated 
canine livers (Geumei et al., 1968). Low doses of 
adrenaline (0.1- 0.2 ug/ml) were found to produce 
jg-adrenoreceptor mediated hepatic artery dilation in 
cats (Greenway et al., 1969). Using dogs Hirsch et 
al. (1976), showed that hepatic artery dilation could 
be produced by hepatic artery or portal vein infusions 
of the jg-adrenoreceptor agonist isoprenaline. Portal 
vein dilation could not be obtained. The dilation was 
shown to be jg-adrenoreceptor mediated using propran­
olol. Koo et al. (1977), using transillumination 
techniques in the rat managed to elicit dilatory resp-
_ Q _ 7
onses in sinusoids during 10 to 10 mol/litre 
portal vein infusions of adrenaline and noradrenaline.
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The response was found to be jg-adrenoreceptor mediated 
Studies have been carried out to iden­
tify the type of jg-adrenoreceptor present in the liver 
vasculature. Isoprenaline and salbutamol (a jg2 sele­
ctive agonist) cause vasodilation of the hepatic 
artery in dogs (Richardson et al., 1977d). This dil­
ation was antagonised by the non-selective jg-adreno- 
receptor blocking drug propranolol but not by the 
selectivejg^ -adrenoreceptor blocker atenolol.
Thus hepatic vasculature jg-adrenoreceptors appear to 
be predominantly of the jg2 subtype. Richardson et 
al.(1978b), using dogs was unable to elicit any portal 
vein vasodilation with isoprenaline. Sinusoidal dila­
tion has been shown in the rat during portal vein 
infusions of isoprenaline and terbutaline (Koo et al., 
1979a). Terbutaline is a selective -adrenorec­
eptor agonist suggesting jg2 mediated dilation. 
Propranolol was effective at antagonising the dilat­
ion but atenolol was not. Reilly et al. (1981), in 
rats using microscopic in situ examination showed that 
isoprenaline can produce both portal vein and sinusoid 
dilation and using the selective jg^  and jg2-adreno- 
receptor blockers (practolol and butoxamine) they 




Seneviratne (1949), Koo et al. (1979a, 
1979b, 1979e) have shown the presence of cholinergic 
receptors in the rat liver sinusoids. Green et al. 
(1959) found cholinergic receptors in the hepatic art­
ery but not in the portal vein. Histamine receptors 
have been demonstrated in the sinusoids, (Seneviratne, 
1949) and in the hepatic artery and portal vein, 
(Schwartz, 1970? Richardson et al., 1976, 1977c, 
1978a). The receptors are dilatory in the sinusoids 
and the hepatic artery but produce constriction in the 
portal vein. Hirsch et al. (1976) and Richardson et al. 
(1977e, 1978c), have also reported the presence of 
dopamine receptors in the hepatic artery vasculature 
of the dog. They remain unconvinced as to the presence 
of portal vein dopamine receptors. Other vasoactive 
substances include sodium nitrite (Geumei, 1969b), 
which was found to produce constriction in both 
vessels. Bradykinin (Richardson et al., 1977d), has 
been shown to be a potent hepatic artery vasodilator. 
5-Hydroxytryptamine at low doses produces portal vein 
dilation but at high doses constriction. In the 
hepatic artery a biphasic dilation followed by a 
constriction was seen (Richardson et al., 1978a). 
Glucagon, secretin, pancreozymin and pengastrin all
cause hepatic artery vasodilation (Richardson et al. 
1977b).
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6 ) HEPATIC ARTERY AND PORTAL VEIN VASCULATURE 
INTERACTIONS.
Experiments by Burton-Opitz (1911), in 
dogs, Condon et al. (1962), in calves and Lautt et 
al. (1977b, 1977c, 1980a, 1981, 1985a, 1985b), in cats 
have shown the existence of an interaction between the 
portal vein flow and the hepatic artery flow known as 
the hepatic artery buffer response. It has been shown 
that noradrenaline and adrenaline can increase hepatic 
artery resistance whether they are infused via the 
hepatic artery or the portal vein, (Green et al. (1959) 
and Richarson et al. (1978b). However, injections 
given directly into the hepatic artery produce a lar­
ger constriction than the same dose given via the 
portal vein. Isoprenaline induced vasodilation of the 
hepatic artery can also be obtained from both hepatic 
artery and portal vein infusions (Green et al., 1959 
and Hirsch et al., 1976). Portal vein resistance seems 
to be unaffected by artery infusion. Richardson et al. 
(1978a), showed that histamine given by the hepatic 
artery or portal vein produces artery dilation and 
portal constriction. Angiotensin produces hepatic 
artery constriction when given by either route (Lautt 
et al., 1984). Adenosine was shown to be a potent 
hepatic artery dilator via either route (Lautt et al.,
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1984). However, Hirsch et al., (1976) showed dopamine 
to be equipotent at increasing hepatic arterial res­
istance through both both routes.
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7) DRUG METABOLISM AND CLEARANCE.
Few parent compounds can be directly 
eliminated from the body and have to undergo biotrans­
formation prior to excretion. This process is known as 
metabolism and the major site of metabolism is the 
liver. Hormones such as aldosterone (Camargo et al., 
1965), inert dyes such as indocyanine green 
(Pumgartner et al., 1970) and drugs such as phenacetin 
(Pang et al., 1978), etidocaine (Tucker et al., 1977), 
imipramine, (Gram et al., 1975), all undergo liver 
metabolism prior to removal.
The purpose of drug metabolism is to 
render parent compounds more water soluble and more 
amenable to excretion. For most drugs the process can 
involve two stages , Phase I and Phase II metabolism.
(a) Drug Metabolism.
Phase I metabolism occurs when the basic 
chemical structure of the parent drug is altered. This 
is usually achieved by the introduction of polar 
groups by oxidation, reduction, hydrolysis or by 
the removal of alkyl groups to "uncover" potential 
polar groups. The process involves the haemoprotein 
cytochrome P45Q of which there are several subtypes. 
The cytochrome is reduced by NADPH-cytochrome c reduc­
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tase to produce active oxygen complexes (Brodie et al., 
1958 and Cooper, 1965). The process is localised with­
in the microsomal fraction of cells (Gillette, 1971), 
and although skin, lung and other tissues may exhibit 
cytochrome P450 activity, (Baron et al., in press), 
the liver is the main site of metabolism.
Phase II metabolism occurs when the 
parent drug or its metabolites are conjugated with one 
of several endogenous substrates such as glucuronic 
acid, sulphate, glycine, glutamine or acetate. Glucur- 
onidation and sulphation are two types of conjugation 
commonly seen in drug metabolism. Glucuronidation is 
localised in the liver microsomal fraction (Issel- 
bacher et al., 1962). The process involves the form­
ation of UDP-glucuronic acid from glucose-l-phosphate 
and the transfer of the glucuronic acid molecule to 
the drug? a reaction catalysed by the enzyme glucuron- 
yl transferase. Sulphation mainly occurs in the cell 
cystol, (Nose et al., 1958). Sulphate is first conv­
erted to the active 3-phosphoadenosine-5-phosphosul- 
phate form (PAPS). The sulphate is then transferred 
to the drug molecule by sulphotransferase. Not all 
drugs undergo Phase I metabolism prior to conjugation, 
for example, digitoxin is almost entirely excreted as 
conjugates of the parent drug.
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(b) Clearance of drugs.
The clearance of a drug represents the 
efficiency with which it is removed by the eliminating 
organs. Total body clearance can be defined as the 
fraction of the apparent volume of distribution cleared 
of drug by the body per unit time. Apparent volume of 
distribution may expressed in terms of blood volume or 
the plasma volume. Total body clearance is the sum of 
clearances by each eliminating organ, for example, 
liver, lung or kidney. These clearances fall into 
two categories; renal clearance and metabolic 
clearance. Renal clearance is defined as the urinary 
drug excretion divided by plasma concentration. Since 
the main site of metabolism for most drugs is the 
liver, the metabolic clearance is normally equivalent 
to hepatic clearance.
Hepatic clearance, (Clh ) is a function 
of liver blood flow and the ability of the liver to 
extract the drug as it passes through the hepatic 
sinusoids.
Cl„ = Q x E Equation 1.7.1n
Q = liver blood flow 
E = extraction ratio of the drug
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E may be defined as the ability of 
the liver to irreversibly remove a given quantity of 
drug in one passage through the liver.
(C - C )
E - - IN 0tJT Equation 1.7.2
C IN
CIN = Hepatic artery and portal vein input 
concentration of drug 
Cq u t  = Hepatic venous output concentration
A quantitative approach to the removal
process is obtained by considering the total intrinsic
clearance. (ClTMm) of the liver. This is the maximal INT
ability of the liver to remove drug irreversibly when 
flow is not limiting. Using this parameter:
(Q X C1TN )
C1H = — -------Equation 1.7.3
<qh + c w
Many drugs are bound to plasma proteins 
and pass through the liver in both the bound and free 
forms. Normally only free drugs may be metabolised but 
where the avidity of the hepatic extraction process is 
high, drug may be stripped from the binding proteins 
during passage through the liver. Uptake of drug may
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be restricted to free drug where protein binding is 
strong but may be unrestricted where bound drug may be 
displaced by the extraction process. The fraction of 
unbound drug in the blood is usually represented by 
fb. Thus:-
C1H = X
( fb  x c r INT> 
(Qh + fb X Cl' )
Equation 1.7.4
Where Cl'INT is the intrinsic clearance
of unbound drug. If Cl' 
binding is constant the part of the equation in square 
brackets approximates to unity and equation 1.7.4 can 
simplified to:-
CIr = Qh Equation 1.7.5
The hepatic clearance of drugs which 
show a high intrinsic clearance will be affected by 
changes in liver blood flow. Whereas for drugs showing 
a lower intrinsic clearance the approximation does not 
hold and these drugs will be affected by changes in 
the maximum veocity of the extraction process. Changes 
in the V^ax of the metabolism process may be 
achieved using cytochrome inducers.
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Drugs may be considered to be relatively 
flow dependent or flow independent. - Drugs which 
show a high CljNT bY the liver and are thus flow 
dependent are propranolol, (Wood et al., 1979;
Branch et al., 1973, oxprenolol, (Mason et al., 1976), 
metoprolol, (Borg et al., 1975) and lignocaine,
(Branch et al.,1973 and Ahmad et al., 1983). Drugs 
showing a low extraction ratio include diphenyl- 
hydantoin (Shand et al., 1975) and warfarin (Esquivel 
et al ., 1978).
Drugs which have high intrinsic clear­
ances such as those outlined above may be used as 
tools to measure liver blood flow since their clear­
ances are flow dependent. This is only true if the 
drugs have a constant extraction ratio and are thus 
flow dependent.
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8 ) SCOPE OF THE STUDY.
The liver has been shown to be a complex 
structure. The functional unit, the acinus, shows a 
degree of heterogeneity, both in structure and func­
tion. The vascular connections to the acinus have also 
been shown to be zone dependent. In addition the two 
liver blood supplies, the hepatic artery and the por­
tal vein may differ in their routes through the liver 
and their enzyme environments. The possibility exists 
that drugs may be metabolised differently by the two 
routes. The hepatic artery and the portal vein also 
respond differently to vasoactive substances and as 
such the physiological normal hepatic artery portal 
vein flow ratio may be altered by these substances.
The present study investigates the 
effect of changes in the hepatic artery portal vein 
(HA:PV), flow ratio and pressure on the metabolism of 
the drug lignocaine in the perfused rat liver. Ligno- 
caine was used as a model drug as it is highly extra­
cted in both rats and humans, (Branch et al., 1973; 
Shand et al. 1975? Ahmad et al., 1983? Lennard et 
al., 1983). It is therefore a liver blood flow depen­
dent drug (Nies et al., 1976). Its metabolism in the 
rat (Hollinger et al., 1960; Keenaghan et al., 1972; 
Nyberg et al., 1977) and in man (Beckett et al.,
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1966; Hermansson et al., 1980; Drayer et al.,
1983), has been well documented (Fig. 1.8.1). Also 
work by Ahmad et al.(1983) has shown that the extract­
ion ratio is dependent on the hepatic artery to portal 
vein flow ratio.
Figure 1.8.1. The Known Metabolism of Lignocaine
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Calcium Chloride - S.L.R. Grade Fisons Loughborough
Glucose - S.L.R. Grade Fisons Loughborough
Hydrochloric Acid - S.L.R. Grade Fisons Loughborough
Magnesium Sulphate - S.L.R. 
Heptachloride
Grade Fisons Loughborough
Potassium Chloride - S.L.R. Grade Fisons Loughborough
Potassium diHydrogen- S.L.R. 
Orthophosphate
Grade Fisons Loughborough
Potassium Hydroxide - S.L.R. Grade Fisons Loughborough
Sodium bicarbonate - S.L.R. Grade Fisons Loughborough 
Sodium Chloride - S.L.R. Grade Fisons Loughborough
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Epinephrine bitartrate, Sigma, England
Atenolol hydrochloride, I.C.I. England
Bupivicaine hydrochloride, (Marcaine 
Plain), Duncan Flockhart, Greenford, 
Middlesex.
Clenbuterol hydrochloride, Dr. Karl 
Thomae, G.M.B.H. Germany.
Dobutamine hydrochloride (Dobutrex), 
Lilly, England.
AB Borfors, Borfors, Sweden




(Saventrine), Pharmax Ltd., Kent, 
England.
Sigma, England.
Lignocaine hydrochloride, (Xylotox) 
Pharmceutical Manufactures, Epsom, 
Surrey, England.
- Lignocaine hydrochloride, New 
England Nuclear, Dupont, Southampton, 
England.
Metoprolol Tartrate, Sigma, England.
Arternolol +bitartrate, Sigma, England
Oxprenolol hyrochloride, Sigma, 
England.
Phentolamine Mesylate, (Rogitine), 
Ciba, Sussex, England.
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In all experiments male Wistar albino 
rats were used. These were C.F.H.B. Bath University 
strain. Rats for perfusion were normally allowed to 
grow up to 450g. Rats for isolated heart experiments 
weighed between 200g and 250g. All animals were kept 
in cages of no more than six and were fed on normal 
laboratory chow. Prior to all experiments the animals 
were allowed free access to food and water.
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4) APPARATUS USED FOR LIVER PERFUSION
All liver perfusion experiments were 
carried out in a perfusion cabinet. This consisted of 
a metal frame eighteen inches wide, thirty inches long 
and thirty six inches high. Attached to the back and 
sides of the cabinet were sheets of plywood 1cm thick. 
These were covered on both sides with Benchkote, 
(Whatman, Maidstone,England), to facilitate cleaning. 
The top of the cabinet consisted of three perspex 
sheets placed side by side, which were easily remov­
able and allowed manipulation within the cabinet. The 
front of the perfusion cabinet was divided into three 
horizontal sections. Each of these sections could be 
accessed during the experiment using one of three 
perspex doors attached to the metal frame of the 
cabinet. These were hinged on their lower surface 
and when opened were supported by chains on each side. 
In the closed position they were held in place by 
clips on the side of the cabinet. This facility 
allowed manipulation within the cabinet with minimum 
heat loss and disturbance.
The cabinet was thermostatically 
controlled at 37°C + 2°C. This was achieved by a
combination of four electric lamps. Two 100W lamps 
were attached to the back of the lower section of the
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cabinet. These were continuously on during perfusion 
experiments but could be adjusted by a potentiometer 
placed on the outside of the cabinet. A further two 
100W lamps were placed in the right upper section 
where the perfused rat was placed. These provided 
a finer control of temperature within this area of 
the cabinet and also a good light source for surgery. 
These two lights were automatically controlled by a 
platinum resistance temperature controller, (R.S. 
components, Northants, England), linked to a platinum 
thermocouple (R.S. components, Northants, England). 
This system was calibrated using a 50 uA - 0 - 50 uA 
voltmeter, (R.S. components, Northants, England).
The temperature controller and the voltmeter were 
housed in a box attached to the outside of the 
cabinet. This system was sufficiently accurate to 
provide overall cabinet temperature control of +2°C 
and finer control of +1.5°C around the rat. The 
floor on the right hand side of the top section of the 
perfusion cabinet consisted of a perspex sheet which 
was used to support the operating board. To the left 
of the cabinet's top and middle sections an internal 
metal frame was built which supported three water 
jacket heaters, two mercury manometers and two 
pressure transducers. Also supported by this frame and
54
extending in to the right middle section of the 
cabinet were two oxygenators. The floor of the left 
middle section consisted of a sheet of perspex and 
supported two magnetic stirrers. The floor in the 
lower section of the cabinet consisted of two sections 
of plywood covered with Benchkote, (Whatman, Maidstone, 
England). Placed on this floor was an electric fan 
and a water heater. The fan was kept permanently 
running throughout the perfusion experiments. The 
heater was a Gallenkamp Thermostirrer 85 (Gallenkamp, 
Loughborough, England) and was used to heat water for 
the jacket heaters. The Thermostirrer was placed in 
a 3 litre plastic beaker and was set at 37°C.
Supplies of perfusion medium to the 
hepatic artery and the portal vein were entirely 
separate each having its own pump, oxygenator, heater 
and bubble trap. The perfusion medium was kept in 
glass beakers. Usually only one reservoir was needed 
but where experiments required separate reservoirs 
two beakers were used each having its own magnetic 
stirrer. Medium from the reservoirs was sucked up 
by peristaltic pumps, (Wastson-Marlow, Falmouth, 
England) these were situated outside the cabinet and 
were preset to deliver the correct flow to each 
supply. Total flow rate to the liver was always kept
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at a constant 10 ml/min, however, the ratio of 
hepatic artery to portal venous flow was varied.
Where one supply exceeded 5 ml/min the medium in 
that supply passed through a jacket heater immediately 
after leaving the reservoir. This ensured sufficient 
warming of the medium at the higher flow rates.
The medium for both the hepatic artery 
and portal vein supplies then passed into oxygenators. 
These consisted of two 500 ml round bottomed flasks 
each of which contained 25 feet of medical grade 
silastic tubing, (Dow Corning, U.K.). The flasks 
contained a mixture of 95% Oxygen and 5% Carbon 
Dioxide at a pressure of 50mmHg. The gas was supplied 
at a rate of 100 ml/sec (measured at atmospheric 
pressure), by a cylinder outside the cabinet. The 
oxygenator was sealed by a rubber bung placed in the 
top of the flask; a vent in the bung controlled the 
gas outflow. A further three holes in the bung were 
made, one for the gas input and the others to allow 
the tubing carrying the perfusion medium to pass in and 
out of the oxygenator. Silastic tubing is porous to 
oxygen therefore fluid flowing within the tubing in an 
oxygen rich environment becomes highly oxygenated. The 
system has advantages over gas bubbling oxygenators 
when the perfusion medium contains red blood cells,
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as it greatly reduces haemolysis due to turbulance.
After passing through the oxygenators 
the medium in each supply passed out of the cabinet, 
through an external pump and returned to pass through 
a water jacket heater situated inside the cabinet. The 
perfusion medium passed into a bubble trap. This cons­
isted of a 2 ml syringe from which the plunger had 
been removed and the rubber end of the plunger sealed 
into the top of the syringe. Inserted through this 
rubber seal were two 15 gauge Luer stub adapters. The 
seals were made airtight and a further connector was 
attached to the nozzle of each bubble trap. The traps 
were positioned at 45° to the vertical with the 
nozzle pointing downwards; in this position they were 
found to remove all air bubbles from the medium. One 
of the top Luer adapters formed the input and the 
nozzle end adapter the output. The third adapter was 
connected to the pressure control and measurement 
apparatus.
The pressure within each trap could be 
controlled using a bulb with an air flow valve. This 
system was used to ensure that the level of fluid in 
each bubble trap was sufficient to prevent air passing 
in to the outlet. Connected to this pressure control 
system was a mercury manometer which was used to give
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quick visual readings of the pressure within the 
supply. Pressure in each supply was also monitored 
using a Bell Howell type 4-422-0001 pressure trans­
ducer , (Bell Howell, Basingstoke, England). The two 
transducers (one for each supply), were in turn conn­
ected to a Devices M2P Amplifier fitted with two DC.2D 
and two .1C modules (Devices, Hertfordshire, England). 
This amplifier was connected to a Devices M2R duel 
channel recorder fitted with a DC.5 and a DC5H module, 
(Devices, Hertfordshire, England). This system allowed 
the measurement of the small pressure changes seen in 
the portal vein and the larger pressure changes seen 
in the hepatic artery. The dual recorder provided a 
permanent record of the perfusion pressures in each 
supply throughout the experiment.
In experiments where no vasoactive 
agents were to be infused, output from the bubble 
traps was connected directly to the artery or the 
portal vein cannulae. However, for experiments where 
vasoactive agents were to be used, an infusion port 
was placed between the bubble trap and the hepatic 
artery and portal vein cannulae. This port consisted 
of a modified plastic three way connector with a self 
sealing rubber membrane secured over one of the inputs. 
The two other branches provided the input and output
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connections for the perfusion medium. Vasoactive 
substances could be introduced into the supply via 
this port either by injection or by slow infusion. The 
slow infusion apparatus employed consisted of a 
slow infusion pump, (Scientific Research Instruments 
No. 5200, Kent, England.), to which 5 ml syringes 
were attached. These were connected to a 24 gauge 
needle unit from a 24 gauge catheter placement unit, 
(Quickcath, Dupont Travenol Laboratories, Ireland).
The needle unit was forced into a length of non- 
sterile portex nylon tubing X diameter (800/110/140/ 
100, Portex, Kent, England). The other end of this 
tubing was connected to a fine hollow needle which was 
used to puncture the rubber membrane placed over one 
branch of the three way connector. This, allowed 
agents to mix with the perfusion medium of each 
supply.
Figure 2.4.1. A Photograph to Show the Apparatus Used for Isolated Liver Perfusion in Situ
Figure 2.4.2. A Diagram to Show the Apparatus Used for Isolated Liver Perfusion in Situ.
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5) PREPARATION OF THE PERFUSION MEDIUM
The perfusion medium consisted of red 
blood cells suspended in Krebs buffer, (Appendix 1). 
The pH of the medium was adjusted, where necessary, 
to pH 7.4 using 0.1 M hydrochloric acid or 0.1 M 
potassium hydroxide. The cells were out-dated human 
red blood cells and obtained from the Area Blood 
Transfusion Centre in Bristol. These cells deterior­
ated rapidly even when refrigerated and were always 
used within one week of delivery.
The cells were washed with Krebs buffer 
prior to being perfused. This process involved mixing 
10 ml of cells with 20 ml of Krebs buffer in 30 ml 
glass centrifuge tubes, inverting the tubes gently 
then centrifuging for ten minutes at 2000g in an IEC 
Centra-7 centrifuge, (Damon, Bedford UK). The super­
natant was then removed and the process repeated until 
the supernatant resembled the clarity of the Krebs 
buffer. The first three washes used Krebs buffer con­
taining heparin, 100 units per ml, added to prevent 
clotting. The cells were normally washed at least six 
times and all the subsequent washing was carried out 
with heparin free Krebs buffer.
The packed washed red blood cells 
were then added to the perfusion medium of Krebs
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buffer to give a final haemoglobin concentration of 
5 to 6 g/lOOml, as measured by a commercial test kit, 
(Sigma, Dorset, England). The perfusion medium was 
found to be sensitive to storage, even if refrigerated 
(4°C) and was freshly prepared for each perfusion.
In experiments in which lignocaine and 
its metabolites were investigated under changing flow 
conditions the substances were added directly to this 
medium. However, for experiments to study the effects 
of vasoactive substances, the agents were infused in 
to the perfusion medium through an infusion port as 
already described.
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6 ) OPERATIVE PROCEDPRES.
For the perfusion experiments male 
albino wistar rats, Bath University (CFHB) strain, 
weighing between 400-450g were used. The animals were 
allowed free access to water and food prior to the 
experiment. They were anaesthetised with 6% penta- 
barbitone (Sagatal, May and Baker, Dagenham England) 
70mg/kg given intraperitoneally. This resulted in full 
surgical anaesthesia with loss of corneal reflex.
After this had been achieved the rat was transferred 
to a 14 inches by 14 inches perspex operating board. 
This allowed the initial procedures to be carried out 
on the bench and transferal of the animal to the cab­
inet for the final cannulations. The time that the 
liver was deprived of a blood supply could be kept to 
a minimum if the final operative procedures were per­
formed within the the perfusion cabinet.
After positioning the animal dorsal side 
down on the operating board, a midline incision was 
made in the skin from the lower abdomen to the neck 
region. The abdominal contents were exposed by a fur­
ther incision made along the linea alba to the xiphoid 
process. The major abdominal vessels were clamped off 
near the xiphoid process to reduce bleeding. Two mid- 
transverse incisions in the body wall to the right and
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left of the midline were made just below the diaphragm 
and below the clamps. A further two mid-transverse 
incisions in the body wall to the right and left were 
made at a level below the kidneys. The two tissue 
flaps were then folded back.
The abdominal contents were gently dis­
placed to the animals left hand side to expose the 
major vessels of the abdomen. At this point, in init­
ial experiments, a P10 cannula (Portex, Kent, England) 
was placed in the bile duct. However, it was found 
that the production of bile during perfusion exper­
iments was extremely small and insufficient for 
analysis. In subsequent preparations the bile duct 
was ligatured.
The thin strands of the hepato-renal 
ligament were cut exposing the vena cava above the 
right renal vein. A loose ligature was then placed 
around the vena cava at this point. The connective 
tissue surrounding the portal vein was cleared and two 
loose ligatures placed around the vessel, one a few 
millimeters below its entry into the liver and the 
other above the convergence of the splenic and gastric 
veins.
The aorta was then located and the path 
of the coeliac artery cleared. The gastric arteries,
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gastroduodenal artery and lineal artery were all iso­
lated and ligatured. At this point all blood passing 
along the coeliac artery now flowed into the liver by 
the hepatic artery. Two loose ligatures were placed 
around the coeliac artery, one as close as possible to 
its divergence from the aorta, the other a few milli­
meters below its divergence into the left and right 
hepatic arteries. Using a curved, fine Spencer Wells 
artery clamp, the artery was clamped just above the 
lower ligature. The artery could then be straightened 
by manoeuvring the clamp, facilitating cannulation of 
the vessel. A cannula was then placed in the artery 
above the clamp using a 24 gauge catheter placement 
unit (Quick Cath, Dupont Travenol Labs, Ireland). This 
was tied in place using the upper loose ligature.
Blood was allowed to flow back along the cannula and 
then 1 ml of Krebs buffer containing 1000 units of 
heparin was injected into the cannula to prevent any 
clots forming and to ensure the viability of the cann­
ula. The second loose ligature was then tied off, the 
clamp removed and a bung placed in the cannula to pre­
vent blood loss.
At this point the rat was transferred to 
the cabinet. Both perfusion pumps were switched on and 
the medium from the outflow allowed to drip into a
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beaker. This ensured that no air bubbles would be pre­
sent in the tubing when the two supplies were conn­
ected. A cannula was then placed in the portal vein 
between the two loose ligatures, using a 20 gauge 
catheter placement unit, (Quick Cath, Dupont Travenol 
Labs, Ireland). This was tied in place using the upper 
loose ligature. The lower ligature was tied to prevent 
bleeding from the portal vein.
The liver was now devoid of any blood 
supply and it was essential to perform the next step 
within one or two minutes. This involved opening the 
chest cavity with two incisions through the rib cage 
and clamping the flap back after freeing it from the 
diaphragm. The vena cava was then cleared from conn­
ective tissue and separated from the vagus nerve. Two 
loose ligatures were placed around the vessel and the 
one nearer the heart tied off. A 14 gauge catheter 
placement unit, (Venflow Viggo, Helsingborg, Sweden) 
was then used to cannulate the inferior vena cava.
This was tied in position using the other loose lig­
ature .
The two supplies were immediately conn­
ected to the portal vein and hepatic artery cannulae 
and an output connected to the vena cava. The loose 
ligature which had been placed around the posterior
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vena cava above the right renal vein was tied off so 
that all liver output was directed out of the inferior 
vena cava cannula. If the proceedure had been sucess- 
ful after approximately one minute of perfusion the 
liver should become an even pink colour. If any dark 
blue blotches of anoxic tissue were seen the prepara­
tion was discarded. Also, any livers which showed a 
high initial pressure after five minutes, that is 
greater than 130 mmHg in the artery or 30 mmHg in 
the portal vein, were discarded* If these two criteria 
were normal then the flaps of tissue were replaced to 
their normal position as far as possible and the liver 
covered with a piece of cotton gauze soaked in the 
perfusion medium to prevent drying out. The prepar­
ation was then left running for 20 minutes to equili­
brate and permit flow and pressure readings to be 
taken.
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7) ANALYSIS OF LIGNOCAINE AND ITS METABOLITES FROM 
PERFUSION EXPERIMENTS*
(a) Collection and treatment of samples.
Samples were collected from the vena 
cava output cannula. A piece of tubing passed outside 
the cabinet to allow collection of samples with the 
minimum of disturbance to the internal environment of 
the cabinet. Perfusate was collected directly into a 
measuring cylinder to allow measurement of flow rate. 
Samples from this were then decanted into 15 ml centi- 
fuge tubes and spun at 2000g (IEC Centra-7, Damon, Bed­
ford, UK). The supernatant was transferred into glass 
vials and frozen at -20°C or analysed that day. It 
was found that the samples were stable for two weeks 
when frozen, but analysis was usually performed within 
four days of storage. In order to calculate extraction 
ratios, liver input samples were also taken. These 
were obtained after completion of the perfusion exper­
iments. The two supplies were allowed to drip into a 
beaker and the sample obtained was then treated in the 
manner as effluent perfusate samples. These liver 
input samples were also used as controls in the 
analysis of metabolite concentrations.
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(b)High Performance Liquid Chromatography 
(HPLC) Apparatus.
Lignocaine and its metabolites were all 
measured using HPLC. The same apparatus being used for 
each assay although different mobile phases were used. 
The apparatus consisted of a 7125 type Rheodyne injec­
tion port fitted with a 100 ul injection loop 
(Rheodyne, California, USA), a Constametric III pump 
(LDC Instruments, Florida, USA), a block heater (Jones 
Chromatography, Glamorgan, Wales), a Spectromonitor 
III ultraviolet detection system (LDC Instruments, 
Florida, USA) and a CR650S recorder (JJ Instruments, 
Southampton). The separating column consisted a 25 cm, 
5 urn hypersil ODS reversed phase analytical column 
fitted to a 5 cm, 5 urn hypersil ODS reversed phase 
precolumn (both from Jones Chromatography, Glamorgan, 
Wales). The main column was kept at 25°C using the 
block heater, the precolumn was not temperature con­
trolled. All high pressure tubing and joints were 
stainless steel, all other connections were made with 
PTFE tubing resistant to solvent attack.
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(c) Analysis of Lignocaine.
5 ml aliquots of perfusate supernatant 
were used to measure both liver input and output 
lignocaine concentrations. Treatment with sulphatase 
(S 3009, Sigma, Dorset, England) and Glucurase (G 4882 
Sigma, Dorset, England) at pH 5 for 16 hours, had no 
effects on both input or output lignocaine concentrat­
ions. This revealed that no sulphate or glucuronide 
of lignocaine were formed. In subsequent lignocaine 
measurements no deconjugation step was necessary.
To each 5 ml aliquot lignocaine sample, 60 ul of 250 
ug/ml bupivicaine hydrochloride solution was added as 
an internal standard. These solutions were then adjust­
ed to pH 11 using 1M hydrochloric acid and 1M potass­
ium hydroxide. 5 ml of diethyl ether was then added to 
each sample. The solutions were mixed on a rotary 
mixer, (Luckman Ltd., Sussex, England) for 20 minutes 
at 1 cycle per second. The tubes were then centrifuged 
for 5 minutes at 2000g (IEC Centra-7, Damon, Bedford, 
UK) to separate the mixture into two layers. The 
diethyl ether layer was removed from each sample using 
a Pasteur pippette and placed in a clean tube. These 
tubes were then placed in a water bath set at 40°C 
and the solvent evaporated using compressed air jets. 
The extraction process was repeated on each sample to
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ensure good recovery. Approximately 90% of the ligno­
caine could be extracted from the sample by this 
method.
The extracted dry samples were then 
mixed with 150 ul mobile phase after the sample had 
dissolved 100 ul of the solution was injected on 
to the column using a Hamilton syringe (Anachem,
Luton, England). For lignocaine analysis the mobile 
phase consisted of 40% methanol, 30% acetonitrile,
30% 0.05M potassium dihydrogen orthophosphate buffer. 
The mobile phase was adjusted to pH 6.90 using 1M 
hydrochloric acid or 1M potassium hydroxide. The 
mobile phase was degassed by bubbling helium through 
the mixture for 10 minutes. The mobile phase was pass­
ed through the column at a flow rate of 1.50 ml/min.
A slight adjustment was made to this 
method for samples which contained phentolamine as 
well as lignocaine. The phentolamine was found to 
interfere with the lignocaine peak and a mobile phase 
of 30% acetonitrile, 30% methanol and 40% 0.05M 
potassium dihydrogen orthophosphate buffer pH 6.9 was 
used under the sample conditions as described above.
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(d) Analysis of metabolites.
The concentrations of metabolites were 
determined using the same HPLC apparatus as that used 
in the lignocaine assay. Four metabolites and an int- 
nal standard were measured in the same assay. The met­
abolites were 3-hydroxylignocaine, (3-OH LIG), 3-hydr- 
oxymonoethylglycine xylidide, (3-OH MEGX), monoethyl- 
glycine xylidide, (MEGX) and glycine xylidide, (GX); 
the internal standard being desbutyl-bupivicaine. 
Conjugated metabolite concentrations were determined 
after selective enzyme deconjugation. The various 
treatments used yielded the free forms of the metabol­
ites which could be measured using the same HPLC 
assay.
5.2 ml aliquots of perfusate supernatant 
were taken, three from each sample. One aliquot under­
went treatment to deconjugate both sulphate and 
glucuronide conjugates prior to analysis by HPLC. The 
process involved adjusting the solution to pH 5 using 
1M hydrochloric acid or 1M potassium hydroxide and 
adding 50 ul of Glucurase, (G 4882, Sigma, Dorset, 
England) and 50 ul Sulphatase solution (S 3009, Sigma, 
Dorset, England). The solution was allowed to incubate 
at 37°C in a shaking water bath for 16 hours.
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To determine metabolite sulphate conc­
entrations, a second 5.2 ml aliquot was adjusted to 
pH 5 but only sulphatase was added as described above. 
To inhibit any glucurase activity in the solution, 200 
ul of 0.2M D-saccharic acid 1,4 lactone (Sigma, Dor­
set, England) was added. This concentration was found 
to inhibit almost all glucurase activity but would 
allow sulphatases to work. The second solution was 
also incubated at 37°C in a shaking water bath for 
16 hours.
A third aliquot of 5.2 ml was taken and 
adjusted to pH 5 and incubated at 37°C for 16 hours 
without any deconjugating enzymes present to determine 
the levels of unconjugated or free metabolites in the 
perfusate. The system of selective deconjugation res­
ults in free metabolites which can be measured by the 
same HPLC method. Using this assay sulphate metabol­
ites are determined from the concentrations seen after 
sulphate deconjugation minus the unconjugated metab­
olites. Glucuronide conjugates are determined from the 
metabolite levels seen after both glucuronide and 
sulphate deconjugation minus the levels after sulphate 
deconjugation.
After selective enzyme treatment all 
samples were treated by the same extraction method.
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The samples were first spun down at 2000g (IEC Centra 
7, Damon, Bedford, UK) for 10 minutes. 5 ml of the 
supernatant was then removed and placed in a separate 
tube to which 50 ul of a 250 ug/ml solution of des- 
butyl-bupivicaine was added as an internal standard. 
The solutions were adjusted to pH 11 using 1M potass­
ium hydroxide. 5 ml of dichloromethane was then added 
to each tube. The tubes were stoppered with teflon 
coated screw caps and mixed in a rotary mixer (Luckman 
Ltd, Sussex) at 1 cycle per second for 20 minutes. The 
samples were then centrifuged at 2000g (IEC Centra-7, 
Damon, Bedford, UK) for 5 minutes. Often in this 
process the dichloromethane layer became white and 
gelatinous. It was found that by repeated shaking and 
centrifugation a clear liquid layer of dichloromethane 
could be obtained. As the dichloromethane is denser 
than water it forms a layer in the bottom of the 
tube. It was removed using long Pasteur pippettes and 
was passed through a type 1 paper filter (Whatman, 
Maidstone, England) which had been soaked in dichloro­
methane. This removed any particulate matter sucked up 
with the solvent. The dichloromethane was filtered 
into fresh tubes which were transferred to a water 
bath at 45°C. The solvent was evaporated using jets 
of compressed air. The extraction process was repeated
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for each sample to ensure good extraction of the 
chemicals. After extraction the dry samples were mixed 
with 150 ul of mobile phase and 100 ul injected onto 
the column using a Hamilton syringe, (Anachem, Luton, 
England). It was found that all four metabolites and 
the internal standard could be separated using a 
mobile phase of 14% acetonitrile and 86% 0.05M potas­
sium dihydrogen orthophosphate buffer. The mobile 
phase was adjusted to pH 6.0 using 1M hydrochloric 
acid or 1M potassium hydroxide. The mobile phase was 
degassed by bubbling helium through the liquid for 
10 minutes. The initial flow rate used in the assay 
was 1.5 ml/min, with an increase to 2 ml/min 7 
minutes after sample injection.
(e) Calculation of lignocaine and metabolite 
concentrations in perfusate.
Calculation of concentrations of the var­
ious chemicals were made from the ratio of the peak 
height of the compound against the peak height of the 
internal standard. These ratios were then compared with 
standard curves of peak height ratios against concen­
tration. In order to produce these standard curves 
solutions of lignocaine, each metabolite and internal 
standards of known concentration were made using
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standard compounds. Lignocaine was obtained from 
The pharmaceutical Manufacturing Company, (Epsom, 
Surrey, England). The metabolites, 3-hydroxylignocaine 
(3-OH LIG), 3-hydroxymonoethylglycine xylidide, (3-OH 
MEGX), monoethylglycine xylidide, (MEGX) and glycine 
xylidide, (all as hydrochlorides), were gifts from 
Astra, UK. Bupivicaine hydrochloride, (Marcain Plain) 
was obtained from Duncan Flockhart, (Middlesex, UK) 
and desbutyl-bupivicaine from A. B. Borfors, (Borfors, 
Sweden).
To obtain standard peak height ratio vs. 
concentration curves, known concentrations of these 
solutions were independently made up in Krebs buffer 
to a final volume of 5.2 ml. To these solutions 1 ml 
of washed packed red blood cells was added as prepared 
by the method previously described. These samples were 
incubated at 37°C for 1 hour in a shaking water 
bath. On removal they were spun at 2000g (IEC Centra- 
7, Damon, Bedford, UK) and 5 ml samples of supernatant 
removed. To lignocaine metabolite solutions 50 ul of 
250 mg/ml solution of desbutyl-bupivicaine was added 
as an internal standard. To solutions of ligocaine 
60 ul of bupivicaine was added as an internal stand­
ard the relevant extraction procedure was then 
performed on the sample to prepare it for HPLC anal-
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ysis. Both the extraction procedure and the analysis 
were exactly the same as described previously for 
perfusate samples. From the ratios of peak height of 
known standard against internal standard, graphs were 
drawn of peak height ratio against free base concen­
tration in ng/ml, (Figs. 2.7.5; 2.7.6; 2.7.7; 2.7.8). 
In all cases these showed a high degree of linear 
correlation (>0.99).
Two standard curves were constructed for 
lignocaine solutions. A high range (Fig. 2.5.3) so 
that lignocaine input concentrations could be determ­
ined and a low range (Fig. 2.5.4) so that low liver 
output levels could be calculated. In experiments 
where input concentrations of metabolites were infused 
in similar molar concentrations to those used with 
lignocaine, the concentration range of the existing 
standard curves was extended to enable input concentr­
ations to be calculated. These higher metabolite conc­
entrations closely followed the linearity of the 
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(a) Lignocaine extraction ratio and 
metabolism during changes in the 
hepatic artery to portal vein flow.
These experiments were carried out on 
male Wistar rats (University of Bath CFHB strain). 
Perfusion of the liver set up as a described in 
sections 4, 5 and 6. During these experiments total 
liver blood flow remained at 10 ml/min. To examine the 
effect of changes in the HA:PV flow ratio on the 
extraction ratio of lignocaine, hepatic artery flow 
contributions of 7.5, 5, 2.5, 1 and 0 ml/min were 
used with the corresponding portal vein flow rate to 
keep total liver blood flow at 10 ml/min. Due to prob­
lems with high perfusion pressures encountered at art­
erial flow rates greater than 5 ml/min, the effect of 
changes in the HA:PV flow ratio on metabolism were 
only assessed at arterial flow rates of 5, 2.5 and 
0 ml/min.
Lignocaine was added to the perfusion 
medium reservoir to give a final concentration of 
4 ug/ml. Each rat liver was perfused for 60 minutes 
with liver output samples being collected 0-10, 10-20, 
20-30, 30-45 and 45-60 minutes after perfusion equil­
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ibrium had been reached. A record of the volume of the 
perfusate output during each time period was made to 
ensure that no leaks were occurring in the preparation. 
Lignocaine and its metabolite concentrations in both 
liver input and output perfusion medium were determ­
ined using the HPLC methods outlined in section 7.
(b) Changes in HA:PV flow ratio on further 
metabolism of lignocaine metabolites.
This series of experiments was again 
performed on the rat liver preparation as described in 
sections 4, 5 and 6. HA:PV flow ratios of 5:5 ml/min 
and 0:10 ml/min were used. All four metabolites were 
infused into the liver in concentrations equimolar to 
4 ug/ml lignocaine infusions. Rat livers were init­
ially perfused at a HA:PV flow ratio of 5:5 ml/min.
Two perfusate samples, 0-10 and 10-20 minute, were 
taken. The hepatic artery was then clamped and the 
portal vein flow increased to 10 ml/min. After a ten 
minute period two consecutive ten minute perfusate 
samples were taken, giving two perfusate samples for 
each flow ratio taken over a period of twenty minutes. 
Metabolite concentrations in both perfusion input and 
outputs were measured using the HPLC methods described 
in section 7.
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(c) Administration of vasoactive agents 
on the liver vasculature.
These experiments were carried out on 
the rat liver preparation as described in sections 4,
5 and 6. An HA:PV flow ratio of 2.5:7.5 ml/min was 
used in all experiments. Initial experiments had shown 
that single injections of potential vasoactive agents 
into either the portal vein or hepatic artery supply 
were ineffective at eliciting any changes in perfusion 
pressure. Thus a slow infusion pump apparatus as desc­
ribed in section 4 was employed to administer contin­
uous doses of vasoactive agents. The experiments 
concentrated on measuring adrenoreceptor populations 
and the foiling protocols were used to measure a and 
ft -adrenoreceptors within the liver vasculature:-
(i) ol -adrenoreceptors.
For these experiments it was found that 
adrenaline and noradrenaline produced vasoconstriction 
as measured by an increase in perfusion pressure in 
both the hepatic artery and portal vein, (figures, 
2.8.1 and 2.8.2). The increase in pressure in both 
vessels was dose related and gave sigmoidal log dose 
response curves. The sigmoidal nature of the log dose
Figure 2.8.1. An Example of Pressure Readings in the Hepatic Artery and Portal Vein During




















L E C T R O M E D  S 2 2 5 0 -I4 -3
Figure 2.8.2. An Example of Pressure Readings in the Hepatic Artery and Portal Vein During 




A£ 1 2 0 - Q_
3 [. 5^  10 7 M k i o L  IIDO£E 2. 5x
i:' ' ’ LU '
L E C T R O M E D  S 2250-14-3
88
response curves for adrenaline and noradrenaline 
allowed the calculation of a ED50% for each curve. 
The ED50% being defined as the dose of adrenaline 
or noradrenaline required to produce 50% of the max­
imum increase in pressure. As both adrenaline and 
noradrenaline infusions produced increases in perfus­
ion pressure in each vessel they may be regarded as 
vasoconstrictors of the liver vasculature. In order 
to assess the effect of a-adrenoreceptor antagonists 
on pressure increases due to adrenaline or noradrenal­
ine infusions, a dose response curve to the vasoconst- 
ictor, (adrenaline or noradrenaline) was first constr­
ucted. Either adrenaline or noradrenaline being tested 
in the hepatic artery or the portal vein. After a 
return to base line pressure in the test vessel an 
a -adrenoreceptor antagonist was infused into the 
vessel and a second dose response curve for the 
vasoconstrictor was contructed. Any change in the 
' ED50% of this second curve as compared to the 
the first would reflect the degree of antagonism by 
the a -adrenoreceptor antagonist.
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figure 2.8.3

















It proved impossible to show any direct 
dilatory jft-adrenoreceptor response as shown by a dec­
rease in perfusion pressure in the hepatic artery or 
vein during infusion of $ agonists into the vessels.
In order for dilatory effects to be seen, tone had to 
be induced in the vessels of the liver. This could be 
achieved using infusions of adrenaline or noradrenaline 
but a constant tone could not be maintained with these
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agents. Variations in ion concentration of the media 
could also induce tone but tended to lead to haemol­
ysis of the red blood cells. As an alternative method, 
adrenaline or noradrenaline dose response curves were 
produced in the test vessel. A f t adrenoreceptor agon­
ist was then infused . A second adrenaline or noradre­
naline dose response curve was then produced during 
!3 agonist infusion. Any changes in log ED50% between 
these two curves could be used as an indirect meas­
ure of j3 -adrenoreceptor mediated dilation.
Figure 2.8.4














To ensure that any changes in log ED50% 
of adrenaline or noradrenaline, seen during jg-adren­
oreceptor agonist infusion, were due to jg agonism and 
not a-adrenoreceptor antagonism, jg -adrenoreceptor 
blocking drugs were used to test the specificity of 
any jg-adrenoreceptor mediated response. jg blockers 
also allowed the classification of the jg-adrenorecep- 
tors in to jg^ and subtypes. jg-adrenoreceptor
activity was measured by the shift in log ED50% of 
adrenaline or noradrenaline as outlined in section
(ii). After a five minute rest from vasoactive stim­
ulation the test vessel was perfused with a jg-adren- 
oreceptor blocking drug by slow infusion into the 
perfusion medium. After a 5 minute period of jg blocker 
perfusion, a jg-adrenoreceptor agonist was co-infused 
with the jg blocker. A third adrenaline or noradrenaline 
dose response curve was then produced during combined 
jg blocker and agonist infusion. Any shift of log ED50% 
in this third constrictor from that obtained in the 
absence of jS -adrenoreceptor blockade was taken as a 
measure of jg -adrenoreceptor blockade. This rather 
complex method was used to test the specificity of 
j8-adrenoreceptor dilation and to characterise the 
13 -adrenoreceptor population in the liver vasculature.
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Figure 2.8,5
A Diagram of the Protocol used to Measure 
_l2. 2. an  ^B  2 -adrenoreceptor Activity.
noradrenaline noradrenaline noradrenaline
or or or











(iv) Portal vein - Hepatic artery vasculature 
interactions.
It was noted that in isolated rat liver 
perfusions, hepatic artery infusions of adrenaline and 
noradrenaline only occasionally produced increases in 
portal vein perfusion pressure. However, portal vein 
infusions of adrenaline or noradrenaline did produce a 
dose dependent increase in hepatic artery perfusion 
pressure. To investigate this interaction isolated rat
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livers were perfused at an HA:PV ratio of 2.5:7.5 ml 
per minute using the standard procedures outlined 
previously. The following protocol was then used:-
1) Standard log dose response curves for 
noradrenaline were obtained in both the hepatic artery 
and the portal vein. A third standard log dose respo­
nse curve was obtained for increases in hepatic artery 
perfusion pressure during portal vein infusions of 
noradrenaline.
2) 1 x 10~6M phentolamine was then infused 
into the portal vein and all three log dose response 
curves re-established.
3) Portal vein phentolamine was then removed 
and selected doses of noradrenaline were used to test 
when the effects of the phentolamine had disappeared.
4) 1 x 10”^M phentolamine was then infused 
into the hepatic artery and all three log dose resp­
onse curves re-established.
(d) Perfusion pressure and lignocaine 
metabolism.
These experiments were again carried out 
on perfused rat livers prepared as described in sect­
ions 4, 5 and 6. The perfusion medium contained ligno­
caine at a concentration of 4 ug/ml and the hepatic
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artery portal vein flow ratio during the perfusion was 
2.5:7.5 ml/min. After an initial twenty minute equili­
bration period the output perfusate was collected for a 
period of five minutes. This sample was used to test 
the extraction ratio and metabolism of lignocaine under 
normal pressure conditions. Adrenaline and noradrena­
line were used as vasoconstrictors in order to raise 
the perfusion pressure these experiments. After the 
initial output sample had been taken, dose response 
curves were obtained for either constrictor, (adr­
enaline or noradrenaline), in both the hepatic artery 
and the portal vein. A dose of constrictor giving a 
70% to 80% maximal increase in pressure was chosen 
for both the hepatic artery (HA dose) and the portal 
vein (PV dose). The liver was then allowed a 
five minute recovery period before the following 
schedule was carried out:-
(i) The artery was infused with HA dose of 
the constrictor. When a constant increased pressure 
was attained the liver was perfused for a further 
three minutes before a five minute perfusate sample 
was taken.
(ii) The infusion of the constrictor was 
stopped and the arterial pressure allowed to return to 
normal.
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(iii) Five minutes after baseline pressure 
had been attained and maintained, 5 x 10~^M phentol­
amine was infused into the hepatic artery supply.
Three minutes after the start of phentolamine infus­
ion a five minute perfusate sample was taken.
(iii) The hepatic artery was then co-admin- 
istered with phentolamine and HA 30Se of constrictor.
No pressure increase was seen in any experiment as the 
phentolamine blocked vasoconstriction. After three 
minutes of co-administration, another five minute 
output sample was taken.
(iv) Constrictor and phentolamine infusions 
were removed and a five minute recovery period allowed.
(v) PV ^Qgg of the constrictor was infused 
into the portal vein. After a constant increased 
portal vein pressure had been attained the liver was 
perfused for a further three minutes before a five 
minute perfusate sample was taken.
(vi) The constrictor infusion was removed 
and after portal pressure had returned to normal a
five minute recovery period was allowed.
-5(vii) 1 x 10 M phentolamine was infused 
into the portal vein and after three minutes a five 
minute perfusate sample was taken.
(viii) The portal vein was then co-infused
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with both PV c|0se of the constrictor and phentolamine 
after a three minute perfusion period a final five 
minute perfusate sample was taken.
(ix) Samples were then measured for ligno- 
caine and metabolite concentrations by the HPLC 
methods in section 7.
(e) Effect of hydralazine on systolic 
blood pressure.
Male Wistar rats weighing 400-450g were 
used and their systolic blood pressure measured by 
tail artery measurements. The apparatus used consisted 
of a tail pressure pneumatic pulse transducer (Narco, 
Texas, USA). A type CR 650S JJ recorder, (JJ instr­
uments, Southampton), was used to record the traces. 
The rats were restrained in a rat restrainer with a 
Mark IV temperature controller, (Narco, Texas, USA), 
set at 37°C.
Rats were first acclimatised to the res­
trainer and after they had given three consecutively 
normal (approximately 120 mmHg) pressure readings they 
were used experimentally. To measure blood pressure in 
this system rats were placed in the restrainer and the 
cuff placed over the tail approximately three quarters 
of the way from the tip. The pulse transducer was then
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attached over a tail artery with Sellotape so that a 
pulse could be seen on the recorder. The recorder 
trace measured the pressure inside the cuff and super­
imposed the pulses on this trace. The cuff was then 
inflated and automatically deflated. As the cuff 
pressure increased so the height of the pen above 
baseline on the recorder also increased. The height at 
which a pulse was lost represented the pressure at 
which internal cuff pressure equaled arterial blood 
pressure. On deflation, the height of the trace at where 
the pulse was regained also represented arterial blood 
pressure. The average of these two heights gives an 
accurate average systolic pressure measurement.
To test the effect of hydralazine on 
systolic blood pressure, two groups of animals were 
used. One group was given an oral dose of water at 
time zero and represented a control group. The 
second group was given hydralazine hydrochloride,
1 mg/kg, in water at time zero. The blood pressures 
of both groups were measured at 15, 30, 45, 60, 90,
120, 180 minutes after dosing.
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(f) Lignocaine clearance after hydralazine 
treatment.
Male wistar rats, Bath University CFHB 
strain, weighing between 400-450g were used in these 
experiments. Rats were divided into four groups; two 
control and two experimental. Control groups received 
water orally, and the other two groups received 
hydralazine hydrochloride, 1 mg/kg, dissolved in water, 
orally. The animals were then left for 40 minutes in 
which time they had free access to water and food.
To one control group and to one experi­
mental group, lignocaine hydrochloride, 20 mg/kg, in 
water, was given orally. To the second control and 
experimental group, lignocaine hydrochloride, 2.5 
mg/kg, was given as an I.V. bolus injection. The lig­
nocaine was dissolved in isotonic saline and given by 
tail vein injection.
At 5, 10, 15, 20, 30, 45, 60, 90, 120 
and 180 minutes after injection blood samples were 
taken by cardiac puncture under light anaesthesia.
One blood sample per rat was taken; then the animal 
was killed by cervical dislocation. Blood samples 
were collected in heparinised tubes and spun at 2000g,
(IEC Centra-7, Damon, Bedford, UK), to separate the 
plasma. Plasma samples were decanted into glass vials,
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which were immediately frozen at -20°C. 1 ml plasma 
aliquots were diluted with distilled water to a volume 
of 5 ml and the lignocaine concentration measured by 
the HPLC method of section 7.
(g) Changes in liver blood flow after 
hydralazine treatment.
Assessment of liver blood flow was 
carried out using the dye indocyanine green and a mod­
ification of the method used by Iga et al. (1980).
This dye is removed from the blood stream only by the 
liver and does not undergo enterohepatic circulation. 
Its disappearance from the circulation is dependent 
on liver blood flow and it may be used as an index 
to compare liver blood flow.
Male Wistar rats, Bath University CFHB 
strain, were used in these experiments. Large animals 
weighing between 500-550g were used to minimise haemo- 
dilution effects. The animals were divided into two 
groups; the control group received water orally, the 
other hydralazine hydrochloride in water, 1 mg/kg, 
given orally. The animals were then left for twenty 
minutes after which both groups underwent the foil-
100
owing procedures.
Animals were anaesthetised with penta- 
barbitone, 75 mg/kg {6% Sagatal, May and Baker, Dagen­
ham, England). The animals were then given heparin 
dissolved in isotonic saline, 1000 units, by intra- 
peritoneal injection and placed on a heated surgical 
board kept at 25°C. The left carotid artery was 
cannulated using a heparinised 20 gauge catheter plac­
ement unit, (Quick Cath, Dupont Travenol, Laborator­
ies, Ireland). A water-tight rubber membrane was then 
placed over the outflow of the cannula. Blood samples 
from the cannula could thus be withdrawn with minimum 
disturbance and blood loss. A second 20 gauge heparin­
ised catheter placement unit, (Quick Cath, Dupont 
Travenol Laboratories, Ireland), was used to place a 
cannula in the right jugular vein. The animals were 
left for 5 minutes. A control 0.3 ml blood sample was 
then taken from the carotid artery cannula. This was 
followed one minute later by a bolus injection of 
indocyanine green, dissolved in saline, 6uM/kg given 
via the jugular vein cannula. The dye was flushed into 
the circulation with a further injection of 0.5 ml of 
isotonic saline. The jugular vein cannula ,was then 
sealed. The time of dye injection was taken as time 
zero and 0.25 ml blood samples were then taken at
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1, 3, 5, 7, 10/ 15/ 20/ 30, 45, 60, 75 and 90 minutes 
after time zero. These samples were spun in a high 
speed, type 54414, Eppendorf centrifuge, (Eppendorf, 
Hamburg, West Germany), for two minutes to separate 
the plasma. A 0.1 ml aliquots of plasma were taken and 
mixed with 0.9 ml of deionised water. The absorbance, 
at 800nm, of these solutions was then measured ten min­
utes later. This assay was carried out on a Pye spectr­
ophotometer, (Pye Unicam, PU 8610, Cambridge, England) 
at 25°C using the initial control plasma sample as 
a blank. All samples were measured between 15 and 20 
minutes after removal from the animal.
A standard curve of absorbance against 
concentration was prepared. This was constructed using 
0.9 ml samples of known dye concentration independ­
ently diluted in deionised water to which 0.1 ml of 
pooled blank rat plasma was added. These samples were 
measured by the same system as the plasma samples. The 
standard curve (fig. 2.8.6), produced had a linear 
correlation coefficient of 0.999.
(h) Lignocaine tissue binding after 
hydralazine pretreatment.
Male Wistar albino rats, Bath University 
















animals were divided into two groups. A control group
received hydralazine hydrochloride dissolved in water
1 mg/kgf orally. The animals were then left for 40
minutes before all were given lignocaine dissolved in
saline, 25 mg/kg, by a bolus tail vein injection. The
14lignocaine solution used contained C-labelled 
lignocaine, (New England Nuclear, Dupont, Southampton 
England.), at an activity of 2 uCi/ml. Immediately 
following the lignocaine injections 1000 units of 
heparin were administered to each rat by intraperit- 
oneal injection.
Two minutes after the lignocaine injec­
tion rats were bled under light ether anaesthesia by 
cardiac puncture. The blood was collected in heparin- 
ised tubes and spun down at 2000g (IEC Centra-7, 
Damon, Bedford, UK.), for 10 minutes to separate the 
plasma. Immediately after bleeding the animals were 
killed by cervical dislocation. The chest cavity was 
then opened by two incisions through the rib cage. A 
cannula was then placed in the inferior vena cava 
using a 14 gauge catheter placement unit, (Venflow 
Viggo, Helsingborg, Sweden). As much remaining blood 
as possible was removed from the circulation. The 
abdomen was opened and the renal arteries and portal 
vein severed. 50 ml of Krebs buffer was then passed
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through the vena cava cannula to remove as much resid­
ual blood as possible from the kidneys and liver.
The heart, lungs, kidneys and liver were 
all removed, damped dry and weighed. A sample of each 
organ, of known weight was taken and finely chopped 
using scissors. The tissue was washed several times 
with Krebs buffer to remove any blood still remaining. 
The samples were then damped dry and mixed with 5 ml. 
of Krebs buffer. The tissues were homogenised using a 
TRI R type 1K41 homogeniser, (TRI R Instruments, New 
York, USA).
0.5 ml of each homogenate and 0.5 ml 
of plasma were then mixed with 10 ml of Optiphase 
"Safe" scintillation fluid, (Fisons, Loughborough, UK) 
in glass counting vials. The radioactivity of each 
sample was measured using an LKB 1215 Liquid Scintill­
ation counter linked to a KODE Model 43 printer, 
(Wallac, Finland), using the appropriate quenching 
corrections.
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(i) Lignocaine binding to red blood cells 
and plasma proteins during incubation 
with hydralazine.
In this experiment whole rat blood was 
obtained from male Wistar rats, CFHB strain, by 
cardiac puncture, under light ether anaesthesia. The 
blood was collected in heparinised tubes and spun down 
at 2000g, (IEC Centra-7, Damon, Bedford, UK.), for ten 
minutes, to separate out the red blood cells. Nine 
tubes were then set up each containing 2 ml of plasma 
and 2 ml of packed red blood cells.
Using a stock solution of lignocaine
hydrochloride, 0.1 mg/kg, having an activity of
2.2 uCi/ml, (New England Nuclear, Dupont, Southampton,
U.K.). Tubes containing 7 ug/ml, 2.5 ug/ml, 0.7 ug/ml
and 0.25ug/ml, final lignocaine concentration were
made up, (two tubes at each concentration). To one
tube of each dilution hydralazine to a final concen-
-4tration of 1 X 10 M was added. To the other four 
tubes the same volume of Krebs buffer was added. A 
ninth tube contained no lignocaine and no hydralazine 
and was used to assess the background activity of the 
solutions used. All tubes were then oxygenated by 
bubbling 95% Oxygen 5% Carbon Dioxide gas through the 
solutions. All were then incubated at 37°C for 1
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hour in a shaking water bath.
After this incubation period the solut­
ions were spun down at 2000g (IEC Centra-7, Damon, 
Bedford, UK), for ten minutes to separate the red 
blood cells. 1 ml of plasma was removed and filtered 
using Amicon MPS 1 YMT 14mm filters, placed in MPS-1 
filtration units, (Amicon, Gloucester, England). The 
plasma samples were spun at 2000g for twenty minutes 
in a Heraceus Christ labfuge 1, (Heraceus Christ GmbH 
Germany). 0.2 ml of the protein free filtrate, 0.1 ml 
of red blood cells and 0.7 ml of whole plasma for 
each lignocaine dilution were placed in glass counting 
vials containing 10 ml. of scintillation fluid, 
(Optiphase "Safe", Fisons, Loughborough, UK). The act­
ivity of each sample was then measured on a LKB 1215 
Liquid Scintillation Counter linked to a KODE model 
43 printer, (Wallac, Finland). Using this method the 
binding of lignocaine to plasma was determined from 
the difference between whole plasma activity and 
protein free filtrate activity. Binding to red blood 
cells was determined directly.
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(i) Effects of Hydralazine on the isolated
perfused heart.
Isolated hearts were perfused retrogr- 
adely. Male Wistar rats, Bath University CFHB strain, 
weighing between 200-250g were killed by cervical 
dislocation. The heart was removed and chilled in ice 
cold Krebs solution to allow easier manipulation. The 
heart was perfused with a Krebs buffer, (Appendix 2).
The Krebs buffer used in the isolated heart experim­
ents differed slightly from that used in liver perfus­
ions. This Krebs buffer was only used on isolated heart 
preparations and will be denoted by Krebs buffer (Heart). 
The isolated hearts were perfused at a flow rate 
of lOml/min using a peristaltic pump, (Watson Marlow, 
Falmouth, England). Perfusion pressure was monitored 
using a Bell Howell type 4-422-0001 pressure trans­
ducer, (Hertfordshire, England), attached to a Gould 
2400 S recorder, (Gould instruments, Ohio, USA). An 
E.C.G. trace was also obtained using needle electrodes 
placed on the right atrium and left ventrical; the 
trace being recorded on a Electromed type MX 216, 2 
channel recorder, (Ormed, Hertfordshire, England).
The trace was also used to determine heart rate.
After the preparation parameters had 
stabilised the heart was left for twenty minutes to
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ensure equilibration. A measurement of heart rate was
-4made. Then Krebs buffer (Heart) containing 10 M 
hydralazine was infused for ten minutes, after which 
heart rate measurements were again taken. Krebs buffer 
(Heart), containing no hydralazine was then perfused 
After a 15 minute period of perfusion heart rate read-
-3
ings were taken. Then Krebs buffer containing 10 M 





1) THE EFFECT OF ALTERATIONS IN THE HA:PV FLOW 
RATIO ON THE METABOLISM OF LIGNOCAINE.
(a) Lignocaine extraction ratio.
The extraction ratio of lignocaine 
was calculated using the formula given in equation 
3 . 1 . 1
E= | | x 100 Equation 3 .1 .1
CIN
E is the extraction ratio.
CIN is the input lignocaine concentration
in both the hepatic artery and portal vein 
C0UT is the output lignocaine concentration.
Figure ( 3 . 1 . 1 )  shows the extraction 
ratio of lignocaine during different HA:PV flow 
ratios. The extraction ratio of the drug increases as 
the portal vein flow contribution is raised. These 
results are similar to those obtained by Ahmad (1983)  
in which he also showed that as portal vein flow cont­
ribution increased, so extraction of lignocaine by the 

















Figure 3.1.1. The Effect of Variation in the 
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HA : PV Flow Ratio
Points represent the mean + sem.
See Appendix 3 for data and n values.
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ations may be put forward to account for these results,
i) Shunting.
One possible explanation for these 
results is the phenomenon of shunting, which occurs 
when blood is diverted or shunted through non-metab- 
olic channels within the liver. Any drug in shunted 
blood will not come into contact with the metabolising 
enzymes and will appear in the venous system. The 
diversion of drug will result in an increase in venous 
concentration and a decrease in hepatic extraction 
ratio. Although shunting occurs in diseased livers, 
(Gross et al., 1975, Groszmann et al., 1977), it also 
occurs to a small degree in normal rat livers (Wood et 
al., 1979), and human liver, (Groszmann et al., 1977). 
Ahmad (1982), found that shunting in the isolated per­
fused rat liver was measurabley greater when the liver 
was perfused through the hepatic artery than when it 
was perfused by the portal vein. Shunting would seem 
to offer one possible explanation for the increase in 
extraction ratio seen with increases in portal vein 
flow contribution as at high hepatic artery flow rates 
shunting is greatest.
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ii) Separate enzyme environments between
the hepatic artery and portal vein.
An alternative explanation for the results 
seen during variation in HA:PV flow ratio is that the 
hepatic artery and the portal vein do not pass through 
the liver via the same sinusoids and/or that those 
sinusoids which receive both portal vein and hepatic 
artery blood do so in proportions which differ from 
the input HA:PV flow ratio. These separate, or more 
highly perfused portal vein or hepatic artery channels, 
may exhibit heterogeneity with respect to their met­
abolising environments. These two phenomena may 
result in blood passing into the liver via the portal 
vein being exposed to a different metabolic environ­
ment to that seen by hepatic artery blood. An increase 
in the proportion of blood flowing into the portal 
vein would increase the quantity of blood exposed to 
the postulated portal environment and may cause 
changes in the overall liver metabolism of input 
drugs.
Evidence for separate portal vein and 
hepatic artery channels through the liver has come 
from experiments using radioactive transit times (Rees 
et al., 1964? Hollenberg et al., 1966; Birtch et al., 
1967). Experiments by Breedis et al., (1954); Solt et
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al., (1977) and Conway et al., (1984) have shown that 
tumour cells receive predominantly hepatic artery 
blood but the surrounding non-diseased tissue 
receives both hepatic arterial and portal venous 
blood. More highly perfused hepatic artery channels 
may exist in the normal liver. The results indicate 
that complete mixing of hepatic artery and portal vein 
blood cannot be assumed. Flexibility of the liver 
blood supply to sinusoids has been shown by Wakin et 
al., (1942); Bloch (1955), and McCuskey (1966) who all 
showed the presence of "static sinusoids" which can be 
switched in and out of the general circulation using 
input and output sphincters. Wakin et al. (1942) 
calculated that at any one time 75% of the liver sin­
usoids may be in this inactive state. Elias et al. 
(1953) and Burkel (1970) in rats have shown the 
existence of direct arteriole connections to sinusoids 
which seem to contain predominantly arterial blood. 
Thus, there is evidence which supports the existence 
of a degree of HA:PV separation within the liver. Also 
as outlined in section 4b of the introduction there is 
a degree of heterogeneity within the liver with 
respect to Phase I and Phase II drug metabolising 
enzymes. However no positive link between drug metab­
olising enzyme heterogeneity and possible separate
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hepatic artery or portal vein channels has been shown.
iii) Physical heterogeneity between separate 
hepatic artery and portal vein channels.
Separate hepatic artery or portal vein 
channels may show physical differences, for example, 
with respect to the size of the space of Disse or 
fenestral diameter. A larger space of Disse would mean 
that solute molecules would have further to travel 
before colliding with the parenchymal surface membrane 
and therefore, extraction of drugs from the plasma 
would be lower. Also, a decrease in fenestral size 
would reduce the passage of molecules out of the 
sinusoid lumen into the space of Disse, also resulting 
in a decrease in extraction of a drug.
Measurement of the apparent space of 
Disse may be achieved using the difference between 
radiolabelled albumin and red blood cell transit 
times through the liver. Albumin is able to enter 
the space of Disse but red blood cells can not. Thus, 
the albumin will be delayed in its passage through the 
liver by entry into this space. The greater the 
delay, the larger the space of Disse. However this 
method is also dependent on fenestral size and number. 
The greater the porosity of the sinusoid wall the
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greater the albumin delay. Experiments by Cohn et al. 
(1969), showed no significant difference in transit 
times of albumin and red blood cells between the 
hepatic artery and portal vein of dogs. However, Ahmad 
(1982), in rats, did show a greater difference in red 
blood cell and albumin transit times when the liver 
was perfused by the hepatic artery as compared with 
portal vein perfusions. Physical differences such as 
space of Disse size or fenestral diameter may account 
for the difference in extraction between the two 
routes. As flow is proportionally increased through 
one route the amount of drug exposed a particular 
environment increases. If the environments differ bet­
ween the two routes this may be reflected by an over­
all change in extraction of a drug.
(b) Effect on metabolic profile of 
Lignocaine.
To investigate possible differences in 
the metabolic environments of the hepatic artery and 
the portal vein, the metabolic profile of lignocaine 
was determined at different flow ratios. Table 3.1.1 
shows the results of varying the HA:PV ratio on 
recovery of lignocaine metabolites either as conjug­
ates or in their free form. Combined total metabolites
Figure 3.1.2. The Known Metabolism of Lignocaine
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Table 3.1.1. Total Output Metabolite Concentration 













5 : 5 
n= 37 
(8 rats)
67.15 + 1.24 
**
31.16 + 1.88 15.45 + 1.20 
**
17.75 + 0.51 
***
2.5 : 7.5 
n = 35 
(7 rats)
60.06 + 2.24 35.16 + 1.70 11.95 + 0.79 12.94 + 0.51
0 : 10 
n = 48 
(10 rats)
67.77 + 1.94 
★*
33.88 + 1.37 21.40 + 1.X 
***
12.54 + 0.45
Values are Percentages + Standard errors of the mean. 
Significance was Measured from the 2.5 : 7.5 Flow Ratio by 
the Unrelated "t" test.
Significance
* p < 0.025
** p < 0.01
*** p < 0.005
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represents the sum of the concentrations of all forms 
of 3-OH MEGX, 3-OH LIG, MEGX, GX and lignocaine in the 
liver output. These values give an indication of the 
recovery of input lignocaine dose. For the perfused 
rat liver the recovery was between 61-68%. This is 
comparable with the results of Keenaghan et al. (1972) 
who showed that the metabolites measured in this study 
should represent 69% of the lignocaine dose when 
measured in the urine of rats. Recovery of the ligno­
caine dose is not complete. This is most likely a 
result of production of metabolites not measured in 
this study, for example, 4-Hydroxy-2, 6-diethylaniline 
or 2,6 xylidine which form approximately 14% of the 
dose recovered in rats, (Keenaghan et al., 1972). 
Conjugates other than sulphates and glucuronides may 
also have been produced and again these would not have 
been measured in the assay. Since it was intended only 
to compare the metabolic routes of de-ethylation and 
hydroxylation, it was not necessary to obtain 100% 
recovery of the lignocaine dose.
The recovery of the lignocaine dose was 
found to alter at the HA:PV flow ratio 2.5:7.5. This 
presented a slight problem as only 61-68% of the input 
dose was recovered and since any changes in metabolic 
profile were likely to be small, this drop in recovery
120
could mean that changes in metabolic profile may be 
masked by changes in recovery. This situation occurs 
frequently in pharmacokinetic studies in patients where 
drug recovery is quite often not consistent. In such 
experiments metabolite concentrations are expressed 
as a percentage of the total recovered metabolites.
The calculation of the results is outlined in Figure 
3.1.3. This way of presenting the results still allows 
both a comparison of Phase I metabolism using the 
values for total 3-OH LIG, 3-OH MEGX, MEGX and GX and 
also Phase II using TOTAL glucuronides and sulphates, 
as well as allowing assessment of individual metabol­
ite concentrations.
various forms of 30H Lignocaine. The Phase I metab­
olism of this compound requires a ring hydroxylation 
of lignocaine.
Diagram to Show the Formation of 3-OH LIG
(i) 3-Hydroxy lignocaine (3-OH LIG) formation





FIG. 3,1.3. To Show the Calculation of Metabolite 
Recovery.




30HLIG + 30HMEGX + MEGX + GX = TOTAL
UNCONJUG- 
+ + + + ATED
METABOLITES
30HLIG + 30HMEGX + MEGX + GX = TOTAL
GLUCURON- 
+ + + + IDES
30HLIG + 30HMEGX + MEGX + GX = TOTAL
SULPHATES
TOTAL TOTAL TOTAL TOTAL 
30HLIG 30HMEGX MEGX GX
TOTAL 30HLIG + TOTAL 30HMEGX + TOTAL MEGX + TOTAL GX
+ TOTAL OUTPUT LIGNOCAINE
COMBINED TOTAL OUTPUT METABOLITE CONCENTRATION
All metabolite concentrations are expressed as a % of 


































To Show the Effect of Variations in the HA:PV Flow 
Ratio on the Recovery 3-OH Lig and its Conjugates. 
Values are Expressed as a Percentage of Combined 
Total Output Metabolite Concentration.
KEY








Total Glucuronides Sulphates Unconjugated
Bars are means + s.e.m.
Data is given in Appendix 4.
* p< 0.025
** p < 0.01
*** p < 0.005
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Total Phase I production of 3-OH LIG
shows a flow ratio dependent pattern as portal vein 
flow contribution is increased, so the recovery of 
3-OH LIG is reduced. The pattern of glucuronide and 
sulphate conjugation does not follow the Phase 1 prod­
uction of 3-OH LIG and so does not remain constant and 
although significant differences occur (p<0.025 and 
p<0.005) occur between the flow ratios no pattern 
emerges.
3-OH MEGX and its conjugates. The Phase I of the meta­
bolism thus required to form this compound involves 
both N-deethylation and ring hydroxylation of ligno­
caine .
A Diagram to Show the Formation 3-OH MEGX from
(ii) 3-Hydroxy Monoethylglycine Xylidide
(3-OH MEGX) formation.






































To Show the Effect of Variations in the HA:PV Flow 
Ratio on the Recovery of 3-OH MEGX and its Conjugates, 
Values are Expressed as a Percentage of Combined 




























0 : 10.0 n 48
(10 rats)
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Glucuronides Sulphates Unconjugated
Bars represent the mean + sem
For data see Appendix 5
* p < 0.025
** p < 0.01
*** p < 0.0C5
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The recovery of total Phase I 3-OH MEGX metabolites was 
not significantly flow ratio dependent. The recovery 
of 3-OH MEGX glucuronide also was not flow dependent. 
3-OH MEGX sulphate does show an increased recovery 
with increasing PV flow which follows the Phase I metab­
olite recovery indicating constant sulphate formation. 
Recovery of unconjugated 3-OH MEGX was significantly 
higher (p < 0.005) at the HA:PV ratio of 2.5:7.5 
ml/min.
and its conjugates. The Phase I formation of GX 
requires the two de-ethylation steps of lignocaine.
Diagram to Show the Formation of GX from Lignocaine
(iii) Glycine Xylidide (GX) formation.
Figure 3.1.6 shows the recovery of GX
M o n o e t h y l g l y c i n e  X y l i d i d e
G l y c i n e  X y l i d i d e


































To Show the Effect of Variations in the HA:PV Flow 
Ratio on the Recovery GX and its Conjugates. 
Values are Expressed as a Percentage of Combined 
Total Output Metabolite Concentration.
K E Y
F l o w  R a t i o  ( m l / m i n ) .  






U n c o n j u g a t e dSulphatesG l u c u r o n i d e sT o t a l
Bars are means + s.e.m. * p <o.025
Data is given in Appendix 6. ** P < 0 *01
*** p <0.005
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Phase I production of this metabolite 
does not seem to be flow dependent. Recovery of GX 
sulphate showed some flow ratio dependency but glucur- 
onidation did not.
(iv) Monoethylglycine Xylidide (MEGX) 
formation.
Figure 3.1.7 shows the recovery of the 
various forms of MEGX. Phase I formation requires only 
1 deethylation step from lignocaine and MEGX is 
thought to be an intermediate for both 3-OH MEGX and 
GX (Keenaghan et al., 1972).
Diagram to Show the Formation of MEGX from Lignocaine
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MEGX was only detected in low concentr­
ations and at the HA:PV flow ratio of 5:5 ml/min 
was undetectable. Total recovery of MEGX shows a flow 




























To Show the Effect of Variations in the HA:PV Flow 
Ratio on the Recovery MEGX and its Conjugates. 
Values are Expressed as a Percentage of Combined 
Total Output Metabolite Concentration.
K E Y
Flow Ratio (ml/min). 
H A  : P V
5.0 : 5.0 n=37
(8 rats)
| | 2.5 : 7.5 n=35
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Total Glucuronides Sulphates Unconjugated
Bars are means + s.e.m.
Data is given in Appendix 7.
* p <0.025
** p < 0.01
*** p < 0.005
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raised. The recovery of free MEGX did show a flow 
ratio dependent pattern but both its conjugates did 
not.
(v) De-ethylated metabolite recovery.
Formation of MEGX and GX require N-de- 
ethylation of lignocaine, the concentrations of these 
metabolites when combined would give an indication of 
any changes in de-ethylated metabolite recovery. These 
results are shown in Figure 3.1.8. The histogram shows 
that the total recovery of deethylated metabolites 
significantly increases (p < 0.005) as PV flow ratio 
increases. Sulphate metabolites follow a similar 
pattern indicating a constant - sulphate prod­
uction but glucuronide and unconjugated metabolite 
formation did not show any significant pattern.
(vi) Phase II metabolism.
Figure 3.1.9 shows the recovery of total 
glucuronide, sulphate and unconjugated lignocaine met­
abolites at the three flow ratios. No real flow depen­
dent pattern emerges for either conjugation processes. 
Glucuronidation formation was shown to be signific­
antly higher (p < 0.005) and sulphate formation 
significantly lower (p < 0.005) at the 2.5:7.5, HA:PV 


































To Show the Effect of Variations in the HA:PV Flow 
Ratio on the Recovery of De-ethylated Metabolites 
and Their Conjugates. Values are Expressed as a 












Total Glucuronides Sulphates Unconjugated
Bars represent the mean + sem
For data see Appendix 8
* p < 0.025
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To Show the Effect of Variations in the HA:PV Flow 
Ratio on the Recovery of Conjugated and 
Unconjugated Metabolites. Values are Expressed as a 
Percentage of Combined Total Output Metabolite 
Concentration
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For data see Appendix 9
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did decrease slightly as portal vein flow contribution 
increased.
vii) Possible explanations for the changes 
in lignocaine metabolite recovery 
during alterations in the HA:PV flow 
ratio.
The results of figures 3.1.4 to 3.1.9 
indicate that Phase I metabolite recovery shows a 
degree of dependency on the HA:PV flow ratio. Whilst 
glucuronide and sulphate conjugations do not proceed at 
a constant rate but during changes in flow ratio, a flow 
related pattern is not seen. As portal vein contribut­
ion increases the recovery of 3-OH LIG (a hydroxylated 
metabolite) decreases, whereas recovery of de-ethylated 
metabolites increases. This pattern could be the 
result of either an increase in de-ethylation and a 
decrease in hydroxylation of lignocaine as portal vein 
flow contribution is increased, or a decrease in 
further metabolism of de-ethylated metabolites and an 
increase in further metabolism of 3-OH LIG as portal 
vein flow contribution increases. 3-OH LIG is known to 
be further metabolised to 3-OH MEGX by a de-ethylation 
process (Figure 3.1.10). However, MEGX can also be 
further metabolised to 3-OH MEGX by a hydroxylation
Figure 3.1.10
The Conversion of 3-hydroxy-Lignocaine to
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3-hydroxy-monoethylglycine Xylidide
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process in addition to forming GX by further de- 
ethylation (Figure 3.1.11). From Figure 3.1.5 it was 
shown that Total 3-OH MEGX recovery does not vary as 
portal vein flow contribution is increased. An explan­
ation for these results might be that as portal vein 
flow contribution is increased the formation of MEGX 
from lignocaine is increased and the formation of 
3-OH LIG from lignocaine is decreased. This would 
account for the increase in MEGX and the decrease in 
3-OH LIG. If the formation of 3-OH MEGX from MEGX app­
roximately corresponds to that from 3-OH LIG and any 
increase in MEGX formation from lignocaine is balanced 
by a decrease in 3-OH LIG formation, the net substrate 
concentration for 3-OH MEGX formation would remain 
constant. This assumes that lignocaine only produces 
3-OH LIG or MEGX as its first stage Phase I metabolites 
and that only these metabolites can form 3-OH MEGX.
From Figure 3.1.6 it can be seen that 
Total GX recovery is constant as portal vein flow 
contribution is increased. Since it would seem that GX 
can only be formed by a further N-deethylation of 
MEGX the concentration MEGX forms the substrate for GX 
formation (Figure 3.1.11). From Figure 3.1.7, MEGX 
recovery increases. However, this does not result in 
an increase in GX recovery. Thus, either the rate of
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formation of GX is proceeding maximally at each flow 
ratio and is unaffected by MEGX concentration, or any 
increase in MEGX concentration is balanced by a decr­
ease in the rate of GX formation, thus keeping final 
GX recovery constant.
The net result of all these changes seem 
to be an increase in de-ethylation and a decrease in 
hydroxylation of lignocaine. As such, with the inc­
rease in portal vein contribution, the de-ethylation 
process in the assumed portal vein channels would need 
to be more efficient and the hydroxylation process 
less efficient than in the assumed hepatic artery 
channels.
An alternative explanation may be 
advanced. MEGX is known to be further metabolised 
in the rat (Figure 3.1.11) to metabolites such as 
2,6 xylidine, not measured in this study. 3-OH LIG,
3-OH MEGX and GX may also undergo further metabolism 
to yet unidentified metabolites. Since only 61-68% of 
the lignocaine dose was recovered, the recovery of 
lignocaine metabolites was not complete and significant 
quantities of unidentified metabolite formation could 
account for this. Initially, lignocaine is thought to 
undergo an N-deethylation step to MEGX or a ring hydr - 
oxylation to 3-OH LIG. (Figure 3.1.12). The production
Figure 3.1.12. The Production of Monoethylglycine Xylidide 
and 3-hydroxy Lignocaine from Lignocaine
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of MEGX and 3-OH LIG may not differ between the two 
routes and the changes in recovery of these two metab­
olites may be due to changes in their further metabol­
ism. These changes if route dependent may show up as 
a route dependency of 3-OH LIG and MEGX recovery but 
would not be due to a route dependency of their prod­
uction. The metabolic steps responsible for further 
metabolism of 3-OH LIG and MEGX may be more important 
in determining HA:PV flow ratio dependent metabolite 
recovery.
In order to explain the results obtained 
using the hypothesis of changes in further 3-OH LIG or 
MEGX metabolism as portal vein flow contribution is 
increased, two criteria must be met. Firstly, an inc­
rease in portal vein flow contribution must result in 
an increase in further metabolism of 3-OH LIG thus dec­
reasing its recovery. Secondly, an increase in portal 
vein contribution must result in a decrease in further 
MEGX metabolism resulting in an increased MEGX recov­
ery. 3-OH LIG is known to be converted to 3-OH MEGX 
(Figure 3.1.10) but it is not known if it gives rise 
to any further Phase I metabolites. MEGX is known to 
produce 2,6 xylidine, 3-OH MEGX and GX (Figure 3.1.2 ). 
Since GX is recovered at a constant concentration, its 
formation is either proceeding at a maximum velocity
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or does infact remain constant. A decrease in 3-OH MEGX 
production from MEGX could account for an increase in 
MEGX and may also cancel out any increase in 3-OH MEGX 
production from 3-OH LIG so that 3-OH MEGX recovery 
remains constant. Also, a decrease in 2,6 xylidine 
ation cannot be ruled out as a mechanism for increased 
MEGX recovery. Postulated changes in the further meta­
bolism of hydroxylated and de-ethylated metabolites 
could account for the changes in lignocaine metabolite 
seen during alterations in the HA:PV flow ratio.
(c) Further metabolism of lignocaine 
metabolites.
An investigation was carried out to test 
the importance of interconversions between the Phase I 
metabolites during changes in HA:PV flow ratio. Each 
metabolite was infused in equimolar concentrations to 
4 ug/ml lignocaine infusions at the HA:PV ratios 
5:5 and 0:10 ml/min. The metabolite concentrations 
were expressed as a percentage of the molar dose given. 
Although this method of expressing the metabolite 
concentrations differed from that used during ligno­
caine infusions, GX undergoes no further metabolism 
and its recovery can only be expressed as a percentage 
of dose, so for clarity all other metabolites were
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similarly expressed. Tables 3.1.2 - 3.1.5 show the 
recoveries of each metabolite during infusions of the 
various lignocaine metabolites.
(i) Changes in Phase I metabolism.
From Table 3.1.2 it can be seen that 
during 3-OH LIG infusion, 3-OH MEGX was the main 
metabolite recovered with 27-28% of 3-OH LIG under­
going no Phase I metabolism and 12-20% being recovered as 
unconjugated 30HLIG. 93-95% of the input lignocaine 
was recovered in the output perfusate. This indicates 
that the metabolism of 3-OH LIG is mainly to metab­
olites measured in this study. 12-26% of 3-OH LIG 
is recovered as MEGX. The formation of MEGX from 
3-OH LIG requires a reduction process (figure 3.1.13); 
an unusual process in drug metabolism.
Table 3.1.3 shows the metabolism of 
3-OH MEGX and here the major metabolite is MEGX form­
ing 44-68% of the recovered dose. To produce MEGX, a 
reduction process is required, (figure 3.1.14). 3-OH 
MEGX was stable in both Krebs and perfusion medium for 
the duration of the perfusion and the formation of MEGX 
from 3-OH MEGX was a product of its passage through the 
liver. 3-OH MEGX was also found to be stable for two 
months when stored at -20°C in Krebs. The considera­
ble formation of MEGX (44-68%) from 3-OH MEGX also
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Table 3.1.2. The Metabolism of 3-OH Lig at the
























11.9 + 1.3 
**
3-OH MEGX
5 : 5 
0 : 10
39.2 + 2.0
56.0 + 1.8 
**
11.7 + 2.9 
19.5 + 2.6
7.8 + 1.1
13.0 + 2.3 
**
19.6 + 2.2 
23.5 + 1.5
MEGX
5 : 5 
0 : 10
26.3 + 0.7
12.1 + 0.5 
**
4.8 + 1.2 
2.1 + 0.8
16.4 + 1.3




SUM 5 : 5 93.3 + 1.2 21.0 + 2.9 27.7 + 1.1 44.5 + 3.7
TOTAL 0 : 10 95.0 + 0.7 30.3 + 1.5 
★
33.3 + 2.2 40.5 + 3.0
Values are Mean % Dose of Metabolite Infused in nM + standard 
error of the mean.
The significance of changes in metabolite recovery between 
the two flow ratios was assessed using the Wilcoxon test.
* p < 0.025
** p < 0.01
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Table 3.1.3. The Metabolism of 3-OH MEGX at the















5 : 5 
0 : 10
7.1 + 0.4




1.9 + 0.3 
1.7 + 0.5
3.9 + 0.1
12.1 + 0.4 
**
MEGX
5 : 5 
0 : 10
68.0 + 2.6
43.8 + 5.0 
**
17.7 + 2.9 
18.5 + 5.7
29.7 + 0.9
2.5 + 0.4 
**
20.5 + 0.5
22.7 + 0.4 
**
GX




0.1 + 0.1 
0.1+ 0.1
0.8 + 0.5 
1.4+ 0.4
8.0 + 0.1 
6.7 + 0.5
SUM 5 : 5 83.8 + 2.6 18.9 + 2.8 32.5 + 1.5 32.4 + 0.5
TOTAL 0 : 10 68.6 + 5.2 
★
21.4 + 5.7 5.6 + 0.6 
**
41.5 + 0.8 
**
Values are Mean % Dose of Metabolite Infused in nM + standard 
error of the mean.
•Hie significance of changes in metabolite recovery between 
the two flow ratios was assessed using the Wilcoxon test.
* p < 0.025
** p < 0.01
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Table 3.1»4. The Metabolism of MEGX at the















5 : 5 
0 : 10
18.0 + 0.6
24.3 + 2.2 
*
5.1 + 0.6




2.4 + 0.4 
1.9 + 0.3
MEGX







11.9 + 1.6 
**
23.6 + 2.0
14.6 + 1.2 
**
GX
5 : 5 
0 : 10
25.9 + 1.9 
20.3 + 1.7
1.2 + 0.7 
0.2+ 0.2
2.1 + 2.0 
0.4+ 0.4
22.6 + 1.1 
19.8 + 2.0
SUM 5 : 5 75.5 + 4.2 11.9 + 1.9 15.1 + 1.4 48.5 + 2.5
TOTAL 0 : 10 73.5 + 2.7 14.6 + 0.9 
*
24.9 + 0.8 36.2 + 2.6 
**
Values are Mean % Dose of Metabolite Infused in nM + standard 
error of the mean.
The Significance of changes in metabolite recovery between 
the two flow ratios was assessed using the Wicoxon test.
* p < 0.025
** p < 0.01
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Table 3,1.5. The Metabolism of GX at the















5 : 5 
0 : 10
96.5 + 1.0 
88.4 + 1.4 
*
0.7 + 0.5 
2.4 + 1.0
0.6 +^ 0.6 
0.9+ 0.5
95.2 + 0.5 
80.0 + 1.8 
•kh
Values are Mean % Dose of Metabolite Infused in nM + standard 
error of the mean.
The significance of changes in metabolite recovery between 
the two flow ratios was assessed using the Wilcoxon test.
* p < 0.025
** P < 0.01
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Figure 3.1.13
The Production of Monoethylglycine Xylidide 
From 3-hydroxy Lignocaine
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leads to the formation of GX (8.2- .8.9%). 69-84% of the 
3-OH MEGX dose was recovered . The lack of complete 
recovery may reflect further 3-OH MEGX metabolism to 
unidentified metabolites. 7-17% of the input dose 
underwent no Phase I metabolism and 4-12% of the 
30HMEGX dose was recovered unchanged.
Table 3.1.4 shows the metabolism of MEGX. 
MEGX forms both GX and 3-OH MEGX in approximately equal 
quantities. Around 30% of the infusion undergoes no 
Phase I metabolism and 15-24% is recovered unchanged. 
74-76% of the dose was recovered and the possibility 
that 2,6 xylidine or other unmeasured metabolites are 
are formed from MEGX in significant quantities cannot 
be ruled out.
Table 3.1.5 shows the results of GX 
infusions. Further metabolism of GX does not seem to 
occur to any great extent as 80-95% of the drug is 
recovered unchanged.
In order to assess the changes in metab­
olite recovery, the change in metabolite concentration 
when portal vein flow contribution is increased was 
calculated. A positive change indicates that recovery 
increased as portal vein flow increased, and a negat­
ive value indicates a decrease in recovery. Figure 
3.1.15 shows the effect of this change in flow ratio
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on further Phase I metabolism of the four lignocaine 
metabolites.
During 3-OH LIG perfusion, recovery of 
3-OH LIG was unaffected by flow, as was the total rec­
overy of the 3-OH LIG dose. However, as portal vein 
flow contribution increased there was a marked increase 
in 3-OH MEGX recovery. This could be due to an increase 
in the de-ethylation of 3-OH LIG or a decrease in the 
reduction of 3-OH MEGX or a combination of both.
During 3-OH MEGX infusion the recovery 
of 3-OH MEGX increased as portal vein flow contribut­
ion increased. This was probably due in part to the 
decrease in reduction of 3-OH MEGX to MEGX. During MEGX 
infusions both 3-OH MEGX and GX were recovered. Changes 
in these metabolite recoveries are small but 3-OH MEGX 
is decreased with increased portal vein flow contrib­
ution. During GX perfusion GX was not significantly 
further metabolised.
The presence of a reduction process in 
the metabolism of lignocaine makes the results of 
the studies using infusions of lignocaine metabolites 
difficult to relate to the results during lignocaine 
infusions. Because of the interconversion between 
3-OH MEGX and MEGX, hydroxylation and de-ethylation 
processes cannot easily be compared. Several pieces of
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information can be inferred from the results. The 
recovery of 3-OH MEGX ,during infusions of 3-OH LIG 
is increased as the portal vein flow contribution is 
raised. Also during 3-OH MEGX infusion further metab­
olism of 3-OH MEGX is reduced with increased portal 
vein flow. During MEGX infusions the production of 
3-OH MEGX was slightly increased. If we assume that 
the metabolism of 3-OH LIG and MEGX during lignocaine 
infusions are the major flow ratio dependent pathways, 
the results of the metabolite infusion experiments pre­
dict an increase in 3-OH MEGX production with increased 
portal vein contribution during lignocaine infusions. 
The predicted increase in 3-OH MEGX recovery being due 
to a reduced metabolism of 3-OH MEGX and a increase 
conversion of 3-OH LIG to 3-OH MEGX as portal vein 
flow contribution is raised. During lignocaine infus­
ions 3-OH MEGX remains relatively constant as portal 
vein flow contribution is increased. It would there­
fore seem unlikely that changes in further metabolism 
are the major flow ratio dependent pathways.
The second possible explanation for the 
changes in metabolite profile with increases in 
portal vein flow contribution during lignocaine 
infusions, is that the initial hydroxylation and 
deethylation steps are the major flow ratio dependent
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pathways. The results from the metabolite infusions 
predict an increase in 3-OH MEGX production during 
infusions of lignocaine as portal vein flow contrib­
ution is increased. This increase does not occur and 
changes in the production of 3-OH LIG and MEGX from 
lignocaine must counteract this predicted increase. 
From the metabolite infusion experiments the major 
pathway for 3-OH MEGX production would seem to be 
from 3-OH LIG. If during increases in portal vein 
flow contribution the production of 3-OH LIG from 
lignocaine is reduced and as a consequence MEGX prod­
uction increased, although overall 3-OH MEGX substrate 
remains the same, the substrate available to the major 
pathway would be reduced. It would thus seem that 
increases in MEGX formation and decreases in 3-OH LIG 
formation from lignocaine ought to result in a fall 
in 3-OH MEGX recovery as portal vein flow contribution 
is increased. However, from the metabolite infusion 
experiments the reduction of 3-OH MEGX decreases 
and the production of 3-OH MEGX from 3-OH LIG incr­
eases as portal vein flow contribution is raised.
These two factors could counteract the reduction in 
3-OH LIG substrate available for 3-OH MEGX formation. 
The result being that if the main flow ratio dependent 
pathways involve the production of 3-OH LIG and MEGX
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from lignocaine, the metabolite infusion experiments 
predict no change in 3-OH MEGX recovery if portal 
vein flow contribution is raised during lignocaine 
infusions. Thus it would seem that the most likely 
explanation for the changes in lignocaine metabolite 
profile is that hydroxylation of lignocaine to 
3-OH LIG is decreased and de-ethylation to MEGX is 
increased when portal vein flow contribution is 
raised.
ii) Changes in phase II metabolism.
Figure 3.1.16 shows the recovery of the 
glucuronide conjugates of the four lignocaine phase I 
metabolites. During 3-OH LIG perfusions the glucuron­
ide conjugates follow a similar pattern of changes as 
those seen by the phase I metabolite recoveries.
The exception is 3-OH LIG which undergoes increased 
glucuronide conjugation as portal vein flow contibut- 
ion is increased. During 3-OH MEGX perfusion the change 
in MEGX glucuronide formation is less than the change 
total Phase I production indicating a decreased 
glucuronidation. The glucuronides formed during MEGX 
infusions closely follow those changes seen in phase 
I recovery suggesting a constant glucuronide formation 
The recovery of GX glucuronide is very low.
Figure 3.1.16. The Effect of Changing the HA:PV Flow Ratio from 5:5 to 0:10 on the Recovery
of Glucuronides During Infusions of Various Lignocaine Metabolites.
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Figure 3.1.17 shows the changes in 
recovery of sulphate conjugates. In most cases the 
changes in sulphate recovery reflect the changes in 
phase I metabolism. Although MEGX sulphate production 
from 3-OH MEGX is lower at the higher portal vein flow.
iii ) Changes in production of unconjugated 
metabolites.
Changes in the recovery of unchanged 
infused metabolites can be used as an assessment of the 
changes in extraction of the metabolites. From figure 
3.1.18 the extraction of 3-OH LIG and MEGX and GX was 
reduced and 3-OH MEGX raised as portal vein flow 
contribution is increased.
Also from tables 3.1.2 - 3.1.5 it can 
be seen that in most cases over 40% of the metabolite 
dose was recovered as unconjugated metabolites. This 
recovery of free metabolite is higher than that seen 
during lignocaine perfusions; below 30% at all HA:PV 
flow ratios. Thus the extraction ratio of the metabol­





Figure 3.1.17. The Effect of Changing the HA:FV Flow Ratio from 5:5 to 0:10 on the Recovery
of Sulphates During Infusions of Various Lignocaine Metabolites.
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Figure 3.1.18. The Effect of Changing the HA:FV Flow Ratio from 5:5 to 0:10 on the Recovery
of Unconjugated Metabolites During Infusions of Various Lignocaine Metabolites.
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d) Summary of the results for changes in 
HA;PV ratio on lignocaine metabolism.
i) Lignocaine extraction ratio increases 
as portal vein flow contribution is raised.
ii) The recovery of the hydroxylated metab­
olite 3-hydroxy lignocaine, (3-OH LIG) is decreased 
as portal vein flow contribution is raised.
iii) The recovery of de-ethylated metabol­
ites increases as portal vein flow contribution is 
raised.
iv) The recovery of glucuronide or sulphate 
conjugates show no general flow ratio related pattern.
v) The major flow ratio related pathways 
for lignocaine seem to be the conversion of lignocaine 
to 3-OH LIG and MEGX.
vi) The results point to the existence of 
separate channels for the passages of blood through 
the liver and that these channels show heterogeneity 
in their metabolism of lignocaine.
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2) DISTRIBUTION OF ADRENORECEPTORS.
(a) Reason for study.
The previous section has outlined the 
changes that occur in metabolism when HA:PV flow 
ratio is altered in the perfused rat liver. It was 
assumed in the discussion that the effects seen were 
a product of altered flow through either route. A 
prerequisite of an increased flow through the hepatic 
artery is a substantial increase in hepatic artery 
perfusion pressure. Portal vein pressure is independ­
ent of flow rate. Thus, changes in the metabolism of 
lignocaine during an increase in hepatic artery flow 
contribution may be caused by a raised perfusion 
pressure in this vessel. This increase in pressure may 
divert perfusate from its normal route through the 
liver causing drug metabolism to be altered. The 
changes seen in metabolism could be due to changes in 
in perfusion pressure rather than a reflection of 
increased perfusion of separate hepatic artery or 
portal vein channels with different metabolising 
environments. A model system was therefore required in 
the perfused rat liver where perfusion pressure could 
be increased or decreased at a constant flow ratio to 
test the effect of perfusion pressure.
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One possible model was to use pharmaco­
logical vasoconstrictors and dilators to increase or 
decrease perfusion pressure in each vessel. Adreno- 
receptor agonists have been shown to induce vasocon­
striction by a  stimulation in dogs (Chakravarti et al., 
1940, Andrews et al., 1955, Green et al., 1959 and 
Noguchi et al., 1970). jg-adrenoreceptor stimulation 
has been shown to result in dilation of the hepatic 
vasculature (Hirsch et al., 1976, Richardson et al., 
1977d, 1978b) in dogs and by Koo et al.,(1979a) in 
rats.
An investigation of adrenoreceptor 
agonism would be likely to produce a model where 
a-adrenoreceptor mediated vasoconstriction 
would produce an increase in vascular resistance 
increasing perfusion pressure and jg -adrenoreceptor 
mediated vasodilation would produce a decrease in 
vascular resistance, decreasing perfusion pressure.
An investigation of both oc and jg receptors was thus 
undertaken in both vessels using the isolated perfused 
rat liver at a constant HA:PV flow ratio of 2.5:7.5 
ml/min which corresponds to the normal physiological 
flow ratio, (Greenway, 1971, and Conway et al., 1984).
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(b) a. -adrenoreceptor activity.
The average perfusion pressure in livers 
prior to any treatment was found to be 98.7 + 3.5 mmHg 
in the hepatic artery and 21.5 + 0.5 mmHg in the 
portal vein (values are averages of all perfusion 
pressures recorded with standard errors on the mean). 
Figure 3.2.1 shows typical log dose response curves 
during infusions of adrenaline in the hepatic artery 
or portal vein. Adrenaline gave a dose related incr­
ease in perfusion pressure in the hepatic artery and 
portal vein. The log dose response curves are sigm­
oidal in both vessels and allow the calculation of an 
ED50%. This represents log the dose required to 
produce an increase in pressure, 50% of the maximum 
attainable increase. Figure 3.2.2 shows typical dose 
response curves for noradrenaline infusions into the 
hepatic artery and portal vein. Noradrenaline caused 
a dose related increase in perfusion pressure in 
either vessel. The maximum increase in pressure is 
similar using both adrenaline and noradrenaline. Nor­
adrenaline stimulates mainly a-adrenoreceptors, but 
adrenaline stimulates both a  and jft-adrenoreceptors. 
The vasoconstriction response (increase in perfusion 























Figure 3.2.1. Typical log Dose Response Curves for Adrenaline.
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Figure 3,2.2 . Typical log Dose Response Curves for norAdrenaline
Hepatic Artery Portal Vein
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response is seen with noradrenaline as well as adrena­
line. This agrees with the results from other workers, 
(Richardson et al., 1977a, 1978b, Koo et al., 1977 and 
Greenway, 1979), who showed that the hepatic vasocon­
striction was a-adrenoreceptor mediated.
Figure 3.2.3 shows the average ED50% of 
adrenaline and noradrenaline in both vessels. The ED50% 
values of both adrenaline and noradrenaline are sign­
ificantly lower in the hepatic artery than the portal 
vein. This suggests that the hepatic artery is more 
sensitive to adrenaline and noradrenaline vasocon­
striction. Also, in the hepatic artery adrenaline has 
a significantly lower ED50% than noradrenaline, indic­
ating the vessel is more sensitive to adrenaline vaso­
constriction. This is unusual because noradrenaline 
would be expected to be more potent as constriction is 
a-adrenoreceptor mediated and noradrenaline is more 
selective. Also adrenaline stimulates jS-adrenoreceptors 
which are thought to be dilatory and therefore would 
reduce the effectiveness of adrenaline on a-adreno- 
receptor mediated vasoconstriction. The results are 
not unique. Richardson et al.,(1982) showed in the dog 
that the dose of noradrenaline needed to double 
vascular resistance was slightly less in the hepatic 

















The ED50% Values for Adrenaline and norAdrenaline 
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vein, a much larger dose of noradrenaline to adren­
aline was required to produce a similar increase in 
resistance. The results may reflect different isomers 
of the agonists being used and their reactivity with 
receptors in each supply. In the present study, nor­
adrenaline and adrenaline were equipotent in the 
portal vein but adrenaline was more potent in the 
hepatic artery.
Figure 3.2.4 shows the effect of 
phentolamine on the log dose response curves of adren 
aline. In both vessels phentolamine infusion results 
in parallel shift in adrenaline dose response curve. 
Figure 3.2.5 shows the effect of phentolamine on the 
noradrenaline dose response curve. The results show a 
similar parallel shift to the right. These results 
indicate that phentolamine competitively antagonises 
the vasoconstriction induced by both constrictors. 
Since phentolamine is a specific a-adrenoreceptor 
antagonist, the vasoconstriction produced by adren­
aline must be due to stimulation of a-adrenoreceptor 
Richardson et al.,(1977a, 1978b) in dogs and Greenway 
(1979) in cats showed a similar phentolamine antag­





















Figure 3.2.4. The Effect of Phentolamine on the log Dose Response Curves
of Adrenaline in the Liver Vasculature
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Figure 3.2.5. The Effect of Phentolamine on the log Dose Response Curves
of norAdrenaline in the Liver Vasculature.




■ =  C o n t r o l
-6
A =
P h e n t o l a m i n e
-8 -7 -6 -5





■  =  C o n t r o l
-5
A =
P h e n t o l a m i n e
-8 7 -6 -5 -4
l o g  n o r A d r e n a l i n e  D o s e  M
P o i n t s  a r e  m e a n s  +  s e m ,
165
166
As the dose response curves show a 
parallel shift/ an ED50% can be calculated for both 
vasoconstrictors in the presence of phentolamine. The 
degree of antagonism due to phentolamine can be repre­
sented by the shift in ED50% from the unantag­
onised to antagonised log dose response curves. The 
calculation of this change is represented schemat­
ically by Figure 3.2.6. Curve "a" represents the nor­
mal unantagonised dose response curve for adrenaline 
or noradrenaline. Curve "b" represents the curve 
during infusions of phentolamine. The difference in 
the ED50% of the two curves is represented by "X". 
The value of "X" can be used as a measure of the deg­
ree of antagonism. The larger the shift in ED50%
the higher the value of "X" and the greater the antag­
onism.
The results of the effect of various 
concentrations of phentolamine on the log dose resp­
onse curves of adrenaline and noradrenaline are given 
in figure 3.2.7. A dose related antagonism by phentol­
amine on both constrictors is seen in both the hepatic 
artery and the portal vein. The antagonism of nor­
adrenaline induced hepatic artery constriction due to
5 X 10-6 M infusions of phentolamine is larger then
-5that caused by 1 X 10 M infusions of phentolamine
A Schematic Representation to Show the Calculation
of the Shift in . ED50% of Constrictor Due to
Infusions of Phentolamine
M A X
R E S P O N S E
50%
M A X
l o g  D o s e
"a" = the normal constrictor log dose response curve.
"b" = the constictor log dose response curve in the 
presence of Phentolamine.










Figure 3.2.7. The Effect of Hepatic Artery and Portal Vein Infusions 
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in the portal vein. This suggests that phentolamine 
may be less effective at antagonising noradrenaline 
vasoconstriction in the portal vein.
Tables 3.2.1 and 3.2.2 show the effect
of infusions of jS-adrenoreceptor blockers on the
ED50% of adrenaline and noradrenaline in the
hepatic artery and the portal vein. Several j3-adreno-
receptor blocking drugs were infused. All show a
degree o f and jg2 activity but atenolol, metop-
rolol and oxprenolol are relatively selective.
Propranolol shows a greater mixed activity but is
more jg  ^ selective and ICI 118 551 is a selective
jQ 2~adrenoreceptor blocking drug, (Arnold et al.,
1985; Bilski et al., 1983). Propranolol Was the only
jSblocker tested which had a significant effect (p <
0.005), on the dose response curves of adrenaline
in the hepatic artery. This may be due to partial
jg-adrenoreceptor agonist activity, although at the
-5concentration used (5 X 10 M), these effects would
be small. All j8 blockers had no significant effect on 
the log dose response curves of noradrenaline in the 
hepatic artery (table 3.2.2). Portal vein infusions of 
the jg blockers produced no significant effects on the 
log dose response curves of adrenaline or noradren­
aline (table 3.2.3).
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Table 3.2.1, The Effect of Beta Adrenoreceptor blockers on 
the ,. ED50% of Adrenaline induced Vasoconstriction in the
Hepatic Artery.
CHANGE IN ED50% FROM CONTROL
Infusion Concentration
BLOCKER 5 X 10“5 M 
n=3
5 X 10"6 M 
n=3
5 X 10~7 M 
n=3
Atenolol 0.04 + 0.03 0.01 + 0.01 -
Propranolol 0.26 + 0.03 
***
-0.05 + 0.07 -0.05 + 0.05
Metoprolol 0.01 + 0.01 0.01 + 0.02 -
Oxprenolol 0.15 + 0.08 0.07 + 0.06 0.01 + 0.01
ICI 118 551 0.16 + 0.06 0.01 + 0.01 0.01 + 0.02
Values are mean changes in ' ED50% + standard error
of the mean.
Significance was assessed using the related "t" test 
*** p < 0.005
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Table 3.2.2. The Effect of Beta Adrenoreceptor blockers on 
the _ ED50% of norAdrenaline induced Vasoconstriction
in the Hepatic Artery.
CHANGE IN ED50% FROM CONTROL
Infusion Concentration
BLOCKER 5 X l(f5 M 5 X 10"6 M
n=3 n=3
Atenolol 0.01 + 0.10 -0.04 + 0.02
Propranolol 0.03 + 0.02 -0.11 + 0.05
Metoprolol 0.09 + 0.02 -0.02 + 0.02
Oxprenolol - -0.04 + 0.03
ICI 118 551 0.12 + 0.06 -0.01 + 0.02
Values are mean changes in ED50% + standard error 
of the mean.
All changes were not stastistically significant when 
assessed using the related "t" test.
Table 3.2.3. The Effect of Beta Adrenoreceptor blockers
on the ED50% of Adrenaline and norAdrenaline induced 
Vasoconstriction in the Portal Vein.
-51 X 10 M Infusions of Beta Blockers
CHANGE IN ED50% FROM CONTROL
Adrenaline norAdrenaline
BLOCKER n=3 n=3
Atenolol 0.03 + 0.03 0.23 + 0.11
Propranolol 0.05 + 0.05 -0.18 + 0.18
Metoprolol 0.07 + 0.04 0.06 0.05
Oxprenolol 0.08 + 0.03 0.04 + 0.03
ICI 118 551 0.02 + 0.03 -0.01 + 0.03
Values represent mean changes in ~ ED50% + standard 
error of the mean.
All values were not statistically significant when 
assessed using the related "t" test.
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The lack of /J-adrenoreceptor blocking 
drug antagonism of the log dose response curves of 
both vasoconstrictor agents in the hepatic artery and 
the portal vein indicate that the constriction induced 
is not j3-adrenoreceptor mediated. Richardson et al. 
(1977a, 1978b) and Hirsch et al. (1976) in dogs found 
propranolol to be ineffective at antagonising adren­
aline and noradrenaline induced vasoconstriction in 
the hepatic artery and the portal vein. The results 
obtained in the perfused rat liver preparation used in 
the present study confirm the results obtained in dogs 
(Richardson et al., 1977a, 1978b and Hirsch et al. 
1976).
The antagonism of the adrenaline and 
noradrenaline log dose response curves by phentolamine 
together with the lack of antagonism with j8 blockers in 
the hepatic artery and the portal vein suggest that 
vasoconstriction is mediated by a-adrenoreceptors in 
both vessels.
c) j8-adrenoreceptor activity.
Richardson et al. (1978b) in dogs and 
Reilly et al. (1981) in rats showed that /J-adreno- 
receptor agonists such as isoprenaline dilate the 
hepatic artery and the portal vein. It was found
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using the perfused rat liver preparation in the pres­
ent study, that infusions of jg-adrenoreceptor agonists 
isoprenaline, salbutamol, clenbuterol and dobutamine 
were unable to produce a decrease in perfusion 
pressure. Other reported vasodilators such as hist­
amine, (Richardson et al., 1978b) and acetylcholine, 
(Andrews et al., 1955), were found to be ineffective 
at dilating the preparation. The most likely explan­
ation for the results obtained is that the preparation 
lacked any intrinsic tone and was in a state of max­
imal dilation. There exist several methods to induce 
tone in isolated preparations.
i) Catacholamines may be infused by adding 
them to the perfusion medium. As shown in section (b) 
adrenaline and noradrenaline infusions result in vaso­
constriction in both the hepatic artery and the portal 
vein. Constant rate infusions of these agents could 
be used to produce a constant tone in each vessel. In 
order to show significant vasodilation approximately 
70% maximal constriction needed to be maintained. 
Infusions of adrenaline and noradrenaline were found 
to induce a constant tone in the portal vein but a 
constant tone could not be maintained under such 
conditions in the hepatic artery. Constant infusions 
of vasoconstrictors in the hepatic artery were only
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able to maintain a constant tone (indicated by a con­
stant increased perfusion pressure), for approximately 
10 minutes. A decrease in vasoconstriction at constant 
constrictor infusion was commonly seen. A similar 
phenomenon was reported in cats during constant 
hepatic nerve stimulation by Greenway et al. (1972).
In order to carry out successful experiments a const­
ant tone in the hepatic artery needed to be maintained 
for over an hour. This method of tone induction was 
unsuitable for the isolated perfused rat liver.
ii) Sympathetic nerve stimulation has also 
been shown to induce vasoconstriction in the hepatic 
vasculature, (Burton-Opitz, 1911b; Green et al., 1959; 
Lautt, 1977d, 1980b and Greenway et al., 1972). Tone 
could therefore be induced by nerve stimulation. The 
hepatic nerves which produce vasoconstriction when 
stimulated are extremely difficult to identify in the 
rat. Also since Greenway et al. (1972) noted vaso­
constriction escape during constant nerve stimulation 
and as outlined in section (i) constant infusions of 
noradrenaline were not able to induce a constant tone, 
similar instability of tone might be expected during 
nerve stimulation.
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iii) A third possible method to induce tone 
in isolated preparations involves changing the ionic 
concentrations of the perfusion medium. An increase in 
potassium will partially depolarise muscle cells and 
induce smooth muscle tone. Potassium chloride infusions 
between 0.1M and 0.2M were required to induce sufficient 
tone. Using these concentrations of potassium chloride 
an increase in haemolysis of red blood cells during 
perfusion was seen. This reduced the viability of 
the preparations and could not be used as a method 
to induce tone.
iv) An indirect method for measuring 
j3-adrenoreceptor activity was found to be effective.
It was noted that ft-adrenoreceptor agonists when 
infused during construction of adrenaline or noradren­
aline log dose response curves shifted the curves to 
the right, (figures 3.2.8 and 3.2.9). This shift was 
due to P -adrenoreceptor mediated vasodilation 
physiologically antagonising the a-adrenoreceptor 
mediated vasoconstriction. The parallel shift in 
log dose response curve for both constrictors may 
be compared using the shift in ED50% as shown in 
figure 3.2.10. The shift in ED50% in figure 3.2.10 
is represented by "X", the larger the value the 


















Figure 3.2.8. The Effect of Isoprenaline on the log Dose Response Curves 
of Adrenaline in the Liver Vasculature.
Hepatic Artery (n=6) Portal Vein (n=5)
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Figure 3.2.9. The Effect of Isoprenaline on the log Dose Response Curves
of norAdrenaline in the Liver Vasculature.
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A Schematic Representation to Show the Calculation
of the Shift in_____ ED50% of Constrictor Due to
Infusions of ff-Adrenoreceptor Agonists.
M A X
R E S P O N S E
50%
M A X
l o g  D o s e
"a" = the normal constrictor log dose response curve.
"b" = the constictor log dose response curve in the 
presence of ^-Adrenoreceptor Agonists.
"X" = the difference in ED50% of curves "a" and "b".
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This indirect method allows the characterisation 
of the /J-adrenoreceptor activity in both the hepatic 
artery and the portal vein. It was also possible 
using selective /3-adrenoreceptor blockers to catag- 
orise the receptors in to /3^  and /32 subtypes.
Figure 3.2.11 shows the effect of the
/3-adrenoreceptor agonist isoprenaline on the log
dose response curves of adrenaline and noradrenaline.
Isoprenaline is effective in the hepatic artery,
(at 5 X 10~5 M p<0.005), and the portal vein,(at 
-51 X 10 M p<0.005), against both vasoconstrictors. 
Isoprenaline is more effective in the portal vein 
than in the hepatic artery against both adrenaline 
and noradrenaline. This may reflect a larger populat­
ion of /3-adrenoreceptors in the portal vein than in 
the hepatic artery.
The results obtained during infusions 
of clenbuterol are presented in figure 3.2.12. Clen- 
buterol is a specific j3^-adrenoreceptor agonist, 
(Waldeck et al., 1985). The agonist is effective on 
adrenaline and noradrenaline induced vasoconstriction 
in both the hepatic artery, (at 5 X 10”^ M p<0.01) 
and the portal vein, (at 1 X 10”  ^ M p<0.005). The 
histogram shows a large difference in the effective­










Figure 3.2,11. The Effect of Hepatic Artery and Portal Vein Infusions
of Isoprenaline on the_____ ED50% of Adrenaline and norAdrenaline
Adrenaline norAdrenaline
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Figure 3.2.12. The Effect of Hepatic Artery and Portal Vein Infusions
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erol is more effective in the portal vein and since 
it is a selective jg2~adrenoreceptor agonist, the 
portal vein must contain a predominance of adre- 
noreceptors.
Figure 3.2.13 shows the results obtained 
when the j3-adrenoreceptor agonist Dobutamine was 
infused. Although this compound is considered to be 
a selective jg^-adrenoreceptor agonist it has been 
demonstrated to have both (} 2 an(3 (X-adrenoreceptor 
agonist activity, (Ruffolo et al., 1981, 1983; 
Maccarrone et al., 1984; Kenakin, 1981). The major 
action of the drug is still thought to be mediated 
via jg^-adrenoreceptors. Dobutamine was found to 
be effective against adrenaline and noradrenaline 
vasoconstriction in the hepatic artery, (at 1 X 10 ^
M p<0.005) and the portal vein, (at 1 X 10~^M 
p<0.005). The histogram indicates that dobutamine is 
more effective in the hepatic artery than the portal 
vein. Since dobutamine has a higher affinity for 
jg^-adrenoreceptors the results suggest that 
jg^-adrenoreceptors predominate in the hepatic 
artery.
The results obtained using the three 
jg-adrenoreceptor agonists indicate a degree of heter- 
geneity between the hepatic artery and the portal
Figure 3.2.13. The Effect of Hepatic Artery and Portal Vein Infusions
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vein with respect to their jg-adrenoreceptor populat­
ions. jg^-adrenoreceptors predominate in the hepatic 
artery whereas jg 2“adrenoreceptors predominate in 
the portal vein vasculature. The results of this 
study contradict the findings of Richardson et al. 
(1977d) who showed that jg ^ -adrenoreceptors predom­
inate in the hepatic artery of the dog. However, 
species differences may be responsible for this 
discrepancy. The results are consistent with those 
of Koo et al. (1979a) and Reilly et al. (1981) who 
showed a predominance of jg 2~aclrenoreceptors in the 
portal vein vasculature on the rat.
Since the measurement of jg-adrenorec­
eptor activity was carried out using an indirect 
method, confirmation was needed to show that jg-adren- 
oreceptor agonism not oc -adrenoreceptor antagonism 
was responsible for the shift in vasoconstrictor 
ED50% seen during infusions of isoprenaline, clenbut­
erol and dobutamine. The specificity of the shift in 
constrictor ED50% due to infusions of the three 
jg-adrenoreceptor agonists was therefore assessed 
using jg-adrenoreceptor blocking drugs. The effect­
iveness of these drugs on jg-adrenoreceptor agonism 
was measured using shifts in ED50% of adrenaline 
and noradrenaline log dose response curves during
186
jg-adrenoreceptor agonist infusion with and without 
)8-adrenoreceptor blockade. Figure 3.2.14 is a 
schematic representation of the log dose curves used 
to calculate the effectiveness of the ]8 blockers. The 
difference between the curve "a" and the curve "c", "X" 
represents the shift in ED50% of the constrictor
due to ]8-adrenoreceptor agonist infusion. The shift 
from curve "c" to "b", shown as "Y", represents the deg­
ree of ft-adrenoreceptor antagonism due to infusions of 
jBblockers. The degree of ^blockade is expressed as a 
% reduction this being (Y/X) x 100. The greater the 
the value of the % reduction the greater the ^-adren- 
oreceptor blockade. All three ]8-adrenoreceptor agonists 
were tested using aH five /? blockers. All the f} blockers 
used show varying degrees of j8^  and j8 2 -adreno­
receptor selectivity. Atenolol, metoprolol and oxpren- 
olol are relatively selective )8^ -adrenoreceptor 
blockers. Propranolol shows a mixed jj ^ and jS^  
antagonism with j8^ predominance. ICI 118 551 is a 
selective  ^ blocker, (Arnold et al., 1985 and 
Bilski et al. 1983). All the )8 blockers were infused 
in concentrations which had been shown to have no 
direct effect on adrenaline or noradrenaline induced 




A Schematic Representation to Show the Calculation 
of The Percentage Reduction on Adrenaline and
norAdrenaline_____ £050%, in the Presence of
B -Adrenoreceptor Agonism and Antagonism
M A X
R E S P O N S E
50%
M A X
l o g  D o s e
"a" = the normal constrictor log dose response curve.
" C s  the constrictor log dose response curve in the 
presence of jg-adrenoreceptor agonism.
"b" = the constrictor log dose response curve in the
presence of jg-adrenoreceptor agonism and jg blockade.
"X"= the difference in ED50% of curves "a" and "c".
"Y"= the difference in ED50% of curves "c" and "b"
% Reduction= (Y/X) x 100
188
Figure 3.2.15 shows the results of the 
|8-adrenoreceptor blocking drugs on isoprenaline act­
ivity in the hepatic artery. Atenolol, propranolol, 
metoprolol and oxprenolol show a statistically signif­
icant (p<0.005) blockade of isoprenaline induced 
shifts in ED50% of adrenaline and noradrenaline. 
Using noradrenaline as the constrictor the j9 blockers 
produced almost complete blockade of isoprenaline.
This shows that isoprenaline was indeed causing its 
effects in the hepatic artery by acting on ]8-adren- 
oreceptors. The 2~adrenoreceptor blocking drug 
ICI 118 551 was ineffective at antagonising isopren­
aline in the hepatic artery. The relatively selective 
^-adrenoreceptor blocking drugs are more effective 
in this vessel and suggest that the hepatic artery 
contains j8-adrenoreceptors predominantely of the p ^  
subtype. The results of a similar experiment carried 
out on the portal vein are given in figure 3.2.16.
Here it would appear that the selective blocker 
ICI 118 551 is more effective than the relatively 
selective f) ^  blocking drugs atenolol, metoprolol 
and propranolol at antagonising isoprenaline. The 
blockade due to ICI 118 551 was almost 100% and 
indicates that effects of isoprenaline are due to 






Figure 3.2.15. The Effect of 5 X 10 6 M Infusions of Various Q Blockers on the Shift in
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Figure 3.2.16. The Effect of 1 X 10 5 M Infusions of Various 3 Blockers on the Shift in
ED50% of Adrenaline and norAdrenaline due to Portal Vein Infusions of 1 X 1CT^ M Isoprenaline
Adrenaline norAdrenaline
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ness of the relatively p selective blockers in the 
portal vein and the effective blockade by ICI 118 551 
indicate a predominance of ]8 2~adrenoreceptors in 
this vessel.
Figure 3.2.17 shows the results of 
experiments to study the effects of p blockers on the 
activity of the p^ selective agonist clenbuterol 
in the hepatic artery. These show the that both j3 ^  
and j8 2 selective adrenoreceptor blocking drugs are 
similar in their ability to antagonise clenbuterol 
activity. It was shown in figure 3.2.12 that although 
clenbuterol produces a significant shift (p<0.01) in 
ED50% of both constrictors in both vessels it is 
more effective in the portal vein. Also from the evid­
ence in figures 3.2.12, 3.2.13, and 3.2.14 j8^-adre- 
noreceptors predominate in the hepatic artery. Clen­
buterol although being a selective p 2-adrenoreceptor 
agonist probably possesses some fj -^-adrenoreceptor 
activity. The p -adrenoreceptor activity of clenb­
uterol recorded in the artery could be a combination 
of weak stimulation of a large number of p ^-adren- 
oreceptors and stimulation of a smaller number of 
p ^ adrenoreceptors. Since both selective p  ^ and p 2 
blockers are equally effective at antagonising clen­
buterol in the artery it would seem that this explan-
Figure 3.2.17. The Effect of 5 X 10 6 m Infusions of Various 3 Blockers on the Shift in
ED50% of Adrenaline and norAdrenaline due to Hepatic Artery Infusions of 5 X 10~5 M Clenbuterol.
Adrenaline norAdrenaline
Metoprolol n=3
Bars are means + sem. Data is given in Appendix 24.
* p < 0.025
** p < 0.01
*** p< 0.005
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ation of its action is probable. The results again 
indicate ]8 -^-adrenoreceptor predominance in the 
hepatic artery. Figure 3.2.18 shows the effect of the 
jgblockers on clenbuterol activity in the portal vein. 
In this vessel the blocker ICI 118 551 is effective 
at antagonising clenbuterol and shows that action of 
clenbuterol is due to j8-adrenoreceptor agonism and 
not a -adrenoreceptor antagonism. The ineffectiveness 
of the relatively selective ft ^-adrenoreceptor 
blockers on clenbuterol indicate that the portal vein 
contains a predominance of ]8 2~a^renoreceptors• 
Antagonism of dobutamine j8-adreno- 
receptor agonism was also studied and the results 
for the hepatic artery are given in figure 3.2.19.
The relatively selective jg ^  blockers atenolol, 
propranolol, metoprolol and oxprenolol produce effect­
ive blockade in the artery. This shows that effects 
of dobutamine are due to ]0-adrenoreceptor agonism 
and not a-adrenoreceptor antagonism. The jB 2 
selective blocker ICI 118 551 is not very effective 
at antagonising dobutamine in the hepatic artery and 
this together with the effectiveness of the q  ^
selective blockers indicates that ]0^-adrenorec- 
eptors predominate in the hepatic artery. Figure 






Figure 3.2.18. The Effect of 1 X 10 5 m Infusions of Various 8  Blockers on the Shift in


















ICI 118 551 n=3
Bars are means + sem. Data is given in Appendix 25
* p < 0.025
** p <0.01
*** p < 0.005
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Figure 3.2.19. The Effect of 5 X 10 6 M Infusions of Various Q Blockers on the Shift in
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ICI 118 551 n=3
Bars are means + sem. Data is given in Appendix 26
* p < 0.025 






Figure 3.2.20. The Effect of 1 X 10 5 M Infusions of Various 3 Blockers on the Shift in












ICI 118 551 n=3
Bars are means + sem. Data is given in Appendix 27
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in the portal vein. All five blockers are similar in 
their ability to antagonise dobutamine. As shown in 
figure 3.2.13 dobutamine is less effective in the 
portal vein than the hepatic artery. This seems to 
point to a predominance of |82-adrenoreceptors in 
the portal vein. Dobutamine may show a weak stim­
ulation of (3 2-adrenoreceptors and a larger affinity 
for a smaller number of j8^-adrenoreceptors in the 
portal vein. If this is the case then infusions of 
fjl and j82 selective blockers would antagonise 
dobutamine to the same degree. The results are thus, 
consistent with the predominance of 0 2-adreno- 
receptors in the portal vein.
In summary the results from experiments 
to study the j8-adrenoreceptor population in the liver 
vasculature have shown:-
i) That the j8-adrenoreceptor agonists 
isoprenaline, clenbuterol and dobutamine all simulate 
j8-adrenoreceptor mediated dilation in the hepatic 
artery and the portal vein.
ii) The selective /?2-adrenoreceptor 
agonist clenbuterol is more effective in the portal 
vein whilst the ]8^-adrenoreceptor agonist dobut­
amine is more effective in the hepatic artery.
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iii) The relatively selective ^-adreno- 
receptor blocking drugs propranolol, atenolol, metop- 
rolol and oxprenolol are in general more effective 
in the hepatic artery. The jf} 2-adrenoreceptor 
blocking drug ICI 118 551 is more effective in the 
portal vein.
iv) The results point to a degree of hetero­
geneity in the j8 -adrenoreceptor population in the 
hepatic artery and the portal vein. The hepatic artery 
possessing a predominance of f) ^ -adrenoreceptors and 
the portal vein a predominance of j8 2-adrenorec- 
eptors.
(d) Interactions between the hepatic 
artery and the portal vein
It was observed in the isolated perfused 
rat liver experiments that infusions of adrenaline or 
noradrenaline into one vessel may produce an increase 
in perfusion pressure not only in the infusion vessel 
but also the other vessel. Experiments were carried 
out in the perfused rat liver to determine the extent 
of this interaction between the two vessels. It was 
found that infusions of noradrenaline into the portal 
vein could produce a dose related increase in pressure 
not only in the portal vein but also in the hepatic
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artery. A log dose response curve could be constructed 
for both vessels during portal vein infusions of nor­
adrenaline. Infusions of high concentrations of nor­
adrenaline in to the hepatic artery were occasionally 
able to produce an increase in portal vein pressure.
A log dose response curve of increase in portal vein 
pressure against log hepatic artery noradrenaline 
dose could not be obtained. The concentration of 
hepatic artery infusions of noradrenaline required 
to produce portal vein constriction were so high 
that frequently the hepatic artery became permanently 
constricted.
The increases in pressure seen in the 
hepatic artery during portal vein infusions of nor­
adrenaline could be due to constriction of the hepatic 
veins. However, if the liver output vessels are con­
stricted during portal vein noradrenaline infusions 
the increase in the hepatic artery and portal vein 
perfusion pressures should be similar. An alternative 
explanation is that there are presinusoid connections 
between the hepatic artery and the portal vein. Stud­
ies by Nopanitaya et al., (1978), Hase et al., (1966), 
Geumei, (1969a) and Grisham et al. (1981) suggest the 
presence of such connections. Also, experiments by 
Green et al., (1959), Richardson et al., (1978a,
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1978b), Hirsch et al. (1976) in dogs and Lautt et al. 
(1984) in cats have shown that infusions of vasoactive 
agents into one vessel may affect the other other 
liver input vessel.
The log dose response curves obtained in 
experiments with the isolated perfused rat liver were 
sigmoidal and allowed the calculation of ED50% values 
for each curve. The results are presented in table 
3.2.4. The ED50% of noradrenaline induced vasoconst­
riction in the hepatic artery due to portal vein 
infusions is greater (p<0.01),than the ED50% in the 
hepatic artery during hepatic artery infusion and the 
portal vein ED50% during portal vein infusion. This 
suggests that portal vein access to the hepatic artery 
resistance vessels is small. Geumei (1969a), demon­
strated the existence of unidirectional arterio-portal 
connections. Since hepatic artery infusions of nor­
adrenaline only occasionally produced an increase in 
portal vein perfusion pressure, any unidirectional 
arterio-portal connections as seen by Geumei (1969a), 
must bypass the portal vein resistance vessels. The 
results of table 3.2.4 do however, indicate that 
connections allowing flow from the portal may exist 
as portal vein noradrenaline infusions produce vaso­
constriction in the hepatic artery.
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Table 3.2.4. The ED50% of norAdrenaline 
Induced vasoconstriction when infused via the Hepatic 
Artery or the Portal Vein
ED50% of Constriction + s.e.m.
Hepatic Portal
Route of Artery Vein
Infusion n=5 n=5
Hepatic Artery 2.57 + 0.14 X ID-7 M a
Portal Vein 6.82 + 1.50 X 10"6 M 1.12 + 0.5 X 10-6 H
"a"indicates that it was not possible to produce a 
complete dose response could not be produced and 
hence an ED50% could not be calculated.
Values are means + standard error of the mean.
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The shift in log dose response curves 
was investigated in each vessel during hepatic artery 
and portal vein infusions of 1 X 10”  ^ M phentol­
amine. The results are given in table 3.2.5. During 
hepatic artery phentolamine infusions there was a 
significant shift (p<0.01), in all three log dose 
response curves. The greatest shift was to the hepatic 
artery log dose response curve during noradrenaline 
infusion into the same vessel. The lowest shift was 
seen in the log dose response curve in the portal 
vein. The hepatic artery log dose response curve due 
to portal vein infusions of noradrenaline showed 
an intermediate shift. If perfusate from the portal 
vein perfusing the hepatic artery passed through the 
the same vessels as that perfusate entering by the 
hepatic artery, it would be expected that phentolamine 
would shift the log dose response curves in the 
hepatic artery by similar amounts. Since this does not 
occur the portal vein perfusate passing into the 
hepatic artery system may perfuse vessels not normally 
highly perfused by the hepatic artery.
During portal vein infusions of phentol­
amine, both hepatic artery log dose response curves 
show a lower shift in ED50% than those seen in the 
portal vein. This indicates that portal vein access to
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Table 3.2.5. The Effect of Portal Vein and Hepatic 
Artery Infusions of 1 X 10 ^ M Phentolamine on the 












HA 1.00 + 0.08 *** a
HA
PV 0.66 + 0.06 *** 0.43 + 0.05 **
HA 0.31 + 0.05 ** a
PV
PV 0.27 + 0.05 ** 0.71 + 0.07 ***
Values are changes in ED50% + Standard error of the mean
"a" indicates that a coirplete dose response curve could not 
be produced.
The Shift in ED50% was compared using the related "t" 
test.
** p < 0.01
*** p < 0.005
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the perfusate in the hepatic resistance vessels is 
small.
The results of the experiments to inv­
estigate vasculature interactions between the hepatic 
artery and the portal vein have shown that connections 
from the portal vein to the hepatic arterial resist­
ance vessels exist but their number is small. Also the 
hepatic artery vessels to which the portal vein has 
access may not be those normally perfused by the 
hepatic artery.
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3) EFFECT OF ADRENORECEPTOR MEDIATED INCREASES
IN PERFUSION PRESSURE ON LIGNOCAINE METABOLISM .
(a) Effect on Lignocaine Extraction 
ratio.
From the results obtained in the isol­
ated perfused rat using adrenoreceptor agonists and 
antagonists it was intended to produce a system where 
perfusion pressure could be increased and decreased 
at constant HA:PV flow ratio. However, it was only poss­
ible to produce direct vasoconstriction in the hepatic 
vessels so only increases in perfusion pressure could 
be investigated. The preparation was found to be 
maximally dilated and vasodilators were without 
effect. Only the effects of increases in perfusion 
pressure on the metabolism of lignocaine at a const­
ant HA:PV flow ratio were investigated. Both adrenal­
ine and noradrenaline infusions were used as vaso­
constrictors to increase perfusion pressure during 
lignocaine perfusion. Although experiments by Dixon 
et al. (1964), had shown in rat liver microsomes that 
incubation for short periods with noradrenaline did 
not effect hydroxylation or dealkylation, the poss­
ibility existed that adrenaline or noradrenaline 
could inhibit the enzymes responsible for lignocaine
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metabolism. In order to overcome this problem phentol­
amine was infused with the vasoconstrictors to prevent 
pressure increases whilst still allowing adrenaline 
and noradrenaline to exert any enzyme inhibition. 
Phentolamine infused alone did not change perfusion 
pressure and was used as a control for phentolamine 
enzyme inhibition.
Perfusions were carried out at the HA:PV 
flow ratio of 2.5:7.5 (as outlined in section 8d of 
materials and methods). A concentration of constrictor 
was infused into each vessel to give a 70% to 80% 
maximal increase in perfusion pressure. This increased 
hepatic artery pressure approximates to that seen 
in experiments where the hepatic artery flow rate is 
5.0 ml/min. Although increases in portal vein pressure 
are negligible when flow is increased in the vessel, 
the effect of increases in portal vein perfusion 
pressure were also investigated.
Figure 3.3.1 shows the effect of incr­
eases in perfusion pressure on the extraction ratio 
of lignocaine. Only where livers are perfused with vaso­
constrictor alone is there an increase in perfusion 
pressure. In all cases where perfusion pressure is 
raised in the hepatic artery and the portal vein, the 
















Figure 3.3.1. The Effect of Adrenaline and norAdrenaline Induced Increases in Perfusion
Pressure on the Extraction Ratio of Lignocaine.
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The decrease is more pronounced in the hepatic artery 
than in the portal vein. The reduction was not due to 
enzyme inhibition as when adrenaline or noradrenaline 
are co-infused with phentolamine no reduction in lig­
nocaine extraction ratio is recorded. Phentolamine 
infusion alone also had no effect on lignocaine 
extraction ratio confirming that the decrease in 
extraction ratio was due to an increase in perfusion 
pressure. The extraction ratios of lignocaine seen 
during increases in hepatic artery perfusion pressure 
(96.59 for adrenaline and 96.25 for noradrenaline), 
are similar to that seen when the hepatic artery flow 
is 5ml/min (96.07, see fig 3.1.1). The increase in 
perfusion pressure could account for the decrease in 
extraction ratio seen during increases in hepatic 
artery flow contribution. Although from figure 3.3.1 
a reduction in portal vein perfusion pressure would 
result in an increase in extraction ratio, portal vein 
perfusion pressure remains relatively constant during 
changes in flow. Thus, during changes in the HA:PV 
flow ratio there would be no compensatory increase 
in extraction ratio due to decreases in portal perfu­
sion pressure, to balance the decrease in extraction 
ratio which occurs during increases in hepatic artery 
perfusion pressure. Since hepatic artery perfusion
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pressure is related to flow and there is a relation­
ship between hepatic artery flow and lignocaine 
extraction ratio, the changes in hepatic artery perf­
usion pressure can account for the decreased ligno­
caine extraction ratio seen during increased hepatic 
artery flow.
Lautt et al. (1976) in rats carried out 
an experiment in which he measured lignocaine extrac­
tion ratio during hepatic nerve stimulation. The nerve 
stimulation caused an increase in both hepatic artery 
pressure, (from 121 mmHg to 134 mmHg) and portal 
vein pressure,(from 5 mmHg to 8 mmHg) The extraction 
ratio of lignocaine was reduced from 33.5% to 29.7% 
during nerve stimulation. The reduction in extraction 
ratio was not found to be significant. However, in the 
cat there is an reduction of vasoconstriction during 
continuous nerve stimulation. The changes in perfusion 
pressure also are small compared with those induced in 
the present study. These two factors could account 
for the lack of a significant drop in lignocaine extr­
action ratio during nerve stimulation in cats.
There are several possible explanations 
to account for the effect of increased perfusion pres­
sure on lignocaine extraction ratio.
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i) Arterio-venous shunting.
This involves the diversion of perfusate 
from its normal route through the liver via non metab­
olic pathways to the venous system. The diversion will 
result in an increase in venous concentration of any 
perfused drug and a decrease in apparent extraction 
ratio. Wood et al. (1982), in rats and Groszmann et al. 
(1977), in humans have shown that shunting occurs in 
normal livers. Ahmad (1982), has shown that shunting 
is larger during hepatic artery perfusion of the 
liver. This may well be a consequence of increase 
in hepatic artery perfusion pressure and could account 
for the decrease in lignocaine extraction ratio seen 
during increases in perfusion pressure.
ii) Changes in the space of Disse.
Ahmad (1982), also showed that the app­
arent space of Disse is greater in rats when the liver 
is perfused via the hepatic artery. An increase in the 
space of Disse may result in a decreased lignocaine 
extraction ratio. An increase in the space of Disse 
may occur due to an increase in hepatic artery per­
fusion pressure during increased flow but it is diff­
icult to see a mechanism by which this may occur. It 
is more likely that the results of Ahmad (1982) refl­
ect an inherent difference in the space of Disse
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between the two supplies.
iii) Changes in fenestral size.
Another possible explanation for the 
decrease in lignocaine extraction ratio during incr­
eases in perfusion pressure comes from experiments 
by Wisse et al. (1980, 1983). He found that the fen­
estrations of the epithelial cells can constrict when 
exposed to noradrenaline. This decrease in fenestral 
diameter could result in a reduction in the rate of 
passage of drug through the sinusoidal epithelium. The 
contact between drug molecules and the surface of the 
parenchymal cells would be reduced and result in a red­
uction of the extraction ratio of the drug. The reduction 
in fenestral size could account for the results seen 
during increases in perfusion pressure if phentolamine 
antagonises the action of the vasoconstrictor on 
changes in fenestral size. Thus, during co-infusion 
of vasoconstrictor and phentolamine the effect of 
adrenaline or noradrenaline on fenestral diameter 
is blocked. The reduction in extraction ratio of 
lignocaine may not be related to the ability of the 
vasoconstrictor to increase perfusion pressure but to 
its effect on fenestral size.
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iv) Diversion of perfusate through different 
enzyme environments.
A fourth explanation to account for the 
effect of perfusion pressure on the extraction ratio 
of lignocaine involves the diversion of the perfusate 
through sinusoids with an unusual metabolic environ­
ment. Increases in perfusion pressure may open 
"static sinusoids", reported by Wakim et al. (1942), 
Bloch (1955) and McCuskey (1966) of direct flow 
through sinusoids not normally perfused by a partic­
ular supply, thus exposing incoming perfusate to a 
different metabolic environment. To investigate this 
possibility the metabolic profile of lignocaine was 
examined during changes in perfusion pressure at a 
constant HA:PV flow ratio of 2.5:7.5 ml/min.
(b) Effect of Changes in perfusion 
pressure on the metabolic profile 
of lignocaine.
Total recovery of lignocaine metabolites 
showed no significant change when pressure was rai­
sed in either the hepatic artery or the portal vein, 
(figure 3.3.2). Although a constant recovery of lig­
nocaine would allow the expression of the results as 
a percent of dose for consistency with the results
Figure 3.3.2. The Effect of Adrenaline and norAdrenaline Induced Increases in Perfusion Pressure














given in Appendix 29.
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presented previously, the metabolite concentrations were 
expressed as a percentage of combined total recovered 
metabolite concentration, (see figure 3.1.3 for expla­
nation of result calculation). Figures 3.3.3, 3.3.4 
and 3.3.5 show the results of the recovery of phase I 
metabolites during changes in perfusion pressure. Only 
where the vasoconstrictor was perfused alone was any 
increase in perfusion pressure recorded. The results 
show that no significant changes in metabolic profile 
of lignocaine occur during increases in hepatic artery 
or portal vein pressure. Figures 3.3.6, 3.3.7 and 3.3.8 
show the effect of alterations in perfusion pressure on 
recovery of phase II lignocaine metabolites. The results 
indicate that no changes in phase II metabolism of 
lignocaine occur during changes in perfusion pres­
sure in the hepatic artery or the portal vein.
The studies carried out to investigate 
the effect of increases in perfusion pressure on the 
metabolism of lignocaine have shown the following:-
i) Increases in both hepatic artery and 
portal vein perfusion pressure due to infusions of 
adrenaline and noradrenaline reduce the extraction 
ratio of lignocaine. This reduction may be due to 
an increase in arterio-venous shunting, a decrease in 
fenestral diameter or a diversion of the perfusion
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medium through "unusual" metabolic environments.
ii) The metabolism of the drug is not alter­
ed during changes in perfusion pressure. This shows 
that an increase in perfusion pressure is unlikely 
to divert perfusion medium through "unusual" metab­
olic channels. The possibility of shunting or reduct­
ions in fenestral diameter being responsible for the 
decrease in lignocaine extraction ratio still exists.
Figure 3.3.3. The Effect of Adrenaline and norAdrenaline Induced Increases in Perfusion Pressure
on the Recovery of Total 3-OH Lignocaine. Values are Expressed as Percentages of Combined Total
Output Metabolite Concentration.
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Figure 3.3.4. The Effect of Adrenaline and norAdrenaline Induced Increases in Perfusion Pressure
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Figure 3.3.5. The Effect of Adrenaline and norAdrenaline Induced Increases in Perfusion Pressure
on the Recovery of Total De-ethylated, (MBGX + GX) Metabolites. Values are Expressed as 


























Figure 3.3.6. The Effect of Adrenaline and norAdrenaline Induced Increases in Perfusion Pressure
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Figure 3.3.7. The Effect of Adrenaline and norAdrenaline Induced Increases in Perfusion Pressure
on the Recovery of Total Sulphates. Values are Expressed as Percentages of Combined Total
Output Metabolite Concentration.
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Figure 3.3.8. The Effect of Adrenaline and norAdrenaline Induced Increases in Perfusion Pressure
on the Recovery of Total Unconjugated Metabolites. Values are Expressed as Percentages of
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Bars are means + sem. Data is given in Appendix 35.
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4) THE EFFECT OF HYDRALAZINE ON THE METABOLISM OF 
LIGNOCAINE.
Hydralazine has been reported to inhibit 
heart oxygenase systems but not the monoamine oxygenase 
systems in the rat liver, (Lyles et al., 1983).
McLean et al. (1980) and Schneck et al. (1984) reported 
an increase in bioavailability of propranolol after 
hydralazine treatment. Heinzow et al. (1984) showed 
that hydralazine increased estimated liver blood flow 
in the dog but increased the bioavailability of prop­
ranolol. The results of Heinzow et al. (1984) would 
seem to be contradictory. Propranolol is a drug which 
is highly metabolised by the liver and its clearance 
is dependent on liver blood flow, (Wood et al., 1979 
and Branch et al., 1973). An increase in liver blood 
flow would be expected to reduce bioavailability. 
Experiments by Johnston (1975), in rabbits showed that 
hydralazine increased heart rate, cardiac output and 
reduced total peripheral resistance, but total liver 
blood flow remained constant. Further investigations 
of the role of hydralazine in the alteration of the 
pharmacokinetics of co-administered drugs are requ­
ired .
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(a) Effect of hydralazine on the 
Extraction ratio of Lignocaine.
Hydralazine may exert its effect on 
drug kinetics by inhibition of their removal by the 
liver. To investigate this possibility lignocaine 
metabolism was studied in the isolated perfused rat 
liver during infusions of hydralazine. Rats were 
perfused at an HA:PV flow ratio of 2.5:7.5 ml/min.
The method used for perfusion is described in chapter 2 
sections 4,5 and 6. Hydralazine was added directly 
to the perfusate in each case. The results of table 
3.4.1 show that infusions of hydralazine into the 
perfused liver had no effect on the extraction ratio 
of lignocaine. This indicates that hydralazine does 
not have a direct effect on the rate of removal of 
lignocaine from the circulation by the liver. Such 
alterations may however, be important for drugs other 
than lignocaine.
(b) Effect of hydralazine on the systolic 
blood pressure of the rat
Figure 3.4.1 shows the effect of hyd­
ralazine on the systolic blood pressure in the rat,
(see Chapter 2 section 8e for methods). Between 30 and
Table 3.4.1
To Show the Effect of Hydralazine on the 








(mean + s .e.m.)
0 97.96 + 0.13
1 x l(T5 M 97.98 + 0.09
5 x 10"5 M 97.85 + 0.29
1 x 10"4 M 97.79 + 0.27
Using the Mann Whitney test no significant 
difference was found between the extraction 






Figure 3.4.1. The Effect of Hydralazine, lmg/kg given Orally, on
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60 minutes after hydralazine (lmg/kg), given orally, 
the blood pressure falls. The blood pressure remains 
below control for a further forty minutes. Thus hyd­
ralazine produces a marked drop in blood pressure 
between 40 and 90 minutes after an oral dose.
(c) Effect of Hydralazine on the plasma 
Clearance of lignocaine
Figure 3.4.2 shows the effect of hydr­
alazine on the plasma clearance of lignocaine,
20 mg/kg, given orally, (see chapter 2 section 8f for 
methods). Treatment with hydralazine, lmg/kg, altered 
the plasma concentration/time curve for lignocaine. The 
pharmacokinetic parameters for the curves are given 
in table 3.4.2. Hydralazine treatment causes an incr­
ease in half life of the o; phase, total elimination 
time and area under the curve. Figure 3.4.3 shows the 
effect of hydralazine treatment on lignocaine, 5mg/kg, 
given by an intravenous bolus injection. Hydralazine 
changes the plasma concentration curve of lignocaine. 
Table 3.4.2 presents the pharmocokinetic parameters 
for both control and treated curves. The results show 
that hydralazine treatment increases the a phase half 
life, total elimination time and area under the curve 
























The Effect of Hydralazine; lmg/kg , Given Orally on 
the Plasma Concentration of Lignocaine/ 2Qmg/kg , Given 
Orally, in the Rat.
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Table 3.4,2
Pharmacokinetic Parameters of Single Oral and I.V. 
Doses of Lignocaine with and without Hydralazine 
Administration
Parameter






















371 601 252 271
AUC O-oo 
(ng/ml. min)
73110 144462 35683 45093
Control Oral AUC \ /  Hydralazine Oral AUC
= 2.05 j ____________________ \= 3.20
Control I.V. AUC / \ Hydralazine I.V. AUC
Concentration at time zero was calculated using linear log concen­
tration plots for the a  phase.
Elimination time was calculated using linear log concentration 
plots for the phase.
AUC 0-oowas calculated using the the trapezoidal rule.
231
ate that hydralazine affects the clearance of ligno­
caine in the rat. Lignocaine has a high intrinsic 
clearance and extraction ratio (Branch et al., 1973; 
Shand et al., 1975? Ahmad et al., 1983 and Lennard 
et al., 1983), and as such its elimination can be 
considered to be blood flow dependent, (Nies et al., 
1976). From section 4 (a) it was shown that lignocaine 
does not inhibit the enzymes responsible for lignoc­
aine metabolism. Hydralazine must therefore be act­
ing by another mechanism to affect the plasma elimin­
ation of lignocaine. Since the elimination of the drug 
is blood flow dependent hydralazine may decrease liver 
blood flow and reduce the rate of elimination.
(d) Effect of Hydralazine on liver blood 
flow
Figure 3.4.4 shows the effect of hyd­
ralazine on liver blood flow as measured using the 
dye indocyanine green, (see Chapter 2 section 8g for 
methods). The dye is extracted exclusively by the 
liver and does not undergo enterohepatic circulation, 
(Caesar et al., 1961). The removal of the dye is 
dependent on the blood flow to the liver and may be 
used as an estimate of relative liver blood flow.




























Figure 3.4.4. The Effect of Hydralazine, lmg/kg , Given Orally on the Plasma 





C o n t r o l
Points are means + sem.
0 -1- Data is given in 
Appendix 38.
20 2 5 30 35 40 45 50 55











0.318 um/ml 0.336 um/ml
Total plasma 
Elimination Time
235 min 244 min




4954.5 ng ml 1min
-1
6501.5 ng ml min
Concentration at time zero was calculated linear log 
concentration plots for the a phase.
Total elimination time was calculated using linear log 
concentration plots for the ft phase.
Area under the curve was calculated using the 
trapezoid rule.
** p < 0.01 using the unrelated "t" test.
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for indocyanine green. The half life of the a  phase 
may be used to .estimate changes in liver blood flow. 
After treatment with Hydralazine, lmg/kg, orally, the 
half life of indocyanine green is significantly 
increased (p<0.01) from 4.33 to 5.38 minutes. This 
represents a 24% decrease in liver blood flow. From 
table 3.4.2 the same dose of hydralazine caused an 
increase in the half life of lignocaine, 2.5 mg/kg, 
when given by I.V. blous injection, from 7.7 to 9.2 
minutes. This represents a 19.5% decrease in the 
rate of lignocaine elimination. Also from table 3.4.2 
hydralazine treatment, (lmg/kg given orally) results 
in a 48% decrease in oral lignocaine elimination. Thus, 
the decrease in blood flow due to hydralazine can 
account for the reduction in removal of an IV dose of 
lignocaine but is insufficient to account for the 
decrease in elimination of lignocaine given orally. 
Hydralazine may also effect the rate at which an oral 
dose is absorbed in to the blood stream.
(e) Effect of hydralazine on lignocaine 
tissue binding
Post et al. (1979), demonstrated that 
lung tissue in rat may accumulate a considerable amount 
of lignocaine. Johnston (1975), reported that hydral-
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azine increased kidney blood flow, however, he did not 
measure pulmonary blood flow. Hydralazine may increase 
pulmonary blood flow and cause increased accumulation 
of lignocaine to lung tissue. This accumulated drug 
will be eliminated from the body at a slower rate and 
will result in a reduction in the rate of plasma elim­
ination of lignocaine. Table 3.4.4 shows the results 
of experiments to determine the binding of lignocaine 
to various tissues, (see Chapter 2 section 8h for
method). The binding of lignocaine is determined using 
14C drug. The tissues are removed 2 minutes after 
an IV dose of lignocaine. This time period allows the 
drug to circulate within the body and also keeps the 
levels of circulating radioactive metabolites to a 
minimum. The results of the binding studies given in 
table 3.4.4 show that hydralazine, lmg/kg, given 
orally did not significantly affect lignocaine bind­
ing to liver, kidney, heart or lung tissues.
(f) Effect of hydralazine on the binding 
of lignocaine to plasma proteins
Experiments by Piafsky et al. (1979), 
Routledge et al. (1980) and McNamara et al. (1981), 
have shown that lignocaine is between 50 and 70% 
bound to plasma protein especially albumin and (X
Table 3.4.4
The Effect of lmg/kg Hydralazine given Orally on 
the Binding of Lignocaine to Various Tissues
DRUG BOUND TO TISSUE ng/g of tissue
LIVER KIDNEY HEART LUNG
CONTROL 3.88 + 0.59 9.08 + 0.78 2.94 + 1.01 4.14 + 0.63
HYDRALAZINE
TREATED
2.60 + 0.49 8.27 + 1.16 1.81 + 0.12 4.22 + 0.99
Values are means + standard error of the mean.
n=5 All values did not show a significant difference 
from controls using the Mann Whitney Test.
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acid glycoprotein. Hydralazine could increase the
binding of lignocaine to such plasma proteins and
reduce the rate of lignocaine elimination. Table
3.4.5 shows the effect of incubating blood with 
-41 X 10 M hydralazine on the binding of lignocaine 
to plasma proteins and red blood cells, (see Chapter 2 
section 8i for method). Hydralazine reduces the lig­
nocaine bound to red blood cells and increases that 
bound to plasma proteins but has little effect on the 
free lignocaine. The changes are not sufficient to acc­
ount for the reduction in lignocaine elmination obser­
ved with hydralazine treatment.
(g) The Effect of Hydralazine on the 
Isolated perfused heart.
Table 3.4.6 shows the effect of hydral­
azine on the heart rate in the isolated perfused 
heart, (see Chapter 2 section 8j for method). The 
normal heart rate in the isolated perfused heart 
preparations used varied between 224 and 248 beats/ 
min with an average of 234 beats/min. The reductions 
in heart rate observed with 1 X 10-  ^ M and 1 X 10-  ^ M 
hydralazine are quite marked. The results are similar 
to those of Koch-Wesser (1974) who only showed a
decrease in guinea-pig pacemaker activity at hydral-
-4azine concentrations above 10 M.
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Table 3.4.5
-4To Show the Effect of 10 M Hydralazine on the 













4.0 36.1 33.9 29.9
1.0 39.3 33.8 26.8
CONTROL
0.4 44.7 35.0 20.3
0.1 46.6 32.8 20.6
4.0 51.9 29.7 18.4
HYDRAL­ 1.0 54.4 24.9 20.6
AZINE
0.4 56.0 28.7 15.3
0.1 50.7 15.3 24.9
Pooled blood was obtained from 10 rats.
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Table 3.4.6. The effect of Hydralazine on the
Heart Rate in the Isolated Perfused Rat Heart
Hydralazine
Treatment
Reduction in Heart Rate 
Beats/min
Mean +_ s.e.m. n
1 X lo-4 M 
1 X 10-3 M
30 + 2.8 3 
83 + 6.5 3
Experiments by Ablad et al. (1962 and 
1963) have shown that hydralazine may induce vasodil­
ation in peripheral vessels in man. Hydralazine may 
thus reduce liver blood flow by a combination of a 
reduction in cardiac output due, to a decrease in heart 
rate and peripheral vasodilation. Both these factors 
may account for the decrease in blood pressure seen with 
hydralazine. However, the doses of hydralazine required 
to produce a decrease in heart rate are far in excess 
of the levels needed to reduce the rate of lignocaine 
elimination or decrease rat blood pressure. Hydralazine 
has been shown to be rapidly cleared from the systemic
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circulation, (Ludden et al., 1980 and Reece et al., 
1980), but its effect is much longer lasting due to 
formation of an active metabolite hydralazine acetone 
hydrazone. This metabolite has been shown to be more 
active than the parent compound at dilating rabbit 
aorta smooth muscle, Barron et al. (1977) and McLean 
et al. (1978). The action of these metabolites may 
be more important in the mechanism of action of hydr­
alazine .
h) Summary of the investigtions on the 
interactions between lignocaine and 
hydralazine
The findings of the work on hydralazine 
can be summerised as follows.
i) The drug does not directly inhibit the 
metabolism of lignocaine.
ii) Hydralazine will reduce the rate of 
elimination of lignocaine from plasma.
iii) Hydralazine will reduce liver blood flow 
as measured by indocyanine green and this may account 
in part, for the reduction in lignocaine elimination.
iv) Binding of lignocaine to either plasma 
proteins, red blood cells and tissues is not altered 
by hydralazine.
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v) The drug will produce a decrease in 
systolic blood pressure and at high concentrations 
a decrease in heart rate. The high concentrations 
needed to produce a reduction in heart rate discount 
this as the mechanism responsible for the fall in 
liver blood flow. However, metabolites of hydralazine 
may be more active and produce a reduction in both 
cardiac output and a peripheral vasodilation which 
could account for changes in liver blood flow and 





In the isolated perfused rat liver, 
changes in the hepatic artery : portal vein 
(HA:PV) flow ratio result in an alterations in the 
extraction ratio of lignocaine. Increases in perfusion 
pressure in the hepatic artery are seen to reduce the 
extraction ratio of lignocaine to a similar degree 
to that seen during increases in hepatic artery 
flow contribution. The effect of the HA:PV flow ratio 
on lignocaine metabolism in the perfused liver seems 
to be a mechanical effect brought about by changes in 
pressure. An increase in arterio-venous shunting 
would seem to be the most likely explanation for the 
results, although changes in fenestral size are 
another possible explanation. Further investigations 
are required to determine the actual cause of these 
observed changes. Shunting may be easily measured 
using radiolabelled microspheres. The effect of 
increases in perfusion pressure on shunting could 
thus be determined. Measurement of fenestral diameter 
is much more difficult and requires the use of 
electron microscopy but using these techniques the 
effect of increases in perfusion pressure could be 
investigated.
Changes in the HA:PV flow ratio also 
resulted in a change in the metabolic profile of
lignocaine. As portal vein flow contribution was 
raised the recovery of de-ethylated metabolites incr­
eased and the recovery of hydroxylated metabolites 
decreased. Perfusion pressure changes were not resp­
onsible for the changes in the metabolic profile seen 
during changes in HA:PV flow ratio. The most likely 
explanation is that separate channels exist in the 
liver for the passage of hepatic artery and portal 
vein blood. These separate channels also possess 
heterogeneous metabolic environments. An increase in 
flow through one route exposes the blood to a more 
arterial or portal environment and this results in 
changes in metabolic profile. Heterogeneity between 
the hepatic artery and the portal vein could be of 
importance in drug metabolism and predictive kinetics 
The route by which a drug enters the liver may, in 
part, determine its metabolism. A drug may produce 
more toxic metabolites during passage through the 
arterial route than by the portal route. Subjects 
who have an altered blood flow ratio either due to 
a surgical shunt, liver damage or as a result of 
drug induced increases in flow may treat a therapeuti 
agent differently from a normal subject.
The existence of separate channels is 
still a matter of controversy. The results of this
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study support their existence but their importance 
in drug metabolism and liver function has yet to 
be determined. The changes in flow induced in this 
study are large and would only be expected to occur 
in the body under extreme circumstances. Studies of 
flow ratio relationships for other drugs are required 
to determine whether a general pattern of hetero­
geneity exists. Also studies of the distribution of 
cytochromes P45Q and conjugating enzymes between the 
two routes are required.
The study also shows that although both 
the hepatic artery and the portal vein possess a -adren- 
oreceptors and jft-adrenoreceptors, heterogeneity exists 
in the distribution of ft-adrenoreceptor subtypes. The 
hepatic artery having a greater ft -adrenoreceptor 
population and the portal vein a greater /32-ad reno- 
receptor population. The reason for this heterogeneity 
is uncertain. If a similar heterogeneity occurs in man 
it may provide a possible selective treatment for 
portal hypertension with minimum effects on general 
circulation.
Care must be taken when using data from 
isolated preparation even in the same species. In this 
study the interaction between hydralazine and ligno­
caine were investigated. Hydralazine was shown to
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reduce the plasma clearance of lignocaine in the whole 
rat but was ineffective on hepatic enzymes. Hydral­
azine reduced liver blood flow in the whole animal 
and it was found that the most likely cause of its 
effect on lignocaine clearance was due to its effects 
on cardiac output. Thus, changes in liver vasculature 
resistance in isolated preparation due to infusions 
of selective j8  ^ and ^-adrenoreceptor agonists 






To Show the concentrations in Salts used in the 
Krebs Buffer for Liver Perfusion Experiments















To Show the concentrations in Salts used in the 
Krebs Buffer for Heart Perfusion Experiments














The Effect of Changes in the FV:HA Flow









7.5 : 2.5 93.18 + 0.40 20
5.0 : 5.0 96.07 + 0.18 40
2.5 : 7.5 97.83 + 0.09 75
1.0 : 9.0 98.78 + 0.19 15
0 : 10.0 99.20 + 0.05 70
ER = Extraction ratio
C. = Input Lignocaine oncentration in both the 
in Hepatic Artery and the Portal Vein.
Cout = Output Lignocaine concentration
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Appendix 4. The Effect of Variations in the HA:FV Flow Ratio 
On the Recovery 3-OH Lignocaine and its Conjugates. Values 
are Expressed as a Percentage of Combined Total Output 












5 : 5 
n = 37 
(8 rats)






4.62 + 0.17 
***
2.5 : 7.5 
n = 35 
(7 rats)
22.93 + 1.03 16.73 + 0.92 2.98 + 0.50 3.16+0.26
0 : 10.0 
n = 48 
(10 rats)




4.05 + 0.42 
*
4.07 + 0.30
Values are Percentages + Standard errors of the Mean. 
Significance was Measured from the 2.5 : 7.5 Flow Ratio by 
the Unrelated "t" test.
Significance 
* p < 0.025
** p < 0.01
*** p < 0.005
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Appendix 5. The Effect of Variations in the HA:FV Flow Ratio 
On the Recovery 3-OH MBGX and its Conjugates. Values 
are Expressed as a Percentage of Combined Total Qitput 












5 : 5 
n = 37 
(8 rats)
43.51 + 0.99 31.34 + 0.95 6.87 _+ 0.61 5.31 + 0.45 
***
7.5 : 2.5 
n = 35 
(7 rats)
45.34 + 0.87 25.61 + 1.80 8.79 + 0.84 10.94 + 0.93
0 :10 
n = 48 
(10 rats)




Values are Percentages + Standard errors of the mean. 
Significance was Measured from the 2.5 : 7.5 Flow Ratio by 
the Unrelated "t" test.
Significance 
* p < 0.025
** p < 0.01
*** p < 0.005
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Appendix 6. The Effect of Variations in the HA:FV Flow Ratio 
On the Recovery GX and its Conjugates. Values are 
Expressed as a Percentage of Combined Total Output 












5 : 5 
n= 37 
(8 rats)
21.98 + 0.59 4.15 + 0.52
4r*4r
2.50 + 0.39 15.37 + 0.79 
**★
2.5 : 7.5 
n = 35 
(7 rats)
21.36 + 0.75 10.63 + 0.93 4.06 + 0.56 6.65 + 0.70
0 : 10 
n = 48 
(10 rats)
24.06 + 0.82 8.13 + 0.81 8.91 + 1.02 
***
7.03 + 0.47
Values are percentages + Standard errors of the mean. 
Significance was Measured from the 2.5 : 7.5 Flow Ratio by 
the Unrelated "t" test.
Significance 
* p < 0.025
** p < 0.01
*** p < 0.005
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Appendix 7. The Effect of Variations in the HA:FV Flow Ratio 
On the Recovery MBGX and its Conjugates. Values are 
Expressed as a Percentage of Combined Total Output 












5 : 5 
n = 37 
(8 rats)






2.5 : 7.5 
n = 35 
(7 rats)
6.83 + 0.57 3.05 + 0.35 3.19 + 0.50 0.56 + 0.11
0 : 10 
n = 48 
(10 rats)
8.70 + 0.34 
**
2.69 + 0.32 4.22 + 0.33 1.78 + 0.32 
**
Values are Percentages + Standard errors of the mean. 
Significance was Measured from the 2.5 : 7.5 Flow Ratio by 
the Unrelated "t" test.
Significance
* p < 0.025 
** p < 0.01 
*** p < 0.005
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Appendix 8. The Effect of Variations in the HA:P V Flow Ratio 
On the Recovery of De-ethythylatedf (GX + MBGX) Metabolites and 
Their Conjugates. Values are Expressed as a Percentage of 










5 : 5 










2.5 : 7.5 
n =  35 
(7 rats)
28.19 + 0.91 13.17 + 0.89 7.26 +  0.63 7.22 +  0.69
0 : 10 
n = 48 
(10 rats)
32.51 + 0.83 
**
11.03 + 0.87 13.29 + 1.21 
* *
8.83 + 0.55
Values are Percentages + Standard errors of the mean. 
Significance was Measured from the 2.5 : 7.5 Flow Ratio by 
the Unrelated "t" Test.
Significance 
* p < 0.025
** p < 0.01
*** p < 0.005
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Appendix 9. The Effect of Variations in the HA:FV Flow Ratio 
On the Recovery of Total Glucuronudesf Sulphates and Unconjugated 
Metabolies. Values are Expressed as a Percentage of Combined 










5 : 5 43.76 + 1.87 25.35 + 1.32 25.29 + 0.84
n = 37
(8 rats) *** *** ***
2.5 : 7.5 55.76 + 1.48 19.04 + 0.97 21.36 + 0.91
n = 35
(7 rats) ***
0 : 10 48.90 + 1.21 30.34 + 1.54 18.93 + 0.87
n = 48
(10 rats) ★** ***
Values are Percentages + Standard errors of the mean 
Significance was Measured from the 2.5 : 7.5 Flow Ratio by 
the Unrelated "t" Test.
Significance
* p < 0.025 
** p < 0.01 
*** p < 0.005
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Appendix 10. The Effect of Alterations in the HA:FV Flow
Ratio on the Recovery of Total Phase 1 Metabolites
During infusion of various Lignocaine Metabolites
Metabolite
Infused











3-OH LIG - 1.6 +1.5 - 1.0+ 1.4 +16.8 + 1.6 -14.2 + 0.9 nd
sig **
3-OH MEGX -15.3 + 4.8 rri + 9.7 + 0.7 -24.2 + 4.1 - 0.7 + 0.6
sig * *★ **
MEGX - 2.5 + 3.5 nd + 6.3 + 2.0 - 3.1 + 2.0 - 5.6 + 2.2
sig *
GX rri nd nd nd -13.2 + 1.0
sig *
Values Show changes in Percentage Dose Recovered when HA:PV 
Flow ratio is altered from 5 : 5 to 0 : 10 ml/min. + standard 
error of the mean.
A negative value indicates a decrease in metabolite production 
as portal vein flow contribution is increased.
"nd" indicates that the metabolite was not detected.
Significance was assessed using the Wilcoxon test.
* p < 0.025
** p < 0.01
All other changes were not statistically significant.
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Appendix 11. The Effect of Alterations in the HA:FV Flow
Ratio on the Recovery of Glucuronides During Infusion
of various Lignocaine Metabolites
Metabolite
Infused


















+ 9.2+ 2.5 
*
-4.07 +1.3 + 7.8 + 1.6 - 2.7 + 0.9 nd
3-OH MEGX 
sig
+ 2.4 + 4.3 nd + 1.6 _+ 0.6 + 0.8 + 4.2 - 0.0 + 0.2
MEGX
sig
+ 3.7 + 1.7 
*
rri + 7.7 + 0.9 
*
- 3.0 + 1.8 - 1.0 + 0.8
GX
sig
id nd nd nd + 1.7 _+ 1.0
Values Show changes in Percentage Dose Recovered when HA:PV 
Flow ratio is altered from 5 : 5 to 0 : 10 ml/min. + standard 
error of the mean.
A negative value indicates a decrease in metabolite production 
as portal vein flow contribution is increased.
"nd" indicates that the metabolite was not detected.
Significance was assessed using the Wilcoxon test,
* p < 0.025
** p < 0.01
All other changes were not statistically significant.
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Appendix 12. The Effect of Alterations in the HA:FV Flow
Ratio on the Recovery of Sulphate Conjugates During
Infusions of various Lignocaine Metabolites
Metabolite
Infused














- 3.5+ 1.9 + 2.8 + 0.7 + 5.2 +^ 0.8 
**





-26.8 + 1.5 
**
nd + 0.1 +_ 0.7 -27.3 + 0.8 
★★
+ 0.2 _+ 0.5
MEGX
sig
+ 9.9+ 2.4 nd + 2.1 + 1.8 + 9.3 + 1.5 
**
- 1.8 + 1.5
GX
sig
nd nd nd nd + 0.2 _+ 0.6
Values Show changes in Percentage Dose Recovered when HA:PV 
Flow ratio is altered from 5 : 5 to 0 : 10 ml/min. + standard 
error of the mean.
A negative value indicates a decrease in metabolite production 
as portal vein flow contribution is increased.
"nd" indicates that the metabolite was not detected.
Significance was assessed using the Wilcoxon test.
* p < 0.025
** p < 0.01
All other changes were not statistically significant.
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Appendix 13. The Effect of Alterations in the HA:FV Flow
Ratio on the Recovery of Unconjugated or Free Metabolites
During Infusions of various Lignocaine Metabolites
Metabolite
Infused











3-OH LIG - 4.0 +1.4 - 7.9+ 0.6 + 3.9+ 1.2 0 + 0 nd
sig **
3-OH MBGX + 9.1 + 0.8 nd + 8.2 _+ 0.5 + 2.2 +_ 0.7 - 1.3+ 0.5
sig ** ** *
MEGX -12.4 + 2.5 nd -0.5+ 0.3 -9.1+ 1.8 - 2.8 + 1.4
sig ** **
GX nd nd nd nd -15.2 + 1.4
sig **
Values Show changes in Percentage Dose Recovered when HA:FV 
Flow ratio is altered from 5 : 5 to 0 : 10 ml/min. + standard 
error of the mean.
A negative value indicates a decrease in metabolite production 
as portal vein flow contribution is increased.
"nd" indicates that the metabolite was not detected.
Significance was assessed using the Wilcoxon test.
* p < 0.025
** p < 0.01
All other changes were not statistically significant.
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Appendix 14. The Effect of Phentolamine on the
ED50% of Adrenaline and norAdrenaline in the Hepatic Artery
Phentolamine
Dose
CHANGE IN ED50% OF CONSTRICTOR
sig Adrenaline sig norAdrenaline
5 X 10”5 M •kick 2.08 + 0.07 kkk 2.05 + 0.01
n=3 n=3
5 X 10"6 M kkk 0.90 + 0.04 kkk 1.35 + 0.02
n=3 n=4
5 X 10”7 M kkk 0.40 + 0.05 *** 0.60 + 0.02
n=3 n=3
Values are mean changes in > ED50% + standard error 
of the mean.
Significance was measured by the related "t" test. 
* p < 0.025
** p < 0.01
*** p < 0.005
Appendix 15, The Effect of Phentolamine on the "
ED50% of Adrenaline and norAdrenaline in the Portal Vein
Phentolamine
Dose
CHANGE IN ED50% OF CONSTRICTOR
sig Adrenaline sig norAdrenaline
1 X 10”5 M ** 1.65 + 0.41 
n=3
*** 1.21 + 0.10 
n=5
1 X 10”6 M ★ 0.46 + 0.15 
n=3
*** 0.82 + 0.07 
n=3
5 X 10“7 M 0.32 + 0.19 
n=3
* 0.33 + 0.12 
n=3
Values are mean changes in ED50% + standard error 
of the mean.
Significance was assessed using the related "t" test.
* p < 0.025
** p < 0.01
*** p < 0.005
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Appendix 16. The Effect of Isoprenaline on the
ED50% of Adrenaline and norAdrenaline in the Hepatic Artery
Isoprenaline
Dose
CHANGE IN ED50% OF CONSTRICTOR
sig Adrenaline sig norAdrenaline
5 X 10-5 N 0.80 + 0.02 
n=6
*** 0.65 + 0.03 
n=6
5 X 10~6 M 0.03 + 0.01 
n=3
0.06 + 0.03 
n=3
Appendix 17. Hie Effect of Isoprenaline on the 
ED50% of Adrenaline and norAdrenaline in the Portal Vein
Isoprenaline
Dose
CHANGE IN ED50% OF CONSTRICTOR
sig Adrenaline sig norAdrenaline
1 X 10“5 M *** 1.00 + 0.12 
n=5
*** 1.14 + 0.09 
n=5
Values for both tables are mean changes in ED50% + standard 
error of the mean.
Significance for both tables was assessed by the related "t" test. 
* p < 0.025
** p < 0.01
*** p < 0.005
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Appendix 18, Hie Effect of Clenbuterol on the
ED50% of Adrenaline and norAdrenaline in the Hepatic Artery
Clenbuterol
Dose
CHANGE IN ED50% OF CONSTRICTOR
sig Adrenaline sig norAdrenaline
5 X l(f5 M *** 0.28 + 0.04 
n=3
** 0.19 + 0.04 
n=3
Appendix 19. Hie Effect of Clenbuterol on the 
ED50% of Adrenaline and norAdrenaline in the Portal Vein
Clenbuterol
Dose
CHANGE IN ED50% OF CONSTRICTOR
sig Adrenaline sig norAdrenaline
1 X l(f5 M *** 0.87 + 0.09 
n=5
*** 1.03 + 0.08 
n=5
Values for both tables are mean changes in ED50% + standard 
error of the mean.
Significance for both tables was assessed by the related "t" test. 
* p < 0.025
** p < 0.01
*** p < 0.005
Appendix 20. The Effect of Dobutamine on the
ED50% of Adrenaline and norAdrenaline in the Hepatic Artery
Dobutamine
Dose
CHANGE IN . ED50% OF CONSTRICTOR
sig Adrenaline sig norAdrenaline
5 X 10-6 M *** 2.35 + 0.07 
n=4
*** 1.72 + 0.03 
n=4
1 X l(f6 M **★ 0.57 + 0.02 
n=8
*** 0.57 + 0.12 
n=8
5 X 10-7 M *** 0.24 + 0.03 
n=3
0.03 + 0.02 
n=3
Values are mean changes in ED50% + standard error 
of the mean.
Significance was assessed using the related "t" test.
* p < 0.025
** p < 0.01
*** p < 0.005
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Appendix 21. The Effect of Dobutamine on the
ED50% of Adrenaline and norAdrenaline in the Portal Vein
Dobutamine
Dose
CHANGE IN ED50% OF CONSTRICTOR
sig Adrenaline sig norAdrenaline
1 X 10"5 M *** 0.66 + 0.10 ** 0.75 + 0.17
n=6 n=6
1 X 10-6 M ★** 0.11 + 0.02 * 0.08 + 0.02
n=3 . n=3
Values are mean changes in . ED50% + standard error
of the mean.
Significance was assessed using the related "t" test.
* p < 0.025
** p < 0.01
*** p < 0.005
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Appendix 22. Hie Effect of Various Beta Blockers on the
shift in Adrenaline and norAdrenaline ED50% due to 








Atenolol 5 X io-6 M 64 + 12.0 *** 99+ 4.6 ***
Propranolol 5 X 10-6 M 68 + 7.8 *** 80 + 11.0 ***




«—1 M 70 + 12.0 *** 96+ 1.2
ICI 118 551 5 X icf6 M 4 + 3.4 16+ 6.2
Values are mean % reduction in the Isoprenaline shift in ED50% 
of the vasoconstrictors Adrenaline and norAdrenaline + standard 
error of the mean.
Significance was assessed using the related "t" test.
*** p < 0.005
All other values were not statistically significant.
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Appendix 23. The Effect of Various Beta Blockers on the
shift in Adrenaline and norAdrenaline 7 ED50% due to 






% Reduction sig % Reduction sig
Atenolol 1 X 10”5 M 32+ 7.6 * 19+ 9.0
Propranolol 1 X io-5M 37+ 8.2 38 + 11.5 *
Metoprolol 1 X io-5M 22+ 7.9 -
Oxprenolol 1 X io-5M - -
ICI 118 551 1 X 10“5 M 85 + 5.8 *** 80 + 3.5 ***
Values are mean % reduction in the Isoprenaline shift in . ED50%
of the vasoconstrictors Adrenaline and norAdrenaline + standard 
error of the mean.
Significance was assessed using the related "t" test. 
* p < 0.025
** p < 0.01
*** p < 0.005
All other values were not statistically significant.
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Appendix 24. The Effect of Various Beta Blockers on the
shift in Adrenaline and norAdrenaline ED50% due to 









Atenolol 5 X Iff6 M 75 + 3.8 *** 77 + 9.9 **
Propranolol 5 X 10"6 M 33 + 10.3 ** 54 + 2.0 ***
Metoprolol 5 X IO-6 M 55 + 7.3 ** 68 + 11.9 **
Oxprenolol 5 X l(f6 M 75 + 13.9 * 68 + 6.0 **
ICI 118 551 5 X 10'6 H 31 + 9.3 77 + 14.0 *
Values are mean % reduction in the Clenbuterol shift in ED50% 
of the vasoconstrictors Adrenaline and norAdrenaline + standard 
error of the mean.
Significance was assessed using the related "t" test. 
* p < 0.025
** p < 0.01 
*** p < 0.005
All other values were not statistically significant.
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Appendix 25. The Effect of Various Beta Blockers on the
shift in Adrenaline and norAdrenaline : ED50% due to








Atenolol 1 X 10”5 M 10+ 4.8 20+ 8.3
Propranolol 1 X io-5 M 48 + 10.0 14+ 5.9
Metoprolol 1 X 10~5 M -5+ 5.6 17 + 5.4 *
Oxprenolol 1 X 10~5 M - -
ICI 118 551 1 X i<f5 M 104 + 17.0 ** 108 + 3.9 ***
Values are mean % reduction in the Clenbuterol shift in . ED50%
of the vasoconstrictors Adrenaline and norAdrenaline + standard 
error of the mean.
Significance was assessed using the related "t" test. 
* p < 0.025
** p < 0.01
*** p < 0.005
All other values were not statistically significant.
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Appendix 26. The Effect of Various Beta Blockers on the
shift in Adrenaline and norAdrenaline . ED50% due to








Atenolol 5 X IO'6 M 52 + 8.7 *** 69 + 13.0 **
Propranolol 5 X
IO1or—1 M 106 + 8.6 *** 82+ 6.7 ***
Metoprolol 5 X l<f6 M 69 + 5.7 ★★★ 100+ 1.1 ***
Oxprenolol 5 X l<f6 M 55 + 3.9 'k'k'k 79+ 9.6 ***
ICI 118 551 5 X icf6 M 8 ± 3.4 19 + 7.0 ★
Values are mean % reduction in the Dobutamine shift in ED50% 
of the vasoconstrictors Adrenaline and norAdrenaline + standard 
error of the mean.
Significance was assessed using the related "t" test. 
* p < 0.025
** p < 0.01
*** p < 0.005
All other values were not statistically significant.
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Appendix 27. The Effect of Various Beta Blockers on the
shift in Adrenaline and norAdrenaline ED50% due to









Atenolol X X 10"5 M 68 + 9.3 *** 43 + 2.6 ***
Propranolol 1 X 10-5 M 46 + 13.8 * 38+ 8.0 *
Metoprolol 1 X 10"5 H 30 + 7.2 * 34+ 7.1
Oxprenolol 1 X IO"5 M 43 + 12.0 * 50 + 15.0
ICI 118 551 1 X IO"5 M 20 + 5.8 108 + 3.9 *
Values are mean % reduction in the Dobutamine shift in ED50% 
of the vasoconstrictors Adrenaline and norAdrenaline + standard 
error of the mean.
Significance was assessed using the related t test.
* p < 0.025
** p < 0.01
*** p < 0.005
All other values were not statistically significant.
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Appendix 28
The Effect of Increases in Perfusion 
Pressure by Adrenaline or norAdrenaline Infusions 







Control 98.53 + 0.07 98.38 + 0.11
HA Constrictor *** 96.59 + 0.30 *** 96.25 + 0.36
HA Phentolamine 98.37 + 0.10 98.33 + 0.05
HA Constrictor 98.42 + 0.09 98.36 + 0.10
+ Phentolamine
PV Constrictor *** 97.63 + 0.12 *** 97.26 + 0.17
PV Phentolamine 98.40 + 0.12 98.34 + 0.08
PV Constrictor 98.37 + 0.08 98.32 + 0.07
+ Phentolamine
*** = significance < 0.005 using the Mann Whitney test. 
Values are percentages + standard errors of the means.
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Appendix 29
To Show the Effect of Increases in Perfusion Pressure 
due to Infusions of Adrenaline or norAdrenaline on 
Combined Total Metabolite Output Concentration 








Control 67.23 + 3.27 67.61 + 6.72
HA Constrictor 60.03 + 2.86 64.00 + 2.75
HA Phentolamine 70.91 + 3.02 65.11 + 2.55
HA Constrictor 70.11 + 3.91 67.93 + 2.04
+ Phentolamine
PV Constrictor 66.90 + 3.63 64.91 + 2.27
PV Phentolamine 70.14 + 2.70 66.34 + 4.84
PV Constrictor 75.20 + 5.08 66.41 + 2.99
+ Phentolamine
Values are percentages + standard error of the means.
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Appendix 30
The Effect of Increases in Perfusion Pressure 
due to Infusions of Adrenaline or norAdrenaline on 
Total 3-OH Lig Metabolite Output Expressed as a 








Control 22.31 + 1.87 21.89 + 1.45
HA Constrictor 22.31 + 1.41 21.74 + 1.51
HA Phentolamine 21.63 + 1.76 22.00 + 1.63
HA Constrictor 22.13 + 1.52 21.51 + 1.31
+ Phentolamine
PV Constrictor 22.20 + 1.16 21.81 + 1.66
PV Phentolamine 21.34 + 1.63 22.93 + 1.51
PV Constrictor • 20.74 + 1.56 21.93 + 1.89
+ Phentolamine
Values are percentages + standard error of the means.
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Appendix 31
The Effect of Increases in Perfusion Pressure 
due to Infusions of Adrenaline or norAdrenaline on 
Total 3-OH MEGX Output Expressed as a Percentage of 






Control 43.73 + 1.56 42.16 + 0.80
HA Constrictor 41.13 + 0.56 40.40 + 1.13
HA Phentolamine 42.90 + 1.13 42.71 + 1.00
HA Constrictor 
+ Phentolamine
41.49 + 0.85 42.57 + 1.02
PV Constrictor 41.14 + 0.84 42.59 + 2.36
PV Phentolamine 40.74 + 1.26 42.70 + 1.46
PV Constrictor 
+ Phentolamine
41.97 + 1.10 43.06 + 1.92
Values are percentages + standard error of the means.
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Appendix 32
The Effect of Increases in Perfusion Pressure 
due to Infusions of Adrenaline or norAdrenaline on 
Total De-ethylated (MEGX + GX) Metabolite Output Expressed 








Control 31.61 + 1.90 33.47 + 1.43
HA Constrictor 27.26 + 4.81 31.71 + 1.89
HA Phentolamine 33.43 + 1.81 32.70 + 1.57
HA Constrictor 34.19 + 1.92 33.47 + 1.33
+ Phentolamine
PV Constrictor 33.23 + 1.65 32.06 + 2.09
PV Phentolamine 35.79 + 2.26 31.66 + 2.35
PV Constrictor 34.97 + 1.85 33.06 + 1.52
+ Phentolamine
Values are percentages + standard error of the means.
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Appendix 33
The Effect of Increases in Perfusion Pressure 
due to Infusions of Adrenaline or norAdrenaline on 
Total Glucuronide Conjugate Output Expressed as a 








Control 61.19 + 1.53 58.00 + 3.00
HA Constrictor 55.27 + 1.84 55.97 + 2.90
HA Phentolamine 62.75 + 2.90 58.94 + 3.70
HA Constrictor 60.60 + 2.30 56.82 + 3.31
+ Phentolamine
PV Constrictor 57.68 + 3.46 59.87 + 4.58
PV Phentolamine 66.24 + 1.65 59.06 + 4.06
PV Constrictor 63.90 + 2.80 55.74 + 3.37
+ Phentolamine
Values are percentages + standard error of the means.
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Appendix 34
The Effect of Increases in Perfusion Pressure 
due to Infusions of Adrenaline or norAdrenaline on 
Total Sulphate Conjugate Output Expressed as a 








Control 17.90 + 2.33 21.38 + 2.65
HA Constrictor 20.04 + 2.58 21.28 + 2.81
HA Phentolamine 19.56 + 3.27 23.13 + 3.42
HA Constrictor 20.94 + 2.28 20.94 + 1.95
+ Phentolamine
PV Constrictor 22.14 + 3.54 18.00 + 3.14
PV Phentolamine 15.89 + 2.67 20.38 + 2.19
PV Constrictor 17.30 + 3.28 22.84 + 1.91
+ Phentolamine
Values are percentages + standard error of the means.
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Appendix 35
The Effect of Increases in Perfusion Pressure 
by Adrenaline or norAdrenaline Infusions 
on Unconjugated Metabolite Output concentration 
Experssed as a Percentage of Combined Total Output 







Control 18.86 + 2.07 18.16 + 4.46
HA Constrictor 19.56 + 2.08 16.71 + 3.34
HA Phentolamine 15.54 + 1.81 15.53 + 2.78
HA Constrictor 16.30 + 1.85 19.03 + 3.48
+ Phentolamine
PV Constrictor 16.74 + 1.65 18.33 + 4.28
PV Phentolamine 15.70 + 2.07 18.13 + 3.34
PV Constrictor 16.16 + 2.59 19.00 + 3.96
+ Phentolamine
Values are percentages + standard error of the means.
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Appendix 36
The Effect of Hydralazine, lmg/kg, given 
Orally on Systolic Blood Pressure
TIME AFTER 
DOSE





0 112 + 3.0 121 + 6.7
15 119 + 4.3 120 + 4.3
30 115 + 9.3 113 + 6.0
45 120 + 5.9 * 95 + 2.8
60 129 + 4.5 ** . 81 + 2.8
90 107 + 4.6 * 90 + 5.0
120 120 + 4.9 129 + 5.3
180 123 + 4.7 118 + 10.3
Values are means + standard error of the mean.
Significance was assessed using the unrelated 
"t" test.
* p < 0.05
** p < 0.01
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Appendix 37
The Effect of Hydralazine, lmg/kg, given Orally
on the Clearance of Lignocaine, 20mg/kg f Orally or
2.5mg/kg, Intravenously
PLASMA CONCENTRATION ng/.ml
ORAL LIGNOCAINE I.V. LIGNOCAINE
Time After Control Hydralazine Control Hydralazine
Dose Treated Treated
(mins) n = 3 n=6 n=3 n=6
5 703 + 7.3 573 + 21.6 1217 + 105.0 1323 + 100.0
10 1642 + 143.3 1221 + 75.7 606 + 5.5 826 + 37.0
15 1794 + 10.4 1531 + 29.2 497 + 2.8 624 + 7.9
20 1101+ 96.5 1750 + 26.2 427 + 12.1 538 + 17.3
30 800 + 36.3 1211 + 50.5 322 + 9.7 420 + 24.4
45 595 + 75.9 865 + 83.0 180+ 31.5 216+ 23.1
60 427 + 12.1 690 + 31.0 123+ 15.4 155 + 20.4
90 178 + 9.1 405 + 20.0 73 + 2.8 100 + 4.9
120 117+ 30.9 280 + 19.7 - -
180 40 + 8.3 160 + 16.0 _  —
Values are means + standard error of the mean.
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Appendix 38
The Effect of Hydralazine, lmg/kgf on the Plasma 
Clearance of Indocyanine Green




Control n=3 Treated n=3
1 0.275 + 0.009 0.290 + 0.005
3 0.192 + 0.011 0.236 + 0.005
5 0.145 + 0.010 0.173 + 0.004
7 0.114 + 0.006 '0.139 + 0.002
10 0.081 + 0.006 0.109 + 0.002
15 0.047 + 0.003 0.064 + 0.001
20 0.036 + 0 0.047 + 0.002
25 0.031 + 0.001 0.037 + 0.001
30 0.027 + 0.001 0.032 + 0
45 0.024 + 0 0.030 + 0
60 0.020 + 0.001 0.026 + 0.001
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